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Background: Ectopic fat is thought to play a central role in the pathophysiology of type 
2 diabetes (T2D). Despite being disproportionately affected by T2D, black populations 
typically exhibit lower levels of ectopic fat compared to white populations; this paradox 
questions the role of ectopic fat in the development of T2D in black populations.   
Aim: To assess ethnic differences in ectopic fat deposition and their relationships with 
metabolic parameters of T2D in white European (WE) and black west African (BWA) 
men at three glycaemic states: normal glucose tolerance (NGT), impaired glucose 
tolerance (IGT) and T2D.  
Methods: Fifty-one WE (23 NGT/10 IGT/18 T2D) and 50 BWA (20 NGT/10 IGT/20 
T2D) men were recruited. All participants underwent: 1) a Dixon-magnetic resonance 
imaging scan to assess visceral adipose tissue (VAT), intrahepatic lipids (IHL) and 
intrapancreatic lipids (IPL); 2) a proton-magnetic resonance spectroscopy scan to assess 
intramyocellular lipids (IMCL); 3) a hyperinulinaemic-euglycaemic clamp, with the 
infusion of glucose and glycerol isotopes, to assess whole-body, hepatic, skeletal muscle 
and adipose tissue insulin sensitivity; and 4) a hyperglycaemic clamp to assess first- and 
second-phase insulin secretory function, insulin secretion rate and insulin clearance. 
Results: In the combined glycaemic cohorts, VAT, IHL and IPL were significantly lower 
in the BWA men compared to the WE men (all p<0.05), however, IMCL did not differ 
by ethnicity (p=0.74). Differences in VAT, IHL, IPL and IMCL by glycaemic state were 
similar in both ethnic groups, indicated by non-significant ethnicity*glycaemic state 
interactions (all p>0.05). Relationships between ectopic fat depots and metabolic 
parameters were generally stronger in the WE men than BWA men. VAT, IHL and IPL 
showed significant inverse associations with adipose tissue insulin sensitivity in WE men 
but not BWA men (all p<0.05). Interrelationships between the ectopic fat depots were 
stronger in WE men than BWA men. 
Conclusion: The greater ectopic fat levels in the T2D states compared to the NGT states 
in both WE and BWA men suggests ectopic fat plays a role in the development of T2D 
in both ethnic groups; however, the weaker relationships between ectopic fat depots and 
metabolic parameters of T2D in BWA men suggests ectopic fat may play a lesser role in 
T2D in BWA men compared with WE men. Furthermore, the lack of association between 
ectopic fat depots and adipose tissue insulin sensitivity in BWA men suggests that the 
role of adipose tissue dysfunction in driving ectopic fat storage may differ by ethnicity. 
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Ectopic fat accumulation is emerging as one of the major factors that contributes to the 
development of type 2 diabetes (T2D) and appears to be a key feature that explains the 
well-known link between obesity and T2D. There is much evidence suggesting that the 
pathophysiology of T2D differs between populations of black and white ethnicity with 
several metabolic features differing between the two ethnic groups. Despite their greater 
prevalence of T2D, black populations typically exhibit lower levels of visceral and 
hepatic fat compared to their BMI-matched white counterparts, which has caused 
researchers to question the role of ectopic fat in the development of T2D in black 
populations. Some studies have suggested that black populations may be more sensitive 
to the detrimental effects of ectopic fat compared to white populations; however, others 
have suggested that ectopic fat plays a lesser role in the development of T2D in black 
populations. Addressing these speculations underlies the purpose of this thesis, which 
includes comprehensive analyses of ectopic fat depots and the metabolic parameters that 
are related to the development of T2D. Since T2D disproportionately affects populations 
of black ethnicity, it is of utmost importance to understand its pathophysiology in this 
high risk ethnic group, which may inform future ethnic-specific prevention and treatment 
strategies. Therefore, the overarching scope of this thesis is to investigate ethnic 
differences in the role of ectopic fat in the development of T2D between men of black 
west African and white European ethnicity across three glycaemic states: normal glucose 
tolerance, impaired glucose tolerance and T2D. The fat depots of interest include: visceral 
adipose tissue (VAT), intrahepatic lipids (IHL), intrapancreatic lipids (IPL) and 




1.2!Type 2 diabetes 
Type 2 diabetes is a complex chronic metabolic disorder characterised by a persistent 
hyperglycaemic state caused by the inadequate production and utilisation of insulin 
(DeFronzo, 1988). T2D is detected clinically by the deterioration of several parameters 
including glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial 
glucose levels (Safai et al., 2018). The quality of life of T2D sufferers is highly affected 
due to the increased risk of macrovascular and microvascular damage, which can lead to 
chronic complications including cardiovascular disease, nephropathy, neuropathy and 
retinopathy (Muggeo, 1998, Jelinek et al., 2017). The treatment of T2D and its 
complications places a great financial strain on the National Health Service (NHS) in the 
UK where it is estimated to consume 10% of the total budget (Hex et al., 2012); therefore, 
there is strong emphasis on early intervention and prevention to minimise complications.  
The prevalence of T2D is increasing worldwide at an alarming rate (Zheng et al., 2017). 
According to data collected by the International Diabetes Federation in 2017, over 2.7 
million adults in the UK have T2D with a further 0.5 million undiagnosed (IDF, 2017). 
The expected global increase in the prevalence of T2D by 2045 is presented in Figure 1.1, 
which shows the greatest increase is expected to occur in Africa (IDF, 2017) mainly due 
to the increase of westernisation and industrialisation (Cho et al., 2018). The current 
burden of T2D in Africa is largely underestimated due to the high percentage of 
undiagnosed cases of T2D in comparison to other regions; indeed, Africa has the highest 
percentage of undiagnosed cases of T2D worldwide with 69% of cases undiagnosed, 








1.2.1!Type 2 diabetes in UK ethnic minority groups 
The disproportionate burden of T2D is not limited to black populations in Africa, since, 
in the UK, black populations are also at greater risk of T2D compared to the general 
population. Individuals that identify as being from an ethnic minority background make 
up 14% of the UK population (ONS, 2011). Of those, 25% identify as being from a black 
African/black Caribbean/black British ethnic group, which is the second largest ethnic 
minority group in the UK (ONS, 2011). Considering the high percentage of ethnic 
minority groups in the UK, the Health Survey for England, conducted in 2004, took a 
specific focus on the health status of these ethnic minority groups (HSE, 2005). The 
resultant report showed that doctor-diagnosed diabetes is greater in several ethnic 
minority groups, including black African and black Caribbean groups, compared to the 
general population. Figure 1.2 shows the prevalence rates of diabetes stratified by 
ethnicity and age, which shows doctor-diagnosed diabetes is 2-3 times greater in black 
ethnic groups than the general population; this trend is also present within the younger 






 Figure 1.2: Prevalence of doctor-diagnosed diabetes stratified by age and 
ethnicity in the UK population. Created from data extracted from the Health 




1.2.2!Normal glucose homeostasis 
To understand the pathophysiology of T2D, it is important to first consider normal 
glucose homeostasis in the human body. In an individual of normal glucose tolerance 
(NGT), when a meal is consumed blood glucose levels increase which signal for 
pancreatic beta-cells to secrete insulin into the circulation (Cernea and Dobreanu, 2013). 
Insulin signals to the peripheral organs, mainly the muscles and liver, to absorb glucose 
for storage as glycogen, as well as signalling to the liver to inhibit the breakdown of 
glycogen into glucose (glycogenolysis); these processes allow glucose to be utilised and 
stored effectively in the body and maintain a normoglycaemic state (Aronoff et al., 2004). 
1.2.3!Pathophysiology of type 2 diabetes 
There is a long-established understanding that T2D is characterised by hyperglycaemia 
that typically results from a combination of insulin resistance and insufficient beta-cell 
insulin secretory function to overcome the insulin resistance (DeFronzo, 1988); however, 
the understanding of the pathophysiology of T2D that underlies these features has evolved 
greatly over the past 100 years. In 1922, the discovery of insulin led researchers to 
propose that it was the inadequate production of insulin by pancreatic beta-cells that was 
the key driver of T2D (Polonsky, 2012). In an attempt to understand the cause of beta-
cell failure, researchers discovered that insulin resistance precedes beta-cell failure, thus 
placing the muscles, liver and pancreas central to the pathophysiology of T2D (DeFronzo, 
1988). However, more recent research suggests that dysfunctional adipose tissue is a 
major cause of insulin resistance and plays a key role in the pathophysiology of T2D 
(Smith and Kahn, 2016, Snijder et al., 2005, Longo et al., 2019).  
Dysfunctional adipose tissue is characterised by several features including low-grade 
chronic inflammation, insulin resistance and a reduced ability to store excess energy as 




in non-adipose tissues including the muscles, liver and pancreas, which is termed ectopic 
fat. The lipid intermediates generated from the flux of these ectopic fat stores are toxic to 
the cells they reside in and are proposed to cause insulin resistance (Snel et al., 2012).  
It is now accepted that the development of T2D is more complex than initially 
appreciated. Even though the muscles, liver and pancreas are the key organs that maintain 
normal glucose homeostasis (DeFronzo, 1988), it has now become apparent that several 
organs may play a role in the onset and progression of T2D (Cornell, 2015, Defronzo, 
2009). Figure 1.3 shows the interaction of various organs with insulin resistance that may 
play a role in the pathophysiology of T2D (Cornell, 2015). The role of the muscles, liver, 
pancreas and adipose tissue in the pathophysiology of T2D are further addressed below 






The established understanding of T2D is supported by longitudinal studies which have 
shown that T2D develops from the simultaneous effects of insulin resistance of the 
peripheral tissues and dysfunction of the pancreatic beta-cells (Martin et al., 1992). In the 
early stages of the development of T2D the peripheral tissues become less sensitive to 
insulin and their absorption of glucose is in turn reduced. In order to compensate for this 
insulin resistance, beta-cells increase the production of insulin to maintain 
normoglycaemia. Over time, with increasing insulin resistance of the peripheral organs, 
Figure 1.3: The interaction of insulin resistance and a range of body organs which 




and, in turn, a moderate increase in blood glucose levels, a state of impaired glucose 
tolerance (IGT), also called prediabetes, develops which is characterised by slight 
hyperglycaemia and marked hyperinsulinaemia. Prolonged overproduction of insulin 
eventually causes beta-cells to become debilitated and subsequently lose their function of 
sufficient insulin production, thus, leading to a further increase of hyperglycaemia and 
the onset of T2D. This progression is demonstrated in Figure 1.4, which shows the 
changes in glucose, insulin and insulin sensitivity levels during the typical progression 
from NGT to IGT to T2D (DeFronzo, 2004). 
Figure 1.4: Plasma glucose, insulin and insulin sensitivity measured during an oral 
glucose tolerance test. Comparison of groups at various glycaemic states including: 
healthy control (CON), obese (OB), obese glucose intolerant (OB- GLU INTOL), obese 
with T2D and high insulin (OB-DIAB Hi INS), and obese with T2D and low insulin (OB-




The advancement from NGT to T2D is a progressive process, which usually occurs over 
several years (Meigs et al., 2003). It is believed that insulin resistance precedes beta-cell 
dysfunction; this has been supported by longitudinal studies which show specific features 
of insulin resistance, such as reduced glucose clearance and hyperinsulinaemia, are 
apparent 10-20 years prior to the onset of T2D (Warram et al., 1990). Similarly, during 
the development of T2D, beta-cell dysfunction begins as early as 12 years before 
diagnosis (UKPDS, 1995). Additionally, it is estimated that 50% of beta-cell function is 
lost by the time an individual has reached an impaired glucose tolerant state (Gastaldelli 
et al., 2004). While the features of the progression of T2D are well established, the role 
of adipose tissue dysfunction and ectopic fat accumulation have only recently gained 
attention. 
1.3!Obesity, adipose tissue and type 2 diabetes 
Obesity is a major risk factor for T2D (Bhupathiraju and Hu, 2016). In fact, the increasing 
prevalence of T2D is partly attributed to the increasing prevalence of obesity worldwide 
(Kopelman, 2000). Obese individuals have an estimated 6-8 times greater risk of 
developing T2D compared to individuals with a healthy body mass index (BMI) 
(Abdullah et al., 2010). Additionally, it is estimated that 90% of people with T2D in the 
UK are classified as clinically overweight or obese (Gatineau M, 2014).  
Other major risk factors for T2D include age, family history and ethnicity; however, total 
body adiposity, determined by BMI, is estimated to account for a third to half of the 
weighting of the risk scores for T2D (Sattar and Gill, 2014). Stressing the importance of 
whole-body adiposity in T2D, studies investigating the relative risk of T2D have shown 
that current BMI, early obesity, weight gain throughout adulthood and waist 




the evident link between obesity and T2D, the study of excess adiposity has been a long-
standing area of interest in T2D research. 
1.3.1!Body fat distribution and type 2 diabetes 
There is much evidence demonstrating that the distribution of body fat is more important 
in determining metabolic risk than general measures of obesity (Meisinger et al., 2006, 
Li et al., 2012). BMI does not consider body fat distribution but is an anthropometric 
measure that is easy to undertake in almost any setting. Strong relationships have 
commonly been reported between BMI and risk of T2D (Colditz et al., 1990) and insulin 
resistance (Ferrannini et al., 1997). Although, despite the well-known link between 
obesity and T2D, about 30% of individuals with an obese BMI are metabolically healthy, 
while, 20-30% of individuals with a healthy BMI are metabolically unhealthy (Wildman 
et al., 2008). Another example of paradoxical relationships between whole-body 
adiposity and T2D risk is the well-known gender differences in T2D risk (Logue et al., 
2011). Even though men typically have lower levels of whole-body fat compared to 
women at any given level of BMI, they are at greater risk of T2D (Kautzky-Willer et al., 
2016). Hence, the relationship between adiposity and T2D is more complex than initially 
appreciated, which has encouraged research into the pattern of body fat distribution as 
opposed to general measures of adiposity such as whole-body fat or BMI (Meisinger et 
al., 2006, Li et al., 2012).  
1.3.1.1!Android versus gynoid obesity 
In 1947, Vague first proposed the classification of obesity into android (apple shape) and 
gynoid (pear shape) type by comparing the fat mass and distribution of men and women 
(Vague, 1947). He found that women could have twice the fat mass of men but still live 
longer while free of metabolic-related diseases, which he attributed to the pattern of fat 




region have a greater risk of cardiometabolic diseases compared to individuals who 
deposit fat in the lower part of the body and extremities (Wiklund et al., 2008, Samsell et 
al., 2014). Therefore, the phenomena of male versus female adiposity, or android versus 
gynoid adiposity, further supports the notion that rather than the amount of adipose tissue, 
its distribution appears to be a key influencer of metabolic health. 
With the advancement of imaging techniques in the 1980s, researchers have been able to 
use computed tomography (CT) scanning to investigate associations between regional fat 
distribution and parameters of metabolic health (Thomas et al., 2013). Using these 
methods, Despres et al. showed that adipose tissue deposited within the visceral cavity, 
termed visceral adipose tissue (VAT), was negatively associated with glucose tolerance 
but this association was not present for subcutaneous adipose tissue (SAT) (Despres et 
al., 1989). This explained the link between android adiposity and T2D because android 
adiposity appears to be an indicator of high VAT deposition.  
Since the discovery of the importance of abdominal obesity in T2D risk, waist 
circumference has been used as an important clinical tool to assess the risk of T2D since 
waist circumference is a marker of VAT deposition (Feller et al., 2010). Supporting the 
use of waist circumference to assess T2D risk, in a large cohort, Wang et al. found that 
waist circumference was a more sensitive predictor of T2D status than BMI and waist-
to-hip ratio (Wang et al., 2005). Furthermore, waist circumference was a stronger 
independent predictor of insulin resistance compared to BMI and waist-to-hip ratio, and 
explained 50% of variation in insulin sensitivity (Wahrenberg et al., 2005). Therefore, 
even when using anthropometric measures, there is much evidence showing that 
abdominal obesity is an important factor in determining the risk of T2D (Li et al., 2012, 




In the 1990s, the development of duel-energy X-ray absorptiometry (DEXA) to determine 
body composition led to extensive studies that examined the relationship between body 
fat distribution and metabolic risk (Laskey, 1996, Shepherd et al., 2017). Using these 
methods, abdominal fat was shown to be a significantly stronger predictor of insulin 
resistance compared to peripheral fat (Carey et al., 1996). In contrast, thigh SAT showed 
inverse associations with insulin resistance indicating a possible metabolically protective 
role of peripheral SAT (Goodpaster et al., 2000). Therefore, the advancement of imaging 
techniques to assess body fat distribution have consistently confirmed that abdominal 
adiposity is closely linked to T2D risk. 
1.3.2!Adipose tissue 
Adipose tissue is a complex organ that functions as a storage compartment for 
triglycerides and is also the largest endocrine organ in the human body that secretes 
hormones and cytokines, termed adipokines (Unger, 2003). Remarkably, cells within 
adipose tissues, termed adipocytes, have the capacity to expand by several thousand-fold 
in volume to accommodate the storage of excess triglycerides, particularly in states of 
positive energy balance (Snel et al., 2012). However, when adipocytes become severely 
enlarged, such as in cases of obesity, they become dysfunctional and become unable to 
efficiently store triglycerides (Jernas et al., 2006). Adipose tissue dysfunction becomes 
progressively worse with increasing obesity; this state is particularly harmful during a 
positive energy balance due to the glycotoxic and lipotoxic effects of prolonged exposure 
to circulating glucose and lipids (Longo et al., 2019). 
Dysfunctional adipose tissue has been closely related to metabolic disturbances that lead 
to T2D (Snel et al., 2012). Adipose tissue expands by increasing adipocyte numbers 
(hyperplasia) and increasing adipocyte size (hypertrophy) or a combination of both 




dysfunction and metabolic disturbances including insulin resistance, dyslipidaemia and 
inflammation which are individually addressed further below (Cuthbertson et al., 2017). 
Studies have shown that adipocyte hypertrophy is associated with insulin resistance (Cruz 
et al., 2002) and is an independent risk factor for T2D (Weyer et al., 2000). While 
investigating T2D in individuals of normal weight, Acosta et al. found that adipocytes 
isolated from patients with T2D were significantly larger in size compared to those 
isolated from the control group without T2D (Acosta et al., 2016). Even though adipose 
tissue dysfunction is closely related to its severe expansion, there is great inter-individual 
variability in the point at which adipose tissue becomes dysfunctional, a phenomenon 
coined the “personal fat threshold” (Cuthbertson et al., 2017, Taylor and Holman, 2015). 
Hence, there is much evidence showing that the way in which adipose tissue expands 
appears to be more crucial in determining the point at which it becomes dysfunctional 
rather than the actual level of expansion. 
Generation of mature adipocytes from preadipocytes, called adipogenesis, is the 
underlying mechanism in adipose tissue hyperplasia (Ghaben and Scherer, 2019). Means 
by which adipogensis can be increased have been explored in an attempt to reduce 
metabolic disease risk (Ghaben and Scherer, 2019). For example, the genetic transcription 
factors involved in adipogenesis are therapeutic targets of some T2D drugs including 
thiazolidinediones (Sattar and Gill, 2014). These drugs stimulate adipose tissue 
transcription factors to promote hyperplasia and, in turn, reduce hypertrophy, which 
results in improved insulin sensitivity by the reduction of adipose tissue dysfunction 
(Hauner, 2002). Therefore, dysfunctional adipose tissue plays a crucial role in the 
pathophysiology of T2D and is proposed to be the key driver of insulin resistance (Longo 




1.3.2.1!Adipose tissue inflammation 
Adipose tissue is a major endocrine organ that secretes a number of hormones which 
includes leptin, adiponectin, resistin as well as several cytokines, called adipokines 
(Guerre-Millo, 2002). When adipocytes become severely enlarged and dysfunctional, 
they release excess inflammatory adipokines that cause an immune reaction in the adipose 
tissue inducing a state of persistent chronic low-grade inflammation (Reilly and Saltiel, 
2017). Part of the immune response is a visible increase of macrophages that infiltrate the 
adipose tissue and function to clear up debris produced from damaged adipocytes 
(Thomas and Apovian, 2017). Figure 1.5 shows the phenotypic modulation of adipocytes 
from normally functioning adipose tissue to enlarged and dysfunctional adipose tissue 
that typically occurs during increased adiposity (Ouchi et al., 2011). 
Figure 1.5: Phenotypic modulation of adipocytes from normal to obese states. As 
adipose tissue becomes severely enlarged, pro-inflammatory cytokines are released in 
excess which induce an immune reaction resulting in recruitment of macrophages and 




Several inflammatory cytokines have been reported to be increased in individuals with 
obesity compared to those of a healthy weight which include interleukin-6 (IL-6), 
interleukin-1! (IL-1!), interleukin-8 (IL-8) and tumour necrosis factor-α (TNF-α) 
(Almuraikhy et al., 2016). These adipokines are also found to be elevated in patients with 
T2D confirming a link between adipose tissue inflammation and glucometabolic 
disorders. Population-wide studies have found that Il-6 is associated with incident 
diabetes independent of obesity and is an independent risk factor for T2D (Goldberg et 
al., 2019, Wannamethee et al., 2007). Furthermore, Il-6 has been causally linked to T2D 
since it has been shown to impair adipose tissue differentiation (Snel et al., 2012), 
stimulate hepatic fatty acid synthesis, (Sattar et al., 2008) and interfere with insulin 
signalling of hepatocytes and adipocytes (Kristiansen and Mandrup-Poulsen, 2005).  
1.3.2.2!Adipose tissue insulin resistance 
Adipose tissue is one of the sites of insulin action (Sobczak et al., 2019); in adipocytes, 
insulin signals to suppress the breakdown of stored triglycerides (lipolysis) and promotes 
the uptake of non-esterified fatty acids (NEFA) to be stored as triglycerides (lipogenesis) 
(DeFronzo et al., 1985). Similar to the liver and muscle tissues, adipose tissue insulin 
sensitivity is reduced in individuals with T2D leading to an over-excretion of NEFAs 
(Gastaldelli et al., 2017). These excess NEFAs are directed to other tissues where they 
deposit as ectopic fat, which is also a key feature of adipose tissue dysfunction, and is 
suggested to cause insulin resistance in the organ it resides in (Sattar and Gill, 2014, Snel 
et al., 2012). The decrease of adipose tissue insulin sensitivity is a progressive process 
that occurs with increasing obesity (Kim et al., 2019, Kim et al., 2017). Furthermore, it 
has been suggested that adipose tissue insulin resistance resulting from dysfunctional 
adipocytes precedes peripheral insulin resistance and is therefore the key link between 




1.3.3!Subcutaneous adipose tissue 
Subcutaneous adipose tissue is the primary and metabolically safest compartment for 
storage of triglycerides (Ibrahim, 2010). In a healthy state, excess energy is ultimately 
stored as triglycerides in the SAT depots. The SAT compartment is considered to be the 
safest storage depot for triglycerides due to its avid capacity to absorb circulating NEFAs 
and triglycerides; this process maintains circulating lipid levels within normal ranges 
(Ibrahim, 2010).  
1.3.3.1!Abdominal versus peripheral subcutaneous adipose tissue 
Even though the storage of triglycerides in the SAT compartment is more favourable in 
comparison to VAT and ectopic depots, abdominal SAT (ASAT) appears to be more 
harmful than peripheral SAT (Patel and Abate, 2013a). An increase of ASAT has been 
more strongly related to T2D compared to peripheral SAT (Patel and Abate, 2013b, Abate 
et al., 1996). Individuals with T2D have a greater amount of ASAT compared to controls 
without T2D (Abate et al., 1996). Considering peripheral SAT, a large cohort study by 
Snijder et al. showed that thigh SAT was independently associated with favourable 
circulating glucose and lipid levels while ASAT was associated with unfavourable 
glucose and lipid levels (Snijder et al., 2005). Additionally, gluteofemoral fat was related 
to favourable circulating lipid profiles including lower total cholesterol, low density 
lipoprotein (LDL) cholesterol and greater high-density lipoprotein (HDL) cholesterol 
(Terry et al., 1991, Williams et al., 1997). A lower ratio of ASAT to peripheral fat is also 
considered favourable; an increase of gluteofemoral fat relative to ASAT is protective 
against insulin resistance and serves as a “sink” for circulatory non-esterified fatty acids 
(Manolopoulos et al., 2010).  
The metabolic differences in the influence of peripheral SAT and ASAT on T2D may be 




adipocytes isolated from ASAT were larger in size than those isolated from leg SAT 
which indicates that abdominal SAT are more likely to be hypertrophic and dysfunctional 
(Azuma et al., 2007). Therefore, there is much evidence suggesting that increased ASAT 
plays a role in metabolic dysregulation and T2D.  
1.3.3.2!Deep and superficial subcutaneous adipose tissue  
To add to the complexity in the field of body-fat distribution and T2D risk, the SAT 
compartment itself is heterogeneous and the distribution of adipocytes within the SAT 
depot is also related to T2D risk. SAT is composed of two distinct compartments: 
superficial SAT (sSAT) and deep SAT (dSAT) which are separated by the fascia-
superficialis; the dSAT is located below the fascia with the sSAT above (Sniderman et 
al., 2007). Structural and functional properties differ between sSAT and dSAT as well as 
their contribution to metabolic disease risk. The dSAT is more metabolically active than 
sSAT; adipocytes isolated from dSAT show greater lipolytic activity compared to those 
from sSAT (Monzon et al., 2002). Furthermore, with increasing adiposity, as the SAT 
increases there is a disproportionate expansion of dSAT compared to sSAT (Marinou et 
al., 2014). Hence, the differences between dSAT and sSAT suggest that an increased ratio 
of dSAT to sSAT is an indicator of dysfunctional adipose tissue. Indeed, dSAT is 
commonly likened to VAT and shows strong associations with VAT but this relationship 
is not present between sSAT and VAT (Marinou et al., 2014). The similarities between 
dSAT and VAT are also evident in their relationships with metabolic risk since dSAT and 
VAT, but not sSAT, showed strong associations with insulin resistance (Kelley et al., 
2000). The disparities between dSAT and sSAT may be due to their structural differences 
since adipocytes from dSAT are large and loosely organised while those of the sSAT are 




1.3.4!Visceral adipose tissue 
As previously mentioned, central adiposity is known to be related to T2D due to the 
increase of VAT. Indeed, increased VAT is an independent risk factor for T2D 
irrespective of overall adiposity and is usually indicated by waist circumference or waist 
to hip ratio (Chan et al., 1994, Despres, 1993). Furthermore, increased VAT is associated 
with insulin resistance and hyperglycaemia and is considered to be detrimental to the 
development of T2D (Despres, 2006, Gastaldelli, 2008). Increased VAT is also related to 
several other features of poor metabolic health such as increased LDL-cholesterol, and 
triglyceride levels (Fujioka et al., 1987, Fujimoto et al., 1994).  
1.3.4.1!Visceral adipose tissue versus subcutaneous adipose tissue 
Several large cohort studies comparing VAT and SAT fat depots have shown that VAT 
is more strongly related to T2D compared to SAT (Wagenknecht et al., 2003, Muller et 
al., 2012). In the Framingham Heart Study, Fox et al. showed that, even though both VAT 
and SAT were associated with metabolic markers of T2D, VAT showed a greater 
association than SAT (Fox et al., 2007). From the same cohort, Porter et al. investigated 
these associations while dividing the data by tertiles of VAT and SAT; they found that 
when stratified across tertiles of VAT, SAT was not associated with a linear increase of 
metabolic risk factors across the tertiles (Porter et al., 2009). This suggests that while 
overall adiposity increases absolute risk of T2D, an increased amount of SAT at the same 
BMI may have protective qualities compared to VAT. Therefore, the ratio of VAT to 
SAT is a sensitive and informative marker of T2D risk in comparison to either measure 
alone. This notion is supported by several studies. When compared to controls without 
T2D, individuals with T2D had significantly lower SAT and greater VAT suggesting that 
an increase of VAT to SAT ratio plays a crucial role in the pathophysiology of T2D 




VAT ratio there was an increase in fasting glucose and triglyceride levels and a decrease 
in HDL cholesterol levels (Kim et al., 2011).  
1.3.4.2!Mechanisms linking visceral adipose tissue to type 2 diabetes 
The negative metabolic effects of VAT compared with SAT has partly been attributed to 
the differences in their structural and functional properties. The cellular structure of 
adipocytes from VAT are larger than those of SAT (Schoettl et al., 2018). VAT 
adipocytes are morphologically and functionally similar to hypertrophic SAT adipocytes. 
As previously mentioned, hypertrophic SAT adipocytes become dysfunctional with 
specific detrimental metabolic characteristics which include: increased release of 
inflammatory adipokines, increased output of NEFAs and reduced insulin sensitivity; 
these characteristics have been extensively reported in studies investigating VAT and its 
role in T2D (Ibrahim, 2010, Wronska and Kmiec, 2012).  
VAT is considered to be more metabolically active compared to SAT showing greater 
vascularisation per kg (Virtanen et al., 2002) and greater lipolytic activity (Petrus et al., 
2017); this results in greater release of NEFAs into the circulation that are subsequently 
deposited as ectopic fat (Gastaldelli, 2008). An increase of VAT has also been linked with 
an increase of inflammatory markers and a greater concentration of immune cells within 
the adipocytes. Therefore, VAT has shown to have great pathogenic potential, which is 
of interest in T2D research due to its link with the promotion of ectopic fat deposition 




1.4!Ectopic fat and type 2 diabetes 
Ectopic fat refers to the deposition of triglycerides in non-adipose tissue depots including 
the liver, pancreas and muscles (Snel et al., 2012). The deposition of ectopic fat is thought 
to occur due to the reduced capacity of the subcutaneous adipocytes to expand leading to 
a dysfunction of the adipocytes (Sattar and Gill, 2014). The dysfunctional adipose tissue 
becomes unable to store excess triglycerides which, in turn, get redirected and stored as 
ectopic fat deposits; this process is summarised in Figure 1.6 (Snel et al., 2012, Brons and 
Grunnet, 2017). Along with low-grade chronic inflammation and insulin resistance, 
ectopic fat deposition is a key feature of dysfunctional adipose tissue that is closely related 
to T2D (Paniagua, 2016). 
 
Figure 1.6: Proposed theory of ectopic fat deposition. The reduced expandability of 
subcutaneous fat depots during a positive energy balance leads to a spill-over of fatty 




Ectopic fat deposits play a role in the pathophysiology of T2D as they are considered to 
interfere with the normal function of the cells and decrease the insulin sensitivity of the 
organ they reside in, a phenomenon called lipotoxicty (Unger, 2003). Ectopic fat relates 
to triglycerides stored within (intra) as well as between (inter) the cells of an organ, both 
of which are considered to contribute to organ lipotoxicity (Brookheart et al., 2009). To 
understand the mechanisms of ectopic fat induced lipotoxicity, several studies have 
examined the effects of triglycerides on various cellular functions. These studies have 
consistently shown that it is not the triglycerides themselves but the lipid intermediates 
produced during the breakdown of triglycerides, such as ceramides, fatty acyl-CoAs and 
diacylglycerol, that have toxic effects on nearby cellular functions (Daemen et al., 2018, 
Snel et al., 2012, Brons and Grunnet, 2017).  
1.4.1!Intrahepatic lipids 
1.4.1.1!The role of the liver in type 2 diabetes 
The liver plays a crucial role in maintaining normal glucose homeostasis since, depending 
on insulin signalling, the liver stores or releases glucose (Defronzo, 2009). During normal 
glucose tolerance, insulin signals to the liver to uptake glucose from the circulation and 
store it as glycogen. The liver breaks down these glycogen stores (glycogenolysis) to 
produce glucose from other sources (gluconeogenesis) and releases it into the circulation 
when blood glucose levels are low and energy is required (Defronzo, 2009). The liver 
also has an important role of maintaining normal circulating glucose levels during sleep, 
since glucose released by the liver accounts for 90% of the total glucose supply to the 
brain during sleep  (DeFronzo, 2004).  
1.4.1.2!Hepatic insulin resistance 
During the pathophysiology of T2D, the liver becomes insulin resistant resulting in the 




high, which adds to the hyperglycaemia. During early T2D, the reduced uptake of glucose 
by skeletal muscles accounts for postprandial hyperglycaemia, however, as T2D worsens, 
hepatic glucose production becomes the major contributor to elevated fasting glucose 
levels (DeFronzo et al., 1989). Individuals with impaired glucose tolerance and T2D have 
reduced hepatic insulin sensitivity during the fasting and insulin-stimulated states 
compared to normal glucose tolerant controls (DeFronzo et al., 1982). There is a strong 
correlation between whole-body insulin sensitivity and hepatic insulin sensitivity 
suggesting the mechanisms involved in insulin resistance occur simultaneously in the 
muscles and liver (DeFronzo et al., 1985). 
1.4.1.3!Hepatic insulin clearance 
In order to prevent hypoglycaemia, the liver has a crucial function of removing insulin 
from the circulation and it is estimated that approximately 80% of insulin clearance 
occurs in the liver (Kotronen et al., 2007). Hepatic insulin clearance is reduced in 
individuals with T2D (Pivovarova et al., 2013). Inverse associations have been reported 
between insulin clearance and insulin secretion during the progression of T2D since, as 
insulin secretion increases to overcome insulin resistance, insulin clearance reduces to 
maintain high circulating insulin levels (Najjar and Perdomo, 2019); this has been 
considered a protective mechanism to raise blood insulin levels and reduce the burden of 
insulin secretion on the beta-cells (Piccinini et al., 2017). 
1.4.1.4!Intrahepatic lipids in type 2 diabetes 
Ectopic fat accumulation in the liver, termed intrahepatic lipid (IHL), plays an important 
role in the pathophysiology of T2D (Bosy-Westphal et al., 2019, Geisler and Renquist, 
2017). IHL is elevated in individuals with T2D, furthermore, greater levels of non-
alcoholic liver disease (NAFLD) are reported in patients with T2D compared with BMI-




metabolic syndrome and atherosclerosis (Adams et al., 2005, Ou et al., 2013). 
Complications relating to excess liver fat are more prevalent in patients with T2D because 
NAFLD can progress to more severe conditions including non-alcoholic hepatosteatosis 
(NASH), cirrhosis and hepatocellular carcinoma (Bhatt and Smith, 2015).  
Intrahepatic lipid is believed to affect the metabolic function of the liver by causing 
lipotoxicity to the cells it resides in. IHL is associated with hepatic and peripheral insulin 
resistance (Hwang et al., 2007); this relationship is independent of BMI, VAT and overall 
adiposity. On a cellular level, IHL is associated with defects in the cellular signalling 
processes that result in the suppression of glycogenolysis by insulin in the liver (Seppala-
Lindroos et al., 2002). IHL is strongly associated with VAT independent of overall 
adiposity (Korenblat et al., 2008); however, while considering the consistent evidence 
linking VAT to increased risk of T2D, it has been suggested that IHL may be more closely 
related to T2D than VAT (Fabbrini et al., 2009).  
The importance of IHL in T2D risk has been demonstrated in a recent study by Okamura 
et al. who investigated the effect of three phenotypes, obesity (BMI >30), high VAT and 
high IHL, individually on incident T2D. The percentage incidence of T2D was presented 
in eight groups that were divided based on the presence of each phenotype shown in 
Figure 1.7 (Okamura et al., 2019). They found that the incidence of T2D was greater in 
the group that had high IHL in the absence of the other two phenotypes compared with 
the groups that had only one of the other phenotypes. This supports the notion that IHL 














One of the key theories that describes the main mechanism of IHL accumulation is the 
portal theory (Item and Konrad, 2012). This theory proposes that excess NEFAs are 
secreted by VAT directly into the portal vein, which subsequently deposit into the liver 
and, over time, accumulate as IHL. The mechanisms of the portal theory are summarised 
in Figure 1.8 (Item and Konrad, 2012). Early studies in the 1980s linked the increased 
flux of NEFAs from VAT to the liver, via the portal vein, to hepatic metabolic 
disturbances (Stromblad and Bjorntorp, 1986). Portal NEFAs have been linked to an 
increase of hepatic gluconeogenesis, a reduction of insulin clearance and the excess 
production of hepatic lipoproteins (Bjorntorp, 1990).  
 
Figure 1.7: Venn diagram showing eight groups divided based on the presence of three 
phenotypes of obesity. The incident of type 2 diabetes in each group is indicated by the 
number of participants with type 2 diabetes (percentage)/all participants in the group 






Over the past two decades, with the increased interest in IHL and its role in T2D, there 
has been increasing evidence to support the portal theory by showing that the deposition 
of IHL is directly linked to VAT (Item and Konrad, 2012, Bergman and Ader, 2000).  
Several studies have shown that IHL strongly correlates with VAT (Gastaldelli et al., 
2007, Guerrero et al., 2009, Item and Konrad, 2012, Nazare et al., 2012). The high 
lipolysis rate of VAT increases the concentration of NEFAs in the portal circulation, 
which has shown to reduce hepatic insulin sensitivity and increase hepatic 
Figure 1.8: Mechanisms of visceral adipose tissue-induced metabolic disturbances of 
the liver termed the 'portal theory'. Increased release of non-esterified fatty acids and 





gluconeogenesis. Item et al. showed hepatic insulin sensitivity decreases in response to 
an increase in NEFAs in the portal circulation; however, no differences in hepatic insulin 
sensitivity were detected in response to an increase of NEFAs in the systemic circulation 
(Item and Konrad, 2012). This provides direct evidence to support the portal theory 
showing that it is portal NEFAs that are detrimental to hepatic metabolic functions.  
1.4.2!Intrapancreatic lipids 
During increased adiposity, like the liver, excess storage of triglycerides also occurs in 
the pancreas which is termed intrapancreatic lipids (IPL). The pathological process of 
triglyceride storage in the pancreas was described in 1933 by Ogilvie who found 
markedly greater fat deposition within the pancreas of cadavers with obesity compared to 
lean controls (Ogilvie, 1933). However, it is only the past decade that there has been an 
increased interest in triglyceride storage in the pancreas due to its posited influence on 
beta-cell dysfunction (Yu and Wang, 2017). Additionally, more recent research in IPL 
has been assisted by the advancement of imaging techniques that allow the non-invasive 
measurement of IPL (Al-Mrabeh et al., 2017). 
Early studies investigating the lipotoxicity of beta-cells in rats with T2D were carried out 
by Lee et al. in 1994 (Lee et al., 1994). They showed that an increase in the accumulation 
of IPL preceded the dysfunction of beta-cells prior to the onset of T2D (Lee et al., 1994). 
Pascoe et al. showed that in-vitro exposure of beta-cells to fatty acids blocked glucose-
stimulated proliferation of the beta-cells indicating that obesity is directly damaging to 
normal beta-cell function (Pascoe et al., 2012).  
More recent studies in humans have shown links between IPL and common clinical 
metabolic parameters related to T2D (Yu and Wang, 2017). Tushuizen et al. found that 
IPL was higher in patients with T2D than age and BMI-matched controls and that IPL 




Furthermore, they also reported that IPL was associated with common measures of 
adiposity including BMI, VAT, IHL, NEFAs and triglycerides. This indicates that with 
increasing whole-body adiposity, there appears to be strong interrelations in the processes 
that drive VAT, IHL and IPL accumulation.  
1.4.2.1!Twin-cycle theory 
The twin-cycle theory describes the possible mechanism that leads to IPL accumulation 
and was first proposed by Roy Taylor in 2008 (Taylor, 2013, Taylor, 2008). This theory 
states that during a prolonged period of positive energy balance, excess glucose is 
metabolised by the liver, which metabolises it into lipids that are released in very low 
density lipoproteins (VLDL). These VLDLs are released into the circulation and are 
deposited as triglycerides in the pancreas where they have detrimental lipotoxic effects 
on the beta-cells. This results in reduced insulin secretion, which leads to an increase of 
blood glucose levels that are subsequently redirected to the liver and metabolised, hence, 
leading to a vicious twin-cycle between the liver and pancreas, which is summarised in 



























Similarly to IHL and IPL, elevated triglycerides stored within the muscle cells, known as 
intramyocellular lipids (IMCL), are also linked with T2D. Increased IMCL levels were 
first linked to insulin resistance in 1980 when Standl et al. used muscle biopsies to 
quantify IMCL depots in individuals with T2D and healthy controls (Standl et al., 1980).  
In a healthy state, the skeletal muscle accounts for approximately 90% of insulin-
mediated glucose disposal (DeFronzo et al., 1985). Insulin resistance of the muscles is 
the major contributor to whole-body insulin resistance during the development of T2D.  
IMCL has been shown to interfere with cellular pathways of glucose uptake in the muscle 
cells thus reducing their insulin sensitivity (Bjornholm and Zierath, 2005).  Several 
Figure 1.9: Twin-cycle theory of pancreatic and hepatic lipotoxicity. Pancreatic fat 
storage is driven by the release of lipids from the liver during a positive energy balance 




studies have confirmed a direct association between IMCL accumulation and insulin 
resistance indicating that IMCL may play a role in reducing muscle insulin sensitivity 
(Ingram et al., 2011, Krssak et al., 1999, Sinha et al., 2002, Thamer et al., 2003).  
1.5!Magnetic resonance imaging for the assessment of fat deposition 
Several techniques have been developed for the assessment of total and regional adipose 
tissue in the body which include skinfold measurement, underwater weighing, air 
displacement, bioelectrical impedance, CT, DEXA and magnetic resonance imaging 
(MRI) (Thomas et al., 2013). Technological advancements that led to the development of 
MRI and CT scanning have allowed the in-depth assessment of individual body 
composition components including fat deposition (Borga et al., 2018). These techniques 
overcome more traditional methods as they are non-invasive, relatively fast to perform 
and provide a direct accurate measure of various body composition components (Thomas 
et al., 2013).  
To understand the metabolic implications of excess adiposity, several body composition 
studies have focused on the regional distribution of fat in the human body including SAT, 
VAT and ectopic fat stores (Wang et al., 2014). Currently, MRI remains the most accurate 
non-invasive technique for quantifying fat depots in the human body, and has been 
validated against invasive methods in human and animal cadavers (Abate et al., 1994, 
Fowler et al., 1992). MRI is superior to CT as it provides high resolution images that are 
more detailed, particularly with respect to soft tissue organs, compared to images obtained 
by CT (Hu, 2012). Furthermore, MRI does not subject individuals to ionising radiation 
and can therefore, be used in children and during pregnancy. 
1.5.1.1!Magnetic resonance imaging for the assessment of ectopic fat 
The use of MRI to assess ectopic fat has been crucial in advancing the current 




Wang, 2017). Until the advent of MRI, the assessment of ectopic fat relied on the ability 
to obtain tissue biopsies, which had considerable limitations and was clearly impossible 
for tissues such as the heart and pancreas (Thomas et al., 2013).  
MRI is particularly useful for assessing adipose tissue due to its unique ability to 
differentiate between fat and non-fat tissues; this separation relies on the natural chemical 
shift differences between the water molecules within fat and non-fat tissues in the human 
body (Springer et al., 2010, Proctor and Yu, 1950). By using certain MRI sequences such 
as the “DIXON” sequence, fat-only and water-only images can be produced, which allow 
clear visual separation between fat tissues and other tissues (Dixon, 1984, Karstaedt et 
al., 1983). Therefore, MRI images can be used to quantify regional and ectopic fat depots 
including SAT, VAT, IHL and IPL. Figure 1.10 shows two fat-only abdominal MRI 
images of an individual with a healthy BMI (A) and an obese BMI (B); the greater SAT 




Figure 1.10: Fat-only axial MRI images of the abdomen. DIXON-MRI sequences allow 
the acquisition of fat-only images which allows visual comparison of a lean individual 
with low intrahepatic lipid and subcutaneous fat (A) with an obese individual with high 




1.5.1.2!Magnetic resonance spectroscopy for the assessment of 
intramyocellular lipids 
The development of magnetic resonance spectroscopy (MRS) is closely related to that of 
MRI as both use the fundamental principles of nuclear magnetic resonance (NMR) to 
differentiate between molecules. Proton-MRS (1H-MRS) uses these principles to produce 
spectra while MRI produces images (Tognarelli et al., 2015). Figure 1.11 shows the 
underlying principles of NMR used in MRI and MRS to differentiate between different 
molecules in vivo (Hwang and Choi, 2015).  
 
 
Figure 1.11: Principles of nuclear magnetic resonance. Magnetic resonance 
spectrometer (a). Random orientation of molecules outside of a magnetic field (b), 
however, under a magnetic field molecules become aligned (c). a longitudinal 
magnetization is generated parallel to the magnetic field by the radiofrequency (RF) 
coil (d) causing molecules to undergo precession and emit energy which is detected by 




Hydrogen atoms are present in huge abundance in all tissues of the human body. The 
protons within the nuclei of hydrogen atoms have an electrical charge and a natural spin, 
so there is a tiny magnetic field associated with each spin. Each proton has a natural 
orientation depending on the chemical structure and polarisation of the molecules within 
its local environment. When a strong magnetic field is applied, such as that within an 
MRI scanner, all the protons tend to align with the direction of the external magnetic 
field, thereby creating a net magnetisation that is in the same direction as the external 
magnetic field. This is described as the longitudinal magnetisation. When the protons 
align with the longitudinal magnetization, they precess at a frequency determined by the 
Larmor equation (Rigden, 1986). In order to measure this magnetisation, a second 
magnetic field is applied orthogonal to the longitudinal magnetisation at the Larmor 
frequency, which is at radio frequencies (RF); this induces a current in the coil. The 
successive pulsing of magnetisation causes the molecules to resonate due to their 
continuous transition between being completely aligned to returning to their natural 
alignment. This continuous precession releases energy, which differs from one molecule 
to another, and is detected by the receiver and converted into a spectra. The resulting 
spectra is composed of separate peaks which represent different components of molecules 
that are separated due to a chemical shift in their energy while under a magnetic field 
(Boesch et al., 1997). 
Proton-magnetic resonance spectroscopy is a valuable tool for quantifying skeletal 
muscle lipids because it is non-invasive and allows the differentiation between lipid 
molecules deposited between myocytes, called extramyocellular lipids (EMCL), and 
lipids stored within myocytes, IMCL (Schick et al., 1993, Boesch et al., 2006). EMCL is 
considered to be metabolically relatively inert, whereas, IMCL has been linked with 




1.6!Type 2 diabetes in populations of black ethnicity 
As previously mentioned, populations of African ancestry suffer disproportionately from 
T2D. In South London, black ethnic groups make up about 20% of the population, 
however, they make up 40% of T2D patients registered at diabetes clinics in the local 
boroughs (Winkley et al., 2013). Furthermore, it is estimated that black populations 
develop T2D at a younger age, up to 10 years earlier, and at lower BMIs than white 
populations (Goff, 2019). Black populations bear a disproportionate burden of the 
morbidity and mortality associated with T2D, with higher rates of retinopathy, 
microalbuminuria, kidney failure, lower extremity amputation and mortality due to T2D 
compared white populations (Marshall, 2005, Harris et al., 1998b, Young et al., 2003). 
The high rates of diabetes complications in black patients with T2D has been attributed 
to poorer glycaemic control with common treatments of T2D being less effective in black 
populations (Marshall, 2005). 
Some studies have attributed the greater prevalence of T2D in black populations to the 
greater prevalence of obesity and a tendency for lower socioeconomic status (Carter et 
al., 1996, Signorello et al., 2007). However, when obesity, socioeconomic status, and 
behavioural factors are adjusted for in statistical models, the greater prevalence of T2D 
persists in black groups compared to white groups; this indicates that not only 
environmental factors but genetic factors are also responsible for the ethnic disparities in 
T2D risk (Bonham and Brock, 1985, O'Brien et al., 1989, McWilliams et al., 2009). This 
notion is supported in a study by Cheng et al. who performed a genetic admixture analysis 
using over 2000 ancestry-informative markers on a large cohort of 7021 African 
Americans (Cheng et al., 2012). They showed that a greater percentage of African 
ancestry was associated with T2D even after adjustments for BMI and socioeconomic 




genetic factors for T2D in African Americans. Hence, not only environmental but 
biological factors are also related to the increased risk of T2D in black populations. 
 
 
1.6.1!Pathophysiology of type 2 diabetes in black populations 
Due to the greater burden of T2D in black populations, research of potential ethnic 
differences in the pathophysiology of T2D between black and white groups has become 
an area of increasing interest. It has become well established that there are several 
metabolic features that are related to T2D that differ between black and white populations 
which include: insulin sensitivity, insulin secretion, insulin clearance, ectopic fat 
deposition, adipose tissue function and lipid metabolism (Goedecke et al., 2017, Alderete 
et al., 2014, Goran, 2008, Bergman et al., 2019). 
Figure 1.12: Relationships between African ancestry and T2D. In a study of over 
2000 African American individuals, a greater percentage of African ancestry was 




1.6.1.1!Insulin sensitivity and insulin secretion in black populations 
Increased insulin resistance and reduced insulin secretory function are two key features 
of T2D regardless of ethnicity, however, black populations generally have lower insulin 
sensitivity and greater insulin secretion compared to their white counterparts (Alderete et 
al., 2014, Goedecke et al., 2017, Hasson et al., 2015). Data from the Insulin Resistance 
Atherosclerosis Study (IRAS), showed that black populations have greater insulin 
resistance and insulin secretion compared to white populations (Haffner et al., 1996). 
Several other studies have also reported lower insulin sensitivity in black groups 
compared to their white counterparts (Uwaifo et al., 2002b, Uwaifo et al., 2002a, Tillin 
et al., 2006).  
Several studies have shown increased insulin secretion in black populations compared to 
white populations (Hughan et al., 2013, Osei and Schuster, 1994). This was also 
demonstrated in a systematic review and meta-analysis conducted by Kodama et al. who 
investigated ethnic differences in relationships between insulin sensitivity and insulin 
response (Kodama et al., 2013). As presented in Figure 1.13, the results showed that even 
though there was a moderate overlap between the study outcomes from populations of 
Caucasian and African ethnicity, the African groups tended to have lower insulin 







The increased insulin secretory function in black populations has been suggested to be a 
compensatory mechanism for the reduced insulin sensitivity compared to whites. 
However, Hannon et al. showed, when matched for insulin sensitivity, African American 
adolescents exhibited greater first-phase insulin secretion compared to white adolescents, 
Figure 1.14 (Hannon et al., 2008). Therefore, there is much evidence showing that there 
are ethnic differences in insulin sensitivity and insulin secretion between black and white 
populations which appears to be present from as early as childhood. However, the reasons 
behind these differences are yet to be fully understood. 
 
 
Figure 1.13: Relationships between insulin sensitivity and insulin response. Each 
circle represents a study population with the size of the study population proportional 





1.6.1.2!Insulin clearance in black populations 
Early studies from the 1990s, investigating insulin secretion in black populations showed 
that, although insulin levels were higher in black populations compared to whites, the 
levels of c-peptide were no different (Osei and Schuster, 1994, Cruickshank et al., 1991). 
This suggested that there were ethnic differences in insulin clearance. Since then, several 
studies have confirmed that insulin clearance is lower in black populations since the ratio 
of c-peptide to insulin is consistently reported to be lower in blacks during the fasting and 
glucose-stimulated states (Harris et al., 2002, Bergman et al., 2019).  
Studies have shown that hepatic insulin clearance correlates with insulin secretion as well 
as insulin sensitivity (Pivovarova et al., 2013). Therefore, prior to frank T2D, with the 
long-term progression of insulin resistance there is an increase of insulin secretion as well 
as a reduction of insulin clearance; both are considered to be mechanisms to prolong 
higher levels of insulin in the circulation in order to overcome insulin resistance. While 
the lower levels of insulin clearance may be a protective mechanism to preserve beta-cell 
insulin secretory function in black populations, it may be another sign of increased insulin 
resistance in this ethnic group (Piccinini et al., 2017, Piccinini et al., 2018). 
Figure 1.14: Insulin sensitivity (A) and insulin secretion (B) in African American (AA) 




1.6.1.3!Lipid metabolism in black populations 
Clinically unfavourable blood lipid profiles, characterised by high circulating 
triglycerides and LDL-cholesterol, and low HDL-cholesterol, are key features related to 
T2D (Reaven, 2006). It has been well documented that patients with T2D have high 
circulating lipids and low HDL-cholesterol levels; this is an indication of ineffective 
storage of excess energy in safe adipose tissue compartments as well as an over-
production of cholesterol by the liver due to a positive energy balance (Chung and Parks, 
2016).  
Despite their greater risk for T2D, black populations consistently exhibit more favourable 
lipids profiles than white populations, indicated by lower circulating triglycerides, LDL- 
and VLDL-cholesterol levels, as well as higher HDL-cholesterol levels (Bentley and 
Rotimi, 2017, D'Adamo et al., 2010, Miljkovic-Gacic et al., 2006). The ratio of 
triglycerides to HDL is considered a sensitive marker for T2D risk, however, it has 
consistently been found to be lower in black populations (Yu et al., 2012). Furthermore, 
triglyceride to HDL ratio did not correlate with measures of insulin resistance in blacks 
as it did in whites (Sumner, 2009, Sumner et al., 2005). Therefore, it has been suggested 
that common clinical lipid markers are not sensitive at detecting T2D risk in black 
populations (Sumner, 2009, Giannini et al., 2011). Overall, this evidence suggests that 
lipid metabolism differs between black and white populations and may impact the 
development of T2D differently in these two ethnic groups. 
1.6.1.4!Obesity in black populations 
Given the greater risk of T2D in black populations, it is expected that they would exhibit 
greater levels of obesity. Indeed, several studies conducted in the US have highlighted a 
greater prevalence of obesity in African Americans compared to white Americans 




circumference and DEXA scans have confirmed a greater level of obesity in African 
Americans observed in children, adolescents and adults (Cossrow and Falkner, 2004, 
Maligie et al., 2012, Gower et al., 1998). However, in the UK, ethnic differences in 
obesity between black and white groups is less straightforward with distinct gender 
differences present. As shown in Figure 1.15, black African and black Caribbean women 
have a greater level of obesity compared to the general female population in the UK 
(Gatineau, 2011). However, black African and black Caribbean men, unexpectedly, show 
slightly lower levels of obesity compared to the general male population, which is 
particularly evident in the black African men (Gatineau, 2011). Therefore, the greater 
levels of obesity among black women may partially explain their greater risk of T2D; 
however, the same cannot be said for black men, which suggests gender differences may 


























1.6.1.5!Body-fat distribution in black populations 
As mentioned previously, black populations have a greater prevalence of T2D compared 
to white populations, however, investigating this further Zhang et al. reported the 
Figure 1.15: Prevalence of obesity in black ethnic groups in the UK in 
comparison to the general population. Created from data extracted from the 




prevalence of T2D by ethnicity and by level of obesity using a large cohort from the 
National Health and Nutrition Examination Survey (NHANES) (Zhang et al., 2009). He 
found that, in the normal weight category, the prevalence of T2D was 5% in blacks which 
was three times greater than in whites who had a 1.5% prevalence. However, this disparity 
decreased greatly as BMI increased; in fact, in the over 35 BMI category, the prevalence 
of T2D was only slightly greater in blacks (20%) compared to whites (18%). This 
suggests that the influence of obesity in the pathophysiology of T2D may differ by 
ethnicity and obesity may not be such a strong determinant in black populations. 
1.7!Ectopic fat deposition in black populations 
Despite the greater prevalence of T2D in black populations, they typically have lower 
levels of ectopic fat compared to white populations, which creates a paradox unique to 
black ethnic groups (Goran, 2008, Guerrero et al., 2009, Goedecke et al., 2017). It is well 
established that, similar to black populations, the prevalence of T2D is also greater in 
South Asian, Native American and Hispanic populations compared to white populations 
(Alderete et al., 2014). Extensive research has also been carried out in the above ethnic 
groups in an attempt to investigate the reasons for their greater prevalence of T2D. Studies 
comparing ectopic fat between each individual ethnic group (South Asian, Native 
American and Hispanic) and white populations have shown a common report: a greater 
level of ectopic fat in these ethnic groups compared to white populations (Alderete et al., 
2014, Chandalia et al., 2007, Sniderman et al., 2007). The greater level of ectopic fat in 
these ethnic minority populations has been used to explain their greater prevalence of 
T2D as they appear to have a greater susceptibility to store ectopic fat at lower levels of 
BMI compared to white populations. However, such cannot be said for black populations 
who consistently exhibit lower levels of ectopic fat (Alderete et al., 2014); this is 




While some researchers have suggested that black populations may be more sensitive to 
the lipotoxic effects of ectopic fat others suggest that ectopic fat may play a lesser role in 
the development of T2D in black populations (Ingram et al., 2011, Alderete et al., 2013). 
These speculations are yet to be clarified, therefore, the study of ectopic fat and its role 
in the development of T2D in black populations continues to be an area of increasing 
interest.  
1.7.1!Visceral adipose tissue in black populations 
Visceral adipose tissue has consistently been shown to be lower in black populations 
compared to white populations (Alderete et al., 2014, Goedecke et al., 2017). In 1995, 
Conway et al. were the first to directly quantify VAT area using CT scanning, which they 
used to conduct an ethnic comparison of VAT between black and white women (Conway 
et al., 1995). Contrary to their expectations, they found that the black women had 
significantly lower VAT compared to the white women. Their findings were further 
confirmed by Lovejoy et al. who reported lower VAT in black women compared to BMI 
and waist-to-hip ratio matched white women; furthermore they found VAT was 
associated with waist-to-hip ratio in white women but not black women (Lovejoy et al., 
1996). The lower levels of VAT in black populations have since been confirmed from 
more recent studies using larger cohorts in both men and women as well as youths 
(Alderete et al., 2014, Ronn et al., 2017). Furthermore, with an increase of whole body 
adiposity there is a lesser increase in VAT in black populations compared to white 
populations. This was demonstrated by Despres et al. who showed that VAT increased to 
a greater extent with increasing body fat in whites compared to blacks as shown in Figure 


































Figure 1.16: Relationships between fat mass and subcutaneous and visceral adiposity 
in white (white circles) and black (black circles) populations. In both men (A and C) 
and women (B and D), with an increase in whole-body adiposity there were similar 
increases in subcutaneous fat in all groups but lower increases in visceral fat in the 




1.7.2!Visceral and subcutaneous adipose tissue in black populations 
While black populations have lower VAT levels in comparison to white populations they 
have higher levels of SAT deposition (Goran et al., 1997, Staiano et al., 2013, Katzmarzyk 
et al., 2010). Considering ethnicity and glycaemic state, Gallagher et al. showed VAT 
was greater, while SAT was lower, in the groups with T2D compared to controls in both 
white and black adults (Gallagher et al., 2009). Not only was VAT lower in the blacks 
compared to the whites, this ethnic difference was present between the healthy and T2D 
groups, shown in Figure 1.17. However, this was not the case for SAT which was 
significantly greater in the black groups than the white groups at both glycaemic states. 
This suggests that during the progression of T2D, as whole body adiposity increases, there 
is a disproportionate increase of VAT in white compared to black individuals. 
Furthermore, black ethnic groups appear to store excess fat more efficiently in the 
metabolically safer SAT depot compared to white populations. Therefore, this adds to the 
paradox that, while black populations exhibit several features of favourable adipose tissue 



















1.7.3!Deep and superficial subcutaneous adipose tissue in black 
populations 
While VAT and SAT deposition have been extensively studied in black populations, 
dSAT and sSAT are only recently gaining attention. Current investigations of dSAT and 
sSAT in black populations have shown inconsistent conclusions which may be explained 
by glycaemic state, level of obesity or gender of the population studied. Liska et al. 
showed no ethnic differences in dSAT between white and black adolescents, however, 
Figure 1.17: Prediction models for relationships between total adipose tissue and 
subcutaneous fat (A) and visceral fat (B). Type 2 diabetes (solid lines: , African 
Americans; , whites) and control (dashed lines: ▪, African Americans; ○, whites 




sSAT was higher in the black group (Liska et al., 2007). Similar findings were reported 
in women by Goedecke et al. (Goedecke et al., 2009) and Lovejoy et al. (Lovejoy et al., 
2001).  
In a large cohort study, Nazare et al. found no ethnic differences in dSAT and sSAT 
between white and black men; however, differing results were reported in the women 
where dSAT was lower in the black women compared to the white women, with no ethnic 
differences in sSAT (Nazare et al., 2012). In contrast, Evans et al. found no ethnic 
differences in dSAT and sSAT between black and white women (Evans et al., 2011). 
Therefore, ethnic differences in dSAT and sSAT appear to be influenced by gender and 
may impact the pathophysiology of T2D differently by ethnicity. 
1.7.4!Intrahepatic lipids in black populations 
Similar to VAT in black populations, it is widely reported that blacks have lower IHL 
deposition compared to their white counterparts (Goedecke et al., 2015, Schwimmer et 
al., 2005, Szczepaniak et al., 2012). Goedecke et al. found IHL was lower in black women 
compared to their white counterparts (Goedecke et al., 2015). Similar findings were 
reported by Naran et al. who also reported a negative association between IHL and SAT, 
indicating that an increase of SAT may act as a protective reservoir for excess 
triglycerides in blacks (Naran et al., 2018). Guerrero et al. reported that with increasing 
total adiposity, IHL increases to a lesser degree in blacks compared to whites (Guerrero 
et al., 2009).  
Ethnic differences in NAFLD have also been commonly reported with lower prevalence 
rates being reported in black populations compared to white populations (Pan and Fallon, 
2014). In a large cohort study, the prevalence of hepatic steatosis was significantly lower 




There is increasing evidence supporting the detrimental role of IHL in the development 
of T2D with some studies showing a greater link between IHL and T2D than VAT 
(Alderete et al., 2013, Lee et al., 2012). Considering this, it is highly paradoxical that 
black populations typically have low levels of IHL. Adding to this paradox, Liska et al. 
found not only was IHL lower in black compared to white adolescents, but in some black 
subjects, IHL deposition was undetectable despite the presence of obesity (Liska et al., 
2007). Figure 1.18 shows the protective circulating lipids and ectopic fat characteristics 
that are typically found in black individuals, which, hypothetically, should result in lower 
T2D risk (D'Adamo et al., 2010). Therefore, there is a lack of clarity in the role of IHL in 




Figure 1.18: Hypothetical origin of cardiometabolic risk profiles of white and African 




1.7.5!Intrapancreatic lipids in black populations 
Unlike VAT and IHL, far fewer studies have investigated IPL in black populations. To 
date, only 5 studies have conducted ethnic comparisons of IPL between black and 
white/Hispanic groups. 
Two of the studies of IPL in black populations compared IPL between African American 
and Hispanic adolescents. Le et al. showed that IPL was significantly lower in African 
American adolescents compared to their Hispanic counterparts (Le et al., 2011). In a study 
on adolescents with prediabetes, Toledo-Corral et al. showed that IHL predicts 
prediabetes status in Hispanics but not African Americans, however, IPL predicted 
prediabetes status in African Americans but not Hispanics (Toledo-Corral et al., 2013); 
this suggests there are ethnic differences in the role of IPL in the development of T2D 
between African American and Hispanic youths.  
Studies of IPL in black adults showed a lower IPL in black women compared to 
white/Hispanic women with a linear relationship reported between IPL and disposition 
index in the black women but not white women (Lingvay I, 2014). Similar to previous 
findings, Szczepaniak et al. showed IPL was lower in black adults compared to white 
adults with positive associations between IPL and disposition index in both ethnic groups 
(Szczepaniak et al., 2012). To date, no ethnic comparison studies of IPL have been 
conducted in black versus white men. Hence, while studies of IPL have been few, they 
suggest that IPL may be more dominant in the development of T2D in comparison to IHL 
in black populations. 
1.7.6!Intramyocellular lipids in black populations 
Similarly to IPL, few studies have investigated IMCL in black populations. To current 
knowledge, all studies that investigated ethnic differences in IMCL deposition between 




Goedecke et al., 2017). Liska et al. showed no ethnic differences in IMCL between white 
and black adolescents with obesity (Liska et al., 2007). While, in a large cohort study, 
Maligie et al. showed IMCL was higher in blacks compared to whites, however, this 
difference diminished after adjustment for confounding factors including BMI (Maligie 
et al., 2012).  
Some studies have suggested that, rather than the amount of IMCL, it may be its 
relationship with insulin sensitivity that may be more crucial in unfolding its influence in 
T2D. Considering this, Lawrence et al. showed even though there were no ethnic 
differences in IMCL, it was inversely associated with insulin sensitivity in whites but not 
blacks, indicating that IMCL may be a significant determinant of insulin sensitivity in 
white but not black populations (Lawrence et al., 2011). Similar findings were reported 
by Ingram et al. who showed no ethnic difference in IMCL between white and black 
adults; but IMCL inversely correlated with insulin sensitivity in white but not black adults 
with a significant interaction by ethnicity (Ingram et al., 2011). Like IPL, to date, no 
ethnic comparison studies of IMCL have been conducted in black versus white men. 
1.7.7!Limitations to current knowledge of type 2 diabetes in black 
populations 
Of note, most ethnicity studies, which focus on the role of ectopic fat on the 
pathophysiology of T2D, have been mainly limited to youths, women and African 
American populations with very few investigating men. Studies of T2D in youth focus 
mainly on severe cases of obesity which induces insulin resistance, thought to be 
mediated primarily from severe lipotoxicity. However, most cases of T2D occur in 
middle-aged populations where the pathophysiology is more complex with a combination 
of insulin resistance and beta-cell dysfunction as well as many other factors which differ 




adolescents, conducted mainly in African American populations, an understanding of 
T2D in black adults is highly warranted. 
1.7.8!Sex differences in type 2 diabetes in black populations 
Studies have shown that the development of T2D differs between men and women even 
in black populations (Høeg et al., 2011). Findings by Goedecke et al. support this, which 
show that insulin sensitivity is lower while insulin secretion is greater in black women 
compared to black men even after adjustments for measures of body fat (Goedecke et al., 
2016). Furthermore, it is widely accepted that the distribution of body fat differs between 
men and women, particularly in ectopic fat deposition as women have consistently been 
shown to have lower VAT and IHL (Schorr et al., 2018, Gillen et al., 2018, Nissen et al., 
2016, Despres et al., 2000). Women have a greater capacity to store fat safely in the SAT 
depot while men have consistently been shown to have greater VAT as well as ectopic 
fat deposition compared to women (Karastergiou et al., 2012, Blaak, 2001). Figure 1.19 
summarises gender differences in parameters that are related to T2D and shows the vast 
and complex differences that must be appreciated when considering the pathophysiology 
of T2D between men and women (Kautzky-Willer et al., 2016). 
Studies specifically investigating black women have shown they exhibit lower levels of 
ectopic fat; however, despite this, there is much evidence to suggest that the severe 
expansion of SAT may be the key driver of T2D in black women compared to white 
women (Goedecke et al., 2013, Goedecke et al., 2017). Additionally, while SAT was a 
more sensitive predictor of metabolic health in black women, VAT was the more sensitive 
predictor in the white women (Goedecke et al., 2013). However, there is a lack of 
evidence to suggest that this is the case in black men due to few studies being conducted 










Figure 1.19: General sex differences in T2D risk and related characteristics. Blue arrows 
indicate differences compared to women and red arrows indicate differences compared 





Ectopic fat deposition is one of the key factors contributing to the development of T2D 
and explains the well-known link between obesity and T2D. Advancements in MRI 
technologies have allowed the accurate quantification of regional body fat distribution 
and the detailed analysis of ectopic fat depots. It has since been established that ectopic 
fat is detrimental to the function of the organ it resides in and causes insulin resistance 
when deposited in the liver and muscles, and disturbs insulin secretion in the pancreas. 
Even though black populations have a greater prevalence of T2D than white populations, 
they typically exhibit lower levels of ectopic fat which creates a paradox unique to black 
ethnic groups. Investigations of relationships between ectopic fat depots and metabolic 
parameters of T2D in black vs white populations have produced inconsistent conclusions. 
While some studies suggest that black populations may be more sensitive to ectopic fat 
storage and experience their detrimental effects at lower levels others suggest that ectopic 
fat may play a lesser role in T2D in black populations compared to their white 
counterparts. Furthermore, there are some suggestions that the pathophysiology of T2D 
may differ between black and white populations, which has mainly been investigated in 
youths and women, and in studies mostly conducted in the US, with a lack of 
investigations conducted in black men. Clinically, black populations are less responsive 
to common treatments of T2D which leads to greater T2D-related complications 
compared to white populations. This is partly attributed to the limited understanding of 
the pathophysiology of T2D in populations of African ancestry, including the role of 
ectopic fat. Understanding the role of ectopic fat in the development of T2D in black 
populations may assist in informing ethnically-tailored treatment and prevention 





It is hypothesised that black west African men will have lower ectopic fat deposition 
compared to white European men at normal glucose tolerance, impaired glucose tolerance 
and type 2 diabetes glycaemic states. Furthermore, there will be stronger relationships 
between individual ectopic fat depots and the relevant metabolic parameters of type 2 
diabetes in the black west African men compared to the white European men. 
1.10!Aims 
The primary aim of this thesis is to assess and compare ectopic fat depots between black 
west African (BWA) and white European (WE) men through the progressive stages of 
type 2 diabetes by comparing three glycaemic states: normal glucose tolerance (NGT), 
impaired glucose tolerance (IGT) and type 2 diabetes (T2D). The secondary aim is to 
investigate relationships between individual ectopic fat depots of interest with the 
relevant metabolic parameters of T2D in each ethnic group at each glycaemic state. 
Within each objective a comparison will be undertaken between the BWA and WE ethnic 
groups as well as between the NGT, IGT and T2D groups. 
Primary objectives - to investigate ethnic differences in: 
1.! Regional abdominal adipose tissue including visceral adipose tissue, abdominal 
subcutaneous adipose tissue (SAT), deep SAT and superficial SAT (Chapter 3) 
2.! Intrahepatic lipid and its relationships with hepatic insulin sensitivity and insulin 
clearance (Chapter 4) 
3.! Intrapancreatic lipid and its relationship with beta-cell insulin secretory function 
(Chapter 5) 





2.1!Overview of the South London Diabetes and Ethnicity Phenotyping 
study 
The work reported in this thesis was conducted as part of the South London Diabetes and 
Ethnicity Phenotyping (Soul-Deep) study, which is an observational study investigating 
ethnic differences in the pathophysiology of T2D between men of BWA and WE 
ethnicity. Within each ethnic group, three glycaemic states are assessed: NGT, IGT and 
T2D; the sample sizes of each are shown in Table 2.1. The Soul-Deep study assessed the 
following parameters: beta-cell insulin secretory function (ISF), insulin sensitivity 
(whole-body, skeletal muscle, hepatic and adipose tissue), regional fat distribution (SAT, 
dSAT, sSAT and VAT) and ectopic fat accumulation (IHL, IPL and IMCL). This thesis 
focuses primarily on the ectopic fat data and the relationships between ectopic fat depots 
and the metabolic parameters that were measured.  
Table 2.1: Sample size of each comparison group of the Soul-Deep study. 
 NGT IGT T2D 
WE 23 10 18 
BWA 20 10 20 
 
Soul-Deep was conducted between April 2013 and April 2019. The study was reviewed 
and approved by the London Bridge National Research Ethics Committee (references: 
15/LO/1121 and 12/LO/1859). Prior to participation, all participants provided written, 
informed consent. The metabolic assessments were carried out at the Clinical Research 
Facility at King’s College Hospital and the MRI visit was conducted at Guy’s hospital, 





Soul-Deep participants were recruited by advertisements in local newspapers, general 
practices, Facebook as well as leaflet distribution in the South London boroughs of 
Lambeth, Southwark, Lewisham and Bromley. The participants with T2D were recruited 
mainly from the database of the South London Diabetes (Soul-D) study, which included 
individuals with a recent diagnosis of T2D that gave consent to be contacted for future 
studies (Winkley et al., 2013). Individuals that showed interest in taking part were invited 
for a screening assessment at the clinical research facility at King’s College Hospital. The 
screening assessments and metabolic visits for the NGT and IGT participants were carried 
out by Toyosi Bello, Dr Meera Ladwa and Dr Chinmay Marathe while, for the 
participants with T2D, they were carried out by Dr Cynthia Mohandas. All MRI and 1H-
MRS assessments were carried out by research radiographers at Guy’s Hospital 
Radiology Department and supervised by Dr Geoff Charles-Edwards. Figure 2.1 shows 
a schematic of the study design and study visits. 
2.2.1!Screening assessments 
Potential participants underwent a screening assessment to assess eligibility. Participants 
completed a screening health questionnaire to report age, self-declared ethnicity of self, 
parents and grandparents, date of diabetes diagnosis if applicable, medical history, current 
medication and contraindications for MRI. A fasting blood test measured full blood count, 
renal and liver function, HbA1c, lipid profile, sickle cell trait and auto-antibodies (anti-
insulin, anti-GAD and anti-A2). Anthropometric measurements were taken and included 
height, weight, waist circumference (measured at the midpoint between the lowest rib and 
the iliac crest) and seated blood pressure measured using an automated 











2.2.2!Oral glucose tolerance test 
The NGT and IGT participants underwent a 75g oral glucose tolerance test (OGTT) 
carried out according to standard procedures outlined by WHO to determine their glucose 
tolerance (WHO, 2003). Prior to the OGTT, participants were instructed to consume at 
least 50g of carbohydrates during their meal on the evening before the OGTT and to 
attend the visit after an overnight fast (10 hours). A cannula was inserted in the antecubital 
fossa vein for blood sampling then a 75g oral glucose load was consumed. Plasma glucose 
was assessed at fasting (-10 and 0 minutes) and at 120 minutes. The participants with 
T2D were not required to have an OGTT; glycaemic state was identified by a documented 
diagnosis of T2D.  
2.2.3!Inclusion and exclusion criteria 
The following inclusion criteria were applied to assess eligibility: NGT participants were 
eligible to take part if they were 1) male, 2) 18-65 years old, 3) had a BMI of 20-40 kg/m2, 
4) were of WE or BWA ethnicity (identified through self-reported birthplace of self, 
parents and grandparents), 5) had a HbA1c level <47.5 mmol/mol (6.5%), 6) had normal 
glucose tolerance determined by a 2-hour plasma glucose <7.8 mmol/l during a 75g 
OGTT. IGT participants were eligible to take part if they were 1) male, 2) 18-65 years 
old, 3) had a BMI of 20-40 kg/m2, 4) were of WE or BWA ethnicity (identified through 
self-reported birthplace of self, parents and grandparents), 5) had a positive family history 
of T2D determined by a first degree relative with T2D, 6) had a HbA1c level ≥38.8 
mmol/mol (5.7%) if WE or ≥41.0 mmol/mol (5.9%) if BWA , 7) had impaired glucose 
tolerance determined by a 2-hour plasma glucose >7.8 <11.1 mmol/l during a 75g OGTT. 
Participants with T2D were eligible to take part if they were 1) male, 2) 18-65 years old, 
3) had a BMI of 25-40 kg/m2, 4) were of WE or BWA ethnicity (identified through self-





diabetes (less than 5 years prior to the study), 6) had a HbA1c level of ≤63.9 mmol/mol 
(8%), and 7) treated with lifestyle and/or metformin only. 
Participants were excluded from the study if they had contraindications for MRI (such as 
metal implants or claustrophobia), were receiving treatment with thiazolidinedione, 
insulin, oral steroids, beta-blockers or any other medication that could affect the study 
outcomes. Participants were also excluded if they showed evidence of liver or kidney 
damage, determined from a serum alanine aminotransferase (ALT) level of 2.5-fold 
above upper limit of the reference range or serum creatinine level above 150 mmol/l, 
respectively, or tested positive to anti-insulin, anti-GAD or anti-A2 auto-antibodies or 
had sickle cell disease. 
2.3!Study design and procedures 
After confirmation of eligibility, participants attended four assessment visits (Figure 2.1), 
which included a MRI and 1H-MRS scan, a hyperglycaemic clamp and a 
hyperinsulinaemic-euglycaemic clamp. Prior to the visits, participants were instructed to 
refrain from 1) strenuous exercise and physical activity for 48-hours, 2) alcohol 
consumption for 24-hours, and 3) food and drink after 22:00 on the evening before. 
Participants with T2D on metformin therapy were instructed to cease taking it for 7-days 
prior to each visit. On the day prior to the three metabolic assessment visits, participants 
were instructed to consume a standardized diet which aimed to provide approximately 
50% of calories from carbohydrates, 30-35% from fat and 15-20% from protein, spread 
evenly throughout the day to ensure no more than 30% of the daily carbohydrates were 
consumed in the evening meal. Assessments were completed in random order within a 






2.3.1!Magnetic resonance imaging scan 
Participants underwent a MRI scan for the assessment of VAT, SAT, dSAT, sSAT, IHL 
and IPL. The MRI and 1H-MRS scan (detailed below) were conducted on a single visit 
between 7:30am and 8:30am at the Clinical Imaging Department at Guy’s Hospital, 
London. Participants first completed an MRI health safety screening form and changed 
into a hospital gown to ensure no metal objects were on the subjects clothing. Each 
participant was scanned, using a 2-point Dixon-based MRI sequence on a 1.5 Tesla 
Siemens Aera scanner, from the neck to the knee (excluding the arms) while lying in the 
supine position with surface coils placed around the scanned body area. Participants were 
instructed by the radiographer to hold their breath for three bouts of 15 seconds while 
abdominal images were acquired to reduce motion artefacts. Each MRI scan produced 
320 contiguous, axial, T1-weighted transverse spin-echo images (repetition time: 6.77ms; 
echo time: 4.77ms (in-phase), 2.39ms (out-of-phase), flip angle: 10°) each with a slice 
thickness of 3mm. The combination of in-phase and out-of-phase images allowed the 
acquisition of water-only and fat-only MRI images. All MRI data were analysed using 
the open source image analysis software HOROS V 1.1.7 (www.horosproject.org; 
accessed 21/10/2017) detailed below. 
2.3.1.1!Analysis of regional abdominal adipose tissue 
Areas of VAT, ASAT, dSAT and sSAT were determined at the L4-5 anatomical position 
from a single fat-only MRI image. Fat tissue is easily identifiable in a fat-only MRI image 
because fat tissue is white while non-fat tissue is black. The L4-5 cross-sectional position 
(between the fourth and fifth lumbar vertebrae) is a commonly used landmark for 
assessing abdominal adipose tissue and roughly corresponds to the position of the 
umbilicus. Axial L4-5 images were identified by using the sagittal view of the abdomen 





Figure 2.2: Identification of the axial MRI image that corresponds to the L4-5 anatomical 
position using a sagittal image. The horizontal line on the sagittal image (right) depicts 
the position of the axial image (left). 
 
Visceral adipose tissue and ASAT were distinguishable as VAT is contained within the 
abdominal cavity, in the centre of the abdominal cross-section, while ASAT is on the 
outer layer of the abdomen. The dSAT and sSAT were distinguishable by identification 
of the fascia superficialis that is visible in a cross-sectional MRI image as indicated by 










Figure 2.3: An axial MRI image at the L4-5 anatomical position with the 





In order to differentiate between adipose tissue and non-adipose tissue the tool ‘Grow 
Region (2D Segmentation)’ was used, which assisted in highlighting all pixels with a high 
intensity which mostly represent fat tissue. Then the areas of VAT, ASAT, dSAT and 
sSAT were determined by manually correcting the highlighted adipose tissue regions 
using the ‘brush’ tool as shown in Figure 2.4. Each of the adipose tissue depots were 



































Figure 2.4: An axial MRI image at the L4-5 anatomical position showing 
the highlighting of VAT (blue), A; and highlighting of dSAT (green) and 





2.3.1.2!Analysis of intrahepatic lipids 
Intrahepatic lipid was quantified in each participant by selecting two abdominal MRI 
images approximately 25-35mm apart which represent the superior and inferior parts of 
the liver as shown in Figure 2.5. The horizontal line in panels B and D represent the 
location of the axial images A and C, respectively. The fat-only and water-only images 
were selected for both the superior and inferior MRI images.  
 
In each pair of fat and water images, four circular regions of interest (ROI) were 
manually drawn in the liver tissue, by using the ‘oval’ tool, in identical locations in the 
fat and water images. ROIs were positioned with the purpose of including the anterior, 
posterior, medial and lateral segments of the liver. The ROI areas ranged from 10-
20cm2 and covered as large an area of liver tissue as possible while avoiding blood 
vessels, bile ducts and obvious artefacts as previously recommended (Campo et al., 
Figure 2.5: Inferior and posterior MRI images of the liver. Coronal MRI images of the 
abdomen B and D with the horizontal line depicting the location of the axial MRI images 





2017). Figure 2.6 shows an example of the ROI placement in two pairs of fat and water 
images that represent two axial locations in the abdomen. In each participant, a total of 
8 ROIs were placed in the liver tissue; IHL was quantified within each ROI and a mean 
of all 8 ROIs was taken.  
 
For each ROI, a pixel signal intensity value is given in both the fat-only and water-only 
images. Figure 2.7 shows a representation of the information provided for each ROI 
which includes the area of the ROI and the signal intensity values which are used to 
calculate the percentage of IHL within each ROI by using the following formula:  
 
 
Where F is the signal intensity of the ROI in the fat-only image and W is the pixel signal 
intensity of the ROI in the water-only image. 
Figure 2.6: Pairs of fat-only and water-only images with four identical regions of interest 






Due to the subjective nature of the MRI analysis of IHL, particularly with regards to the 
selection of appropriate MRI images and the positioning of ROIs within the liver tissue, 
the inter-observer variability in IHL was assessed. For this analysis, MRI data from 42 
participants were analysed by a blinded independent observer (Esma Bulut, KCL 
student) to quantify IHL. A comparison analysis between the IHL results presented in 
this thesis and those from the second independent observer showed a mean coefficient 
of variation (CV) of 7.1% (SD 6.5%). Furthermore, there was a strong correlation 
between the IHL values between the two analyses (r= 0.99, P<0.001) indicating high 
agreement between the two analyses. 
Figure 2.7: MRI images showing the information provided in the HOROS software for 
each region of interest from which the pixel signal intensities are used to determine 






2.3.1.3!Analysis of intrapancreatic lipids 
Intrapancreatic lipid was quantified in each participant by first identifying the pancreas, 
which is located adjacent to the inferior section of the liver, below the stomach and above 
the small intestines, as shown in Figure 2.8. Fat-only and water-only MRI images were 
used to quantify IPL. Figure 2.9 shows the location of the pancreas on axial MRI images 
of corresponding fat and water MRI images.  
 
 
Figure 2.8: Anatomical location of the pancreas shown on a 
sagittal MRI image. 






Once the pancreas was identified, one circular ROI of area 1cm2 was positioned on each 
of the head, body and tail regions in identical locations of fat and water MRI images. Due 
to the curved shape of the pancreas, different MRI slices were used with the greatest area 
of pancreatic tissue on the head, body and tail regions. An example of the positioning of 
the three ROIs within the pancreas is shown in Figure 2.10. The relatively small areas of 
ROIs was used due to recommendation by a recent review of magnetic resonance methods 
used to determine IPL; this ensures the ROIs are within the pancreatic borders and avoids 
contamination of the ROIs with VAT and the splenic vein (Al-Mrabeh et al., 2017). 
Additionally, to ensure the accurate positioning of the ROIs in the head, body and tail 
regions of the pancreas, the MRI analysis of IPL was conducted alongside a consultant 
radiologist with expertise of MRI pancreas anatomy (Dimitra Christodoulou). 
The following formula was used to calculate percentage IPL within each ROI:  
 
 
Where F is the signal intensity of the ROI in the fat-only image and W is the pixel signal 
intensity of the ROI in the water-only image. 
Using the pixel signal intensity data of each ROI, the pancreatic fat fraction was 
calculated in each region: IPLHEAD, IPLBODY, and IPLTAIL; IPLMEAN was calculated as the 
average of the head, body and tail regions. Due to the subjective nature of the IPL analysis 
with respect to positioning the ROIs on the head, body and tail of the pancreas, IPL 
quantification was repeated by a second independent investigator (Zoya Billoo, KCL 
student). Comparison of the IPL results presented in this thesis and those of the 
independent investigator showed an inter-observer CV of 14% and a significant 
























2.3.2!Magnetic resonance spectroscopy 
Each participant underwent a 1H-MRS scan of the soleus muscle (located in the posterior 
of the calf) on a 1.5T Seimens system to assess IMCL and EMCL. While lying in the 
supine position, an extremity radiofrequency coil was placed on the right leg to obtain 
images of the soleus muscle. A radiographer used these images to identify a volume of 
interest and placed a voxel (dimension: 1.3x1.3x3.0 mm3) in the soleus muscle while 
avoiding gross marbling of fat. Localized proton spectra were acquired using a point 
Figure 2.10: Positioning of regions of interest in corresponding fat and water 





resolved spectroscopy (PRESS) sequence (TR 2000 ms; TE 30 ms) to obtain two spectra: 
a water-suppressed lipid spectra and a lipid-suppressed water spectra. The water 
resonance was set to 4.7ppm, which resulted in the IMCL and EMCL resonances to occur 
at frequencies of 1.3ppm and 1.5ppm, respectively.  
2.3.2.1!Analysis of intramyocellular lipids 
Proton-magnetic resonance spectroscopy spectra obtained from the 1H-MRS scans of all 
participants were analysed on the Java-based Magnetic Resonance User Interface 
(jMRUI) version 5.0. Figure 2.11 shows a typical 1H-MRS spectrum obtained from a 1H-
MRS analysis with the four main lipid peaks identified. These lipid peaks correspond to 
resonances of the hydrogen bonds from the methylene (CH2) and methyl (CH3) groups of 
IMCL and EMCL which are merged together between 0.8-1.7ppm. The large lipid peak 
shown in the original spectra is separated into the 4 lipid components by a deconvolution 
process with the use of prior knowledge of the peaks that is entered to the software to 
assist with identification of the individual peaks. The prior knowledge information that 
was added to the software was taken from previously published lipid fitting models (Rico-
Sanz et al., 1998). This included knowledge of individual resonance frequencies of the 
EMCL CH2, IMCL CH2, EMCL CH3 and IMCL CH3 peaks which are 1.5, 1.3, 1.1 and 
0.9 ppm, respectively (Schick et al., 1993). Also, the line width (width of the peaks) of 
the EMCL CH2 and IMCL CH2 peaks and the EMCL CH3 and IMCL CH3 peaks were set 
to equal ratios.  
After deconvolution of the lipid peaks, the amplitude of each peak is generated by the 
software which corresponds to the amount of the specific metabolite that the peak 
corresponds to. IMCL and EMCL were expressed in arbitrary units as the relative ratio 
of the methylene IMCL or EMCL peaks to internal water; which is commonly used to 





(Ingram et al., 2011). The amplitude of the internal water peak was determined by 
deconvolution of the water peak (resonance frequency 4.7ppm) from the unsuppressed 
water spectra.  
 
2.3.3!Assessment of insulin secretory function: hyperglycaemic clamp 
A 2-hour hyperglycaemic clamp was conducted to assess intravenously stimulated insulin 
secretory function (ISF) and insulin clearance; this assessment was conducted according 
to the protocol of DeFronzo et al. 1979 (DeFronzo et al., 1979). Participants had a cannula 
inserted into an antecubital fossa vein for the infusion of glucose and a second cannula 






inserted retrogradely into the dorsum of the hand for blood sampling. During this 
assessment participants were administered with a primed infusion of 20% dextrose to 
achieve a hyperglycaemic state of 6.9mmol/l above basal; this hyperglycemic state was 
maintained for 120 minutes by adjusting the glucose infusion rate every 2 minutes for the 
first 10 minutes and monitored every 5 minutes thereafter and adjusted where necessary. 
Blood samples were collected at -20, -10, 0, 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, 90, 
105, and 120 minutes to measure glucose, insulin and c-peptide concentrations. 
2.3.3.1!Calculations to determine measures of insulin secretory 
function 
Measures of ISF and insulin clearance determined from the hyperglycaemic clamp test 
were modelled by Professor Riccardo Bonadonna, Dr Linda Boselli and Dr Meera Ladwa 
using previously described methods, which are summarised below (Cobelli et al., 2007, 
Cali et al., 2008, Malandrucco et al., 2012). Insulin secretion rate was calculated using a 
pre-defined two compartment minimal model of c-peptide kinetics called deconvolution; 
this model uses plasma c-peptide concentrations to determine insulin secretion rate during 
the intravenous glucose challenge and while considering c-peptide kinetics. C-peptide is 
used in the modelling of ISF because it is co-secreted with insulin in equimolar amounts 
but has a longer half-life in the circulation and has relatively constant kinetics that are 
well defined. Hence, plasma c-peptide concentrations are truly reflective of pancreatic 
insulin secretion. 
To determine measures of glucose sensitivity, minimal modelling was performed while 
considering both insulin secretion rate and plasma glucose concentrations. This modelling 
method is a mathematical representation of the dynamic relationship between glucose 
concentrations and insulin secretion. First, the incremental area under the curve (iAUC) 





challenge were calculated using the trapezoidal rule. ISF, which is a measure of beta-cell 
glucose sensitivity, is divided into first-phase and second-phase insulin secretion. To 
obtain an index of first- and second-phase insulin secretion during the hyperglycaemic 
clamp, the iAUC for c-peptide was calculated at 0-10 minutes for first-phase and 10-120 
minutes for second-phase insulin secretory functions (DeFronzo et al., 1979). Using c-
peptide, glucose and insulin iAUC data, ISF was modelled on the simulation, analysis, 
and modelling software (SAAM-II 1.2 software; SAAM Institute, Seattle, WA) (Barrett 
et al., 1998). The main outputs from the software that are presented in this thesis include: 
1) glucose sensitivity of first-phase secretion (first-phase ISF), expressed as the amount 
of insulin secreted in response to a rate of increase in glucose of 1 mmol/l between time 
0 and 1 minutes of the intravenous glucose challenge, in (pmol.m-2BSA)/(mmol.l-1.min-
1); 2) glucose sensitivity of second-phase secretion (second-phase ISF), expressed as the 
steady state insulin secretion rate in response to a step increase in glucose of 1 mmol/l 
above baseline, in (pmol.min-1.m-2BSA)/(mmol.l-1).  
2.3.3.2!Calculation to determine insulin clearance 
Average insulin clearance was determined from the minimal modelling using the 




Where AUCISR is the area under the curve of insulin secretion rate, AUCI is the area under 
the curve of insulin concentration, IFinal is the insulin concentration at the end of the clamp, 
IBasal is the insulin concentration at the beginning of the clamp and MRTIns is the mean 
residence time of insulin,  which was assumed to be 27 minutes as reported by Navalesi 





2.3.4!Assessment of insulin sensitivity: hyperinsulinaemic euglycaemic 
clamp 
A two-step hyperinsulinaemic-euglycaemic clamp with the infusion of stable glucose and 
glycerol isotopes was used to assess whole-body, peripheral (primarily skeletal muscle), 
hepatic and adipose tissue insulin sensitivity. The hyperinsulinaemic-euglycaemic clamp 
was conducted according to the protocol of DeFronzo et al. 1979 (DeFronzo et al., 1979). 
A cannula was inserted into an antecubital fossa vein for infusions and a second cannula 
was inserted retrogradely into the dorsum of the hand for blood sampling.  
Participants were first administered with primed continuous infusions of [6,6 2H2] glucose 
(concentration: 2.0 mg/kg, rate of infusion: 0.02 mg kg-1 min-1) and [2H5] glycerol 
(concentration: 0.12 mg/kg, rate of infusion: 0.0067 mg kg-1 min-1) (CK Gases Ltd, UK) 
for 120 minutes before the first insulin infusion. After the infusion of the isotope tracers 
during the basal period, a 2-step hyperinsulinaemic-euglycaemic clamp was started. Upon 
starting the clamp, participants were administered with a 120-minute insulin infusion at 
a rate of 10mU/m2 BSA/min (low dose) followed by 120-minute insulin infusion at a rate 
of 40mU/m2 BSA/min (high dose).  
Throughout the clamp, plasma glucose concentrations were maintained at 5mmol/l by 
adjusting the infusion of 20% dextrose enriched with [6,6 2H2] glucose according to 
plasma glucose readings taken every 5 minutes using an automated glucose analyser 
(Yellow Spring Instruments, 2300 STAT Glucose Analyzer, Ohio, USA). Blood samples 
were taken at -30, -20, -10, 0, 30, 60, 90, 100, 110, 120, 150, 180, 210, 220, 230 and 240 
minutes, where time 0 represents the start of insulin low dose infusion, to measure plasma 
insulin, glucose and glycerol concentrations and enrichments. Figure 2.12 shows a 
timeline of infusions and blood sampling during the clamp procedure (Goff, 2013). 





of the clamp, while, whole-body and peripheral insulin sensitivity were determined 
during the high-dose step of the clamp. The glucose infusion rate during the last 30 




2.3.4.1!Calculations to determine measures of insulin sensitivity 
The total insulin mediated glucose disposal represents whole-body insulin sensitivity (M-
value) and was calculated as the mean of the glucose infusion rate (adjusted with a 
correction factor ‘space correction’) in the final 30 minutes of the hyperinsulinaemic-
euglycemic clamp (DeFronzo et al., 1979). Peripheral glucose utilisation (glucose rate of 
disappearance, Rd), endogenous glucose production (EGP) (glucose rate of appearance, 
Figure 2.12: Schematic of the timeline of infusions and blood sampling during the 





Ra) and whole-body lipolysis (glycerol rate of appearance, Ra) were calculated using 
Steele’s non-steady state equations modified for stable isotopes assuming a volume 
distribution of 22% body weight (Steele et al., 1956). The calculation of glucose kinetics 
was also modified for inclusion of [6,6-2H2]-glucose in the dextrose infusion (Finegood 
et al., 1987). Before the calculation of glucose kinetics, enrichment and concentrations 
were smoothed using optical segments analysis (Finegood and Bergman, 1983).  
Peripheral glucose utilisation (glucose Rd) was calculated during the basal state and 
during the final 30 minutes of the high-dose stage of the hyperinsulinaemic-euglycaemic 
clamp. The percentage increase in glucose Rd (% increase glucose Rd) from the basal to 
the stimulated state was used as a measure of muscle insulin sensitivity (Fabbrini et al., 
2009). Endogenous glucose production (glucose Ra) was calculated by subtracting the 
exogenous glucose infusion rate from total glucose Ra. Glucose Ra was calculated during 
the basal state and during the final 30 minutes of the low-dose stage of the clamp. The 
percentage suppression of glucose Ra from the basal to the low-dose stage was used as a 
measure of hepatic insulin sensitivity which is defined as the insulin mediated 
suppression of hepatic glucose production (Yoshino et al., 2012).  
2.3.5!Biochemical analyses 
Plasma glucose concentrations were determined using an automated glucose analyser 
(Yellow Spring Instruments, 2300 STAT Glucose Analyzer, Ohio, USA). Serum insulin 
concentrations were determined by immunoassay using chemiluminescent technology 
(ADVIA Centaur System, Siemens Healthcare Ltd. Camberly, UK); where the inter-assay 
and intra-assay CVs were ≤ 5.9% and 4.6%, respectively. Serum c-peptide concentrations 
were determined using a radioimmunoassay (Millipore Ltd, Hertfordshire, UK). The 
glucose and glycerol enrichment in plasma were determined by gas chromatography-





UK) using selected ion monitoring. The isotopic enrichment of glucose was determined 
as the penta–O-trimethylsilyl-D-glucose-O-methyloxime derivative (Shojaee-Moradie et 
al., 1996). The isotopic enrichment of plasma glycerol was determined as the tert-butyl 
trimethylsilyl glycerol derivative (Flakoll et al., 2000). 
2.4!Statistical analyses 
The Soul-Deep study was designed to include 20 participants per group (two ethnic 
groups at three glycaemic states) to allow a difference of one standard deviation to be 
detected with a power of 90% and two-sided significance for the primary outcome 
variable (beta-cell insulin secretory function). Variables were tested for normality using 
Shapiro-Wilks test, histograms and assessment of the Q-Q plots. Variables that followed 
a non-parametric distribution were log-transformed to achieve a normal distribution with 
the purpose of using parametric tests on them. A 2-way between-within groups analysis 
of variance (ANOVA) was used to test differences in variables of interest by ethnicity 
and glycaemic state. Significance of differences in variables of interest between the two 
ethnic groups at a specific glycaemic state were tested using an independent samples t-
test on numeric parametrically-distributed data or chi-squared test on ordinal data. Data 
are presented as mean with standard deviation (SD) for normally-distributed data, 
geometric mean with 95% confidence interval (CI) for log transformed data or median 
with interquartile range (IQR) for non-parametric data. Data presented in box plots 
express the median and IQR. Relationships between variables of interest were assessed 
using Pearson correlations with partial correlations used when adjustments for 
confounders were required. Statistical analyses were conducted with SPSS version 25.0 





Chapter 3:!Ethnic differences in regional 
abdominal adipose tissue deposition between men 




Obesity is a major risk factor for T2D (Bonham and Brock, 1985). The worldwide 
prevalence of obesity is reaching epidemic proportions which is directly impacting the 
prevalence rates of T2D (Bhupathiraju and Hu, 2016). While the link between obesity 
and T2D is well established, the mechanisms of adiposity induced insulin resistance are 
not fully understood. Considering the worldwide epidemics of T2D and obesity, the study 
of adipose tissue has become an area of paramount importance. Whole-body adiposity is 
commonly assessed using BMI, however, since BMI is not a biological trait but a 
calculated value used to characterise the obese phenotype, it is essential to look beyond 
the BMI to understand the role of excess adiposity in the development of T2D (Muller et 
al., 2016). 
Data presented in this chapter have been published in (appendix I):  
 
Hakim O, Bello O, Ladwa M, Christodoulou D, Bulut E, Shuaib H, 
Peacock JL, Umpleby AM, Charles-Edwards G, Amiel SA, Goff LM. 
Ethnic differences in hepatic, pancreatic, muscular and visceral fat 
deposition in healthy men of white European and black west African 






While obesity is known to cause metabolic dysfunctions, it is estimated that 
approximately 55% of individuals with obesity are metabolically healthy i.e. do not have 
hypertension, dyslipidaemia or disturbances in glucose metabolism (Jung et al., 2017). 
Conversely, approximately 30% of individuals with a healthy BMI are metabolically 
unhealthy (Wildman et al., 2008). Further investigations of these paradoxical phenomena 
have shown that not only the amount of adiposity but also the location of adipose tissue 
is important in determining metabolic risk. There is a growing body of evidence showing 
that increased central deposition of adipose tissue is strongly linked to several obesity-
related morbidities including T2D (Despres, 2006). Indeed, studies investigating 
individuals with the obese but metabolically healthy phenotype have shown they 
characteristically have lower levels of VAT than their counterparts with obesity and 
metabolic diseases (Stefan et al., 2008b). Furthermore, normal weight individuals that are 
metabolically unhealthy often have high VAT and low SAT levels; thus, such phenotypes 
have been termed ‘thin on the outside, fat on the inside’ (Thomas et al., 2012a). Therefore, 
there is much evidence showing that regional distribution of adipose tissue is important 
in determining risk of T2D.  
With the advancement of imaging technologies such as CT and MRI, regional distribution 
of adiposity has gained much traction within T2D research (Thomas et al., 2013). The 
deposition of adipose tissue in the central body region is more closely linked to T2D than 
other measures of whole-body adiposity and gluteofemoral adiposity (Despres, 2006, 
Smith et al., 2012). Demonstrating the importance of direct measurement of regional 
adipose tissue, Figure 3.1 shows cross-sectional abdominal MRI images from 9 
individuals with equivalent BMI levels but noticeably different SAT and VAT levels 
(Thomas et al., 2012a). These differences can only be appreciated using imaging methods 






Increased central adiposity occurs due to increased VAT or abdominal SAT (ASAT) or a 
combination of both. Furthermore, the ASAT compartment can be subdivided into deep 
(dSAT) and superficial SAT (sSAT) which are separated by a fascial plane called the 
fascial superficialis (Despres et al., 1989).  
Studies conducted on sSAT, dSAT and VAT have shown distinct structural and 
functional differences between the three fat depots. The sSAT is the primary source of 
storage of triglycerides and is considered to be the most metabolically safe fat storage 
compartment. During excess energy intake, the sSAT compartment increases and during 
its severe increase there is a disproportional increase of dSAT, which is a secondary 
Figure 3.1: Axial MRI images at the level of the umbilicus of 9 males who have 






storage compartment of fat. The adipocytes within the dSAT are typically larger than 
those of sSAT indicative of dysfunctional hypertrophic expansion of adipocytes 
(Lundbom et al., 2013). During obese states, there is a disproportionate expansion of 
dSAT with the increase of SAT, which indicates that sSAT has a finite capacity after 
which it becomes overwhelmed and the increase of SAT occurs mainly by the increase 
of dSAT (Golan et al., 2012). As the SAT compartment increases and with further 
increase of dSAT, the adipocytes become dysfunctional and unable to adequately store 
excess triglycerides during energy surplus. This causes a spill-over of NEFAs into the 
circulation which deposit within the VAT compartment (Sattar and Gill, 2014).  
The properties of VAT are similar to those of dSAT, however, are more deleteriously 
exaggerated. The properties of sSAT, dSAT and VAT are summarised in Table 3.1, which 
shows the metabolically safest fat storage compartment is sSAT followed by dSAT 
followed by VAT, which is considered to have the greatest pathogenic potential 
(Sniderman et al., 2007). Marinou et al. showed that dSAT is associated with VAT, 
however, sSAT is not, suggesting that both dSAT and VAT expand due to similar 





Table 3.1: Characteristics of adipose tissue compartments, adapted from a review by 
Sniderman et al., 2007 (Sniderman et al., 2007). 
 
Investigations of regional adipose tissue deposition in black populations have mostly 
focused on VAT and SAT and their associations with metabolic risk markers of T2D. It 
is well accepted that VAT is lower in black populations compared to their white 
counterparts (Alderete et al., 2014, Goedecke et al., 2017), which is present from as early 
as childhood (Goran, 1999, Goran et al., 1997). However, studies of SAT are inconclusive 
with some reporting greater levels of SAT in black populations (Hasson et al., 2010, 
Lovejoy et al., 2001) while others report no difference in comparison to white populations 
(Szczepaniak et al., 2012, Bacha et al., 2003, Hughan et al., 2013, Liska et al., 2007, van 
der Merwe et al., 2000).  
  SSAT  DSAT  VAT  
Development 
sequence 
Primary  Secondary  Secondary  
Demarcation of 
lobules 
Best demarcated  Intermediate  Least demarcated  
Vascularity of lobules Least vascular  Intermediate  Most vascular  
Stability of 
triglyceride stores 




















The study of dSAT and sSAT in black populations has been limited; generally greater 
levels of sSAT in blacks compared to whites have been reported with no ethnic 
differences in dSAT (Liska et al., 2007, Evans et al., 2011, Goedecke et al., 2011, Lovejoy 
et al., 2001). While the relationships between VAT and insulin sensitivity have been 
extensively studied in white and black populations, no current reports have investigated 
the relationships between dSAT and sSAT with insulin sensitivity in a black population. 
Therefore, the contributions of dSAT and sSAT in the progression of T2D are 
understudied in black populations.  
The illogical phenomenon of low levels of VAT but greater prevalence of T2D in black 
populations has caused speculation that black populations may be more sensitive to the 
detrimental effects of VAT and become more insulin resistant at lower levels. To 
elucidate these speculations, investigations of the relationships between VAT and 
metabolic parameters of T2D in black populations are necessary; such investigations are 
limited in the literature but will be addressed in this chapter. Additionally, investigations 
between ASAT, dSAT and sSAT with metabolic parameters are also warranted in black 







The primary aim is to assess ethnic differences in VAT, ASAT, dSAT and sSAT between 
WE and BWA men of NGT, IGT and T2D glycaemic states. The secondary aim is to 
investigate ethnic differences in the relationships between 1) VAT and whole body, 
skeletal muscle, hepatic and adipose tissue insulin sensitivity; and 2) ASAT, dSAT and 








The data presented in this chapter were acquired from the methods described in chapter 
2 (sections 2.3.1, 2.3.1.1, 2.3.4, 2.3.4.1). In brief, areas of VAT, ASAT, dSAT and sSAT 
were determined from a single axial MRI image at the L4-5 anatomical position. VAT 
and SAT areas determined at the L4-5 position correlate strongly with the respective 
volumes determined using consecutive MRI images from the whole abdominal cavity in 
both black and white populations (Demerath et al., 2007). Measures of insulin sensitivity 
were determined using a hyperinsulinaemic-euglycaemic clamp test with the infusion of 
stable glucose and glycerol isotopes to determine whole-body insulin sensitivity (M-
value), hepatic insulin sensitivity (% suppression of endogenous glucose production 
[EGP]), muscle insulin sensitivity (% change in glucose rate of disappearance [Rd]) and 
adipose tissue insulin sensitivity (% suppression of lipolysis).  
3.3.2!Statistical analysis 
Participant characteristics, insulin sensitivity and regional adiposity data presented in this 
chapter for the WE and BWA men of NGT, IGT and T2D groups were compared using 
2-way between-groups ANOVA. Ethnicity and glycaemic state were included in the 2-
way between-groups ANOVA as independent variables to assess the main effect of each 
of the independent variables, as well as their interaction (ethnicity*glycaemic state), on 
the outcome measures (dependent variables). Ethnic differences between regional fat 
depots of interest were tested using independent samples t-tests.  
Strength of relationships between variables of interest were tested using Pearson’s 
correlation test; partial correlation was used when assessing relationships while adjusting 













The clinical characteristics of the WE and BWA men of NGT, IGT and T2D groups are 
presented in Table 3.2. There were no ethnic differences in age, weight, height, BMI, 
BSA, blood pressure and fasting plasma glucose. Waist circumference was significantly 
greater in the WE men. HbA1c was greater in the BWA men which was driven by the 
greater HbA1c in BWA men with IGT. Considering measures of fasting plasma lipids, 
the WE men had greater total cholesterol levels (trend towards significance) compared to 
the BWA men with no differences in LDL- and HDL-cholesterol. Furthermore, fasting 
triglycerides were significantly greater in the WE men. In the T2D glycaemic group, the 
WE and BWA men had similar duration of diabetes, metformin use and anti-hypertensive 
drug use. The number of participants taking statins was slightly greater in the WE men, 
which approached statistical significance. All clinical characteristics differed 
significantly by glycaemic state except for height and HDL-cholesterol; these are 
indicative of the typical pattern of deterioration in several parameters related to T2D in 
the progression from NGT to T2D. The lack of significant ethnicity*glycaemic state 
interaction for waist circumference and triglycerides indicates that, although both these 
characteristics were significantly lower in the BWA men, this was present at all glycaemic 
states. This suggests that both lower waist circumference and plasma triglycerides are 
ethnic traits in populations of African descent in comparison to their European 
counterparts. 
3.4.2!Metabolic characteristics 
Measures of whole-body and tissue specific insulin sensitivity in the WE and BWA men 
of NGT, IGT and T2D are presented in Table 3.3. Even though all measures of insulin 





counterparts, there were no statistically significant ethnic differences in all measures of 
insulin sensitivity between the WE and BWA men overall. As expected, all measures of 
insulin sensitivity were significantly lower in the T2D and IGT groups compared to the 






Table 3.2: Clinical characteristics of the WE and BWA men of NGT, IGT and T2D glycaemic states. 
 NGT IGT T2D    






























0.13 <0.001 0.76 












0.26 <0.001 0.69 
Height (cm) 180.3 ± 5.8 177.4 ± 7.5 178.1 ± 5.6 177.0 ± 6.0 177.6 ± 5.7 175.5 ± 7.2 0.13 0.28 0.87 
BMI (kg/m2)  26.5 ± 4.5 27.0 ± 3.4 31.6 ± 3.1 31.1 ± 3.8 31.5 ± 4.1 30.0 ± 3.5 0.51 <0.001 0.53 
Body surface area (m2) 2.1 ± 0.2 2.0 ± 0.2 2.17 ± 0.18 2.18 ± 0.19 2.2 ± 0.20 2.1 ± 0.15 0.38 0.052 0.60 
Waist circumference 
(cm)  
93.8 ± 14.6 88.2 ± 8.9 109.2 ± 10.3 102.6 ± 11.5 111.9 ± 13.0 104.9 ± 9.7 0.011 <0.001 0.96 
HbA1c (%) 5.45 ± 0.24 5.58 ± 0.47 5.67 ± 0.33 6.13 ± 0.39 6.64 ± 0.70 6.76 ± 0.70 0.032 <0.001 0.44 
HbA1c (mmol/mol) 35.9 ± 2.9 37.5 ± 5.2 38.6 ± 3.5 43.5 ± 4.3 49.1 ± 7.61 50.4 ± 7.80 0.033 <0.001 0.49 
Fasting plasma glucose 
(mmol/l) 
5.20 ± 0.39 5.14 ± 0.47 5.88 ± 0.70 5.60 ± 0.44 6.88 ± 1.33 6.71 ± 0.96 0.32 <0.001 0.87 
Systolic BP (mm Hg) 121.9 ± 9.1 122.3 ± 13.0 130.4 ±13.3 132.7 ± 10.0 130.9 ± 14.2 137.5 ± 13.7 0.24 <0.001 0.53 












0.14 <0.001 0.56 
Total cholesterol 
(mmol/l) 





Data presented as mean ± SD or geometric mean (95% CI) for log transformed data (*). P eth: main effect for ethnicity, P gly: main effect for glycaemic state, P eth*gly: 
interaction effect for ethnicity*glycaemic state determined using a 2-way between-groups ANOVA. P-values determined using Fisher’s exact test for ordinal data (†). 
LDL-cholesterol 
(mmol/l) 















0.72 0.22 0.71 












0.001 <0.001 0.96 
Diabetes duration 
(years)* 
- - - - 3.1 ± 1.0 2.7 ± 1.3 0.38   
Metformin use (number 
of participants (%))† 
- - - - 10 (40) 15 (60) 0.31   
Statin use (number of 
participants (%))† 
- - - - 16 (57) 12 (43) 0.067   
Antihypertensive drug 
use (number of 
participants (%))† 





Table 3.3: Metabolic parameters of insulin sensitivity in the WE and BWA men of NGT, IGT and T2D glycaemic states. 




















sensitivity (M-value)  
(mg/m2 BSA min-1) 
309.6 ± 127.5 313.5 ± 77.0 214.6 ± 99.8 197.0 ± 59.9 154.4 ± 76.2 191.0 ± 85.3 0.71 <0.001 0.56 
Skeletal muscle insulin 
sensitivity (% increase in 
glucose Rd) 
286.2 ± 138.4 299.4 ± 114.4 176.0 ± 127.0 183.2 ± 86.0 154.1 ± 107.5 203.5 ± 126.2 0.39 <0.001 0.79 
Hepatic insulin sensitivity 













0.60 <0.001 0.54 
Adipose tissue insulin 
sensitivity (% suppression 
of lipolysis) 
53.8 ± 17.4b 43.4 ± 25.2 47.8 ± 7.6c 46.8 ± 14.0d 35.5 ± 14.5g 37.2 ± 16.0f 0.45 0.027 0.39 
Data presented as mean ± SD or geometric mean (95% CI) for log transformed data (*). P eth: main effect for ethnicity, P gly: main effect for glycaemic state, P eth*gly: 





3.4.3!Abdominal adipose tissue deposition 
Measures of regional abdominal adipose tissue deposition are presented in Table 3.4 for 
the WE and BWA men of NGT, IGT and T2D. Significant main effects for glycaemic 
state were present for all abdominal adipose depots, which were greater in the IGT and 
T2D groups compared to the NGT groups. There were significant ethnic differences in 
VAT, VAT:ASAT ratio and dSAT:sSAT ratio between the WE and BWA men, with no 
ethnic differences in ASAT, dSAT and sSAT. Ethnic comparisons were conducted for 
each of the regional abdominal adipose depots within each glycaemic state, which are 
addressed below. 
3.4.3.1!Visceral adipose tissue and abdominal subcutaneous adipose 
tissue 
As shown in Figure 3.2, VAT was significantly lower in the BWA men compared to the 
WE men which was present at all glycaemic states. As expected, VAT was greater in the 
IGT and T2D glycaemic states compared to the NGT groups in both WE and BWA men; 
however, this difference in VAT appeared to be greater in WE men indicated by a greater 
mean difference between in the T2D groups (mean difference = 59.7cm2) compared to 
the NGT groups (mean difference = 51.5cm2). However, there was no significant 
interaction by ethnicity*glycaemic state (Pinteraction =0.61) indicating that VAT appears to 
increase similarly in the WE and BWA men from NGT to T2D. There were no ethnic 
differences in ASAT at all glycaemic states as shown in Figure 3.3. Furthermore, there 
was no difference in ASAT by ethnicity*glycaemic state (Pinteraction=1.00) indicating that 
ASAT is similarly greater in the IGT and T2D states than the NGT state in both ethnic 
groups. The ratio of VAT:ASAT was significantly lower in the BWA men in the NGT 





significantly lower VAT in the BWA men since there were no ethnic differences in 
ASAT. 
3.4.3.2!Deep and superficial subcutaneous adipose tissue 
Individual values of dSAT and sSAT areas in the WE and BWA men of NGT, IGT and 
T2D groups are shown in Figures 3.4 and 3.5, respectively. Neither dSAT or sSAT 
differed by ethnicity in the NGT, IGT, or T2D glycaemic states. The ratio of dSAT to 
sSAT was significantly greater in the WE men than BWA men in the combined glycaemic 
groups, Table 3.4. Further investigation of dSAT:sSAT in each glycaemic group showed 
no ethnic differences in the NGT groups (P=0.24), a trend towards a significantly greater 
dSAT:sSAT in the WE men of IGT (P=089) and a significantly greater dSAT:sSAT in 
the WE men with T2D compared to the BWA men (P=0.029). No significant interactions 
by ethnicity*glycaemic state were present for dSAT (Pinteraction=0.97), sSAT 










Table 3.4: Abdominal adipose tissue deposition in the WE and BWA men of NGT, IGT and T2D glycaemic states. 



















VAT (cm2)* 79.0 (55-112) 46.1 (34-61) 174.5 (126-241) 86.5 (63-119) 187.4 (152-230) 128.1 (103-159) <0.001 <0.001 0.60 
ASAT (cm2)* 193.2 (149-249) 181.9 (136-243) 274 (227-330) 258.1 (191-348) 302.3 (251-364) 285.6 (247-330) 0.56 <0.001 0.99 
VAT:ASAT* 0.46 (0.34-0.59) 0.30 (0.20-0.39) 0.69 (0.48-0.91) 0.37 (0.24-0.50) 0.68 (0.52-0.85) 0.48 (0.39-0.58) <0.001 0.002 0.50 
dSAT (cm2)* 109.8 (76-159) 102.6 (73-145) 182.6 (147-227) 160.3 (116-221) 196.7 (164-236) 175.3 (150-205) 0.41 <0.001 0.98 
sSAT (cm2)* 75.5 (62-93) 76.6 (60-97) 88.6 (72-109) 96.4 (72-130) 103.7 (83-129) 108.8 (93-127) 0.59 0.003 0.95 
dSAT:sSAT 1.68 ± 0.84 1.42 ± 0.49 2.16 ± 0.70 1.70 ± 0.38 1.95 ± 0.46 1.65 ± 0.35 0.007 0.034 0.82 
Data presented as mean ± SD or geometric mean (95% CI) for log transformed data (*). P eth: main effect for ethnicity, P gly: main effect for glycaemic state, P eth*gly: 























































Figure 3.2: Visceral adipose tissue (VAT) area determined at the 
L4-5 anatomical position in the WE and BWA men of NGT, IGT 
and T2D groups. 
Figure 3.3: Abdominal subcutaneous adipose tissue (ASAT) area 
determined at the L4-5 anatomical position in the WE and BWA men of 








Figure 3.4: Abdominal deep subcutaneous adipose tissue (dSAT) 
area determined at the L4-5 anatomical position in the WE and 
BWA men of NGT, IGT and T2D groups. 
Figure 3.5: Abdominal superficial subcutaneous adipose tissue 
(sSAT) area determined at the L4-5 anatomical position in the WE 





3.4.3.3!Total abdominal adipose tissue 
Mean total abdominal adipose tissue is presented by the proportions of mean VAT, dSAT 
and sSAT for the WE and BWA men within each glycaemic state in Figure 3.6. While 
total abdominal adipose tissue was lower in the BWA men, this was not significant 
between the NGT groups (P=0.34) but approached significance between the IGT 
(P=0.091) and T2D (P=0.094) groups. This was mostly driven by the lower VAT in the 
BWA men in all glycaemic states. 
 
 
Figure 3.6: Means of total abdominal adipose tissue showing the proportion 





3.4.4!Interrelationships between regional adipose tissue depots 
Interrelationships between the abdominal adipose tissue depots were investigated in the 
WE and BWA men in combined cohorts of all glycaemic states which are presented in 
Table 3.5. VAT was associated with dSAT and sSAT in both WE and BWA men. Since 
dSAT and sSAT are strongly associated with each other, to eliminate their possible 
influences on the relationships of VAT with dSAT and sSAT, partial correlation was 
conducted while adjusting for either dSAT or sSAT. After adjusting for dSAT, the 
associations between VAT and sSAT completely diminished in both ethnic groups; 
however, after adjusting for sSAT, the relationship between VAT and dSAT remained 
significant in the WE men but not the BWA men. 
 
Table 3.5: Pearson’s correlation and partial correlation coefficients showing 








VAT r p r p 
dSAT 0.57 <0.001 0.50 <0.001 
Adjusted for sSAT 0.39 0.006 0.22 0.13 
sSAT 0.45 <0.001 0.46 0.001 





3.4.5!Relationships between visceral adipose tissue and measures of 
insulin sensitivity 
Relationships between VAT and measures of insulin sensitivity are presented in Table 
3.6 and Figures 3.7, 3.8 and 3.9 for the WE and BWA men in all glycaemic cohorts 
combined (panels A). Naturally, with increasing age and BMI, VAT increases while M-
value decreases (Kurniawan et al., 2018, Hunter et al., 2010); therefore, to reduce their 
influence on the relationships between VAT and measures of insulin sensitivity, the above 
relationships were adjusted for both age and BMI, Table 3.6.  
VAT was inversely associated with whole-body insulin sensitivity in the WE and BWA 
men, however, after adjusting for age and BMI, this relationship remained significant in 
the BWA but not the WE men. In a similar manner to the relationship with whole-body 
insulin sensitivity, VAT was inversely associated with hepatic insulin sensitivity in the 
WE and BWA men, however, after adjusting for age and BMI, this relationship remained 
significant in the BWA men but not the WE men. Interestingly, VAT was inversely 
associated with adipose tissue insulin sensitivity in the WE men but this relationship was 
not statistically significant in the BWA men. Furthermore, unlike the relationships of 
VAT with whole-body insulin sensitivity and hepatic insulin sensitivity, the relationship 
of VAT with adipose tissue insulin sensitivity remained significant in the WE men after 
adjusting for both age and BMI. Analysis of interaction by ethnicity for the above 
relationships showed the only significant ethnicity interaction was for the relationship 
between VAT and adipose tissue insulin sensitivity (Pinteraction=0.030), Figure 3.9. 
Relationships between VAT and measures of insulin sensitivity in the WE and BWA men 
analysed separately in the NGT and T2D glycaemic states are presented in Table 3.7 and 
Figures 3.7, 3.8 and 3.9 (panels B). While the sample sizes are markedly lower in 





influence of glycaemic state in the relationships between VAT and insulin sensitivity. 
This analysis showed similar trends with respect to ethnic differences in the NGT and 
T2D states. VAT was inversely associated with whole-body and hepatic insulin 
sensitivity in both WE and BWA men of NGT and T2D groups (except for VAT and 
hepatic insulin sensitivity in WE men with T2D). However, VAT was only associated 
with adipose tissue insulin sensitivity in the WE men but not BWA men within both NGT 
and T2D glycaemic groups. 
 
Table 3.6: Pearson’s correlation and partial correlation coefficients showing 
relationships between VAT and measures of insulin sensitivity in WE and BWA men of all 
glycaemic states. 
an: WE=49, BWA=46; bn: WE=42, BWA=43; cn: WE=39, BWA=42 
 
 WE BWA 
VAT r p r p 
Whole-body insulin sensitivitya -0.70 <0.001 -0.62 <0.001 
Adjusted for BMI -0.43 0.002 -0.41 0.005 
Adjusted for age -0.50 <0.001 -0.51 <0.001 
Adjusted for BMI and age -0.22 0.14 -0.34 0.025 
Hepatic insulin sensitivityb -0.51 0.001 -0.70 <0.001 
Adjusted for BMI -0.27 0.085 -0.58 <0.001 
Adjusted for age -0.27 0.094 -0.60 <0.001 
Adjusted for BMI and age -0.10 0.53 -0.50 0.001 
Adipose tissue insulin sensitivityc  -0.68 <0.001 -0.11 0.48 
Adjusted for BMI -0.43 0.007 -0.11 0.47 
Adjusted for age -0.55 <0.001 -0.16 0.40 






Table 3.7: Pearson’s correlation coefficients showing relationships between VAT and measures of insulin sensitivity in WE and BWA men of 
NGT and T2D groups. 
 
 NGT T2D 
 WE BWA WE BWA 
VAT r p r p r p r p 
Whole-body insulin sensitivity -0.81 <0.001 -0.45 0.058 -0.53 0.028 -0.55 0.019 
n 23  18  17  18  
Hepatic insulin sensitivity -0.52 0.015 -0.57 0.013 -0.41 0.19 -0.47 0.079 
n 21  18  12  15  
Adipose tissue insulin 
sensitivity 
-0.58 0.005 0.06 0.81 -0.72 0.018 -0.22 0.43 






Figure 3.7: Relationships between VAT and whole-body insulin sensitivity (M-value) 
in the WE and BWA men in the combined glycaemic cohorts (NGT, IGT and T2D), A; 




















Figure 3.8: Relationships between VAT and hepatic insulin sensitivity (% suppression 
of EGP) in the WE and BWA men in the combined glycaemic cohorts (NGT, IGT and 





Figure 3.9: Relationships between VAT and adipose tissue insulin sensitivity (% 
suppression of lipolysis) in the WE and BWA men in the combined glycaemic cohorts 





3.4.6!Relationships between regional subcutaneous adipose tissue 
depots and whole-body insulin sensitivity  
Relationships between regional subcutaneous adipose tissue depots and whole-body 
insulin sensitivity are presented in Table 3.8 for the WE and BWA men in all glycaemic 
cohorts combined; partial correlation coefficients are shown for these relationships while 
adjusting for BMI and age. ASAT, dSAT and sSAT were inversely associated with 
whole-body insulin sensitivity in both WE and BWA men; however, these relationships 
diminished in both ethnic groups after adjustments for age and BMI. Of note, while there 
were significant relationships between all measures of abdominal adiposity and whole-
body insulin sensitivity, including VAT, ASAT, dSAT and sSAT, in both ethnic groups, 
these relationships were consistently stronger in the WE men. 
Relationships between regional abdominal adipose tissue depots and whole-body insulin 
sensitivity are presented separately for the NGT and T2D groups in Table 3.9. While the 
sample sizes are lower than those of the all glycaemic cohorts combined, this analysis 
showed some clear patterns. In the WE men, ASAT, dSAT and sSAT were inversely 
associated with whole-body insulin sensitivity in the NGT and T2D groups; however, in 
the BWA men, ASAT, dSAT and sSAT were inversely associated with whole-body 





Table 3.8: Pearson’s correlation and partial correlation coefficients showing 
relationships between measures of regional subcutaneous adipose tissue and whole-body 











M-value r p r p 
ASAT -0.72 <0.001 -0.53 <0.001 
Adjusted for BMI and age -0.24 0.10 -0.12 0.43 
dSAT -0.73 <0.001 -0.53 <0.001 
Adjusted for BMI and age -0.23 0.12 -0.11 0.47 
sSAT -0.57 <0.001 -0.48 0.001 







Table 3.9: Pearson’s correlation coefficients showing relationships between regional adipose tissue depots and whole-body insulin sensitivity in 
WE and BWA men of NGT and T2D groups. 
 
 









M-Value r p r p r p r p 
ASAT -0.61 0.002 -0.80 <0.001 -0.73 0.001 -0.31 0.22 
dSAT -0.52 0.011 -0.81 <0.001 -0.74 0.001 -0.31 0.21 






The purpose of this chapter was to investigate ethnic differences in regional abdominal 
adipose tissue deposition between WE and BWA men across three glycaemic states: 
NGT, IGT and T2D. Ethnic comparisons were conducted between WE and BWA men of 
all glycaemic states combined as well as within each of the glycaemic groups. The main 
findings recognise ethnic differences in regional adipose tissue distribution and the 
relationships between specific adipose tissue depots and measures of insulin sensitivity. 
The BWA men had significantly lower VAT levels compared to WE men in all glycaemic 
states, however, there were no ethnic differences in ASAT, dSAT and sSAT. 
Relationships between VAT and measures of insulin sensitivity showed similar patterns 
in both ethnic groups where VAT was inversely associated with whole-body and hepatic 
insulin sensitivity in WE and BWA men, however, VAT was significantly inversely 
associated with adipose tissue insulin sensitivity in only WE men.  
3.5.1!Ethnic differences in regional adipose tissue deposition 
The lower levels of VAT in the BWA men supports the findings of previous studies that 
have consistently shown VAT is lower in black populations compared to their white 
counterparts (Alderete et al., 2014, Goedecke et al., 2017). Also similar to previous 
studies, is the lack of ethnic differences in ASAT levels (Lee et al., 2011, Liska et al., 
2007). Contrastingly, some studies report greater ASAT in black populations compared 
to whites, however, a commonality of these studies is that they were all conducted in 
women who have a greater capacity to store SAT compared to men. Indeed, several 
studies showed ASAT was significantly greater in black women compared to black men 
(De Lucia Rolfe et al., 2015, Tulloch-Reid et al., 2004). The consistently lower VAT 
levels, at similar levels of adiposity, in black populations compared to white populations 





have a reduced susceptibility to store excess triglycerides in the VAT depot at all 
glycaemic states. 
The sSAT depot is the primary source of triglyceride storage and is the most metabolically 
safe storage location of excess triglycerides (Sniderman et al., 2007). With gradual 
expansion of sSAT, there is an expansion of dSAT which is composed of more 
disorganised and dysfunctional adipocytes that have greater lipolytic activity compared 
to those of sSAT. In this analysis, there were no ethnic differences in dSAT which is 
similar to previous reports from studies conducted in adolescents (Liska et al., 2007), 
women (Evans et al., 2011, Goedecke et al., 2011, Lovejoy et al., 2001, Nazare et al., 
2012) and men (Nazare et al., 2012). Similarly, sSAT did not differ between the WE and 
BWA men which is similar to previous findings in men (Nazare et al., 2012) but opposes 
previous studies that showed greater sSAT in black women (Lovejoy et al., 2001, Liska 
et al., 2007, Evans et al., 2011, Goedecke et al., 2011) and children (Liska et al., 2007). 
This may be explained by gender or by differences in the level of whole-body adiposity 
because the studies that have shown sSAT to be greater in black populations investigated 
only groups with severe obesity while the participants in this study had an overweight or 
mildly obese BMI. In support of this explanation are findings by Evans et al. who reported 
significantly greater sSAT in black women with obesity but not lean black women in 
comparison to their BMI-matched white counterparts (Evans et al., 2011).  
Increased ratios of VAT:SAT and dSAT:sSAT are indicative of unfavourable patterns of 
adipose tissue deposition, where, with increasing adiposity there is a greater susceptibility 
of triglyceride storage in the VAT and dSAT compartments. The analysis presented here 
showed VAT:SAT ratio was significantly lower in the BWA men compared to the WE 
men which was mostly driven by lower VAT in the BWA men. These findings are 





2008, Nazare et al., 2012, Liu et al., 2014). Furthermore, dSAT:sSAT was also 
significantly lower in the BWA men compared to WE men which is similar to previous 
findings in black men (Nazare et al., 2012). These findings indicate a preferential storage 
of triglycerides in the SAT compared to VAT, and sSAT compared to dSAT, in the BWA 
men. Hence, the lower VAT: SAT and dSAT:sSAT ratio in the BWA men suggests that 
the greater risk of T2D in black populations compared to white populations may not be 
explained by body fat distribution. 
3.5.2!Interrelationships between abdominal adipose tissue depots 
Previous studies have shown VAT associates with dSAT but not sSAT implying that the 
expansion of VAT occurs due to similar mechanisms related to the expansion of dSAT 
(Marinou et al., 2014, Kelley et al., 2000). In contrast to previous reports, the current 
analysis showed both dSAT and sSAT were associated with VAT in the WE and BWA 
men. However, the relationships between sSAT and VAT diminished after controlling for 
dSAT in both ethnic groups indicating that dSAT may be an influencer of VAT 
expansion. Interestingly, after controlling for sSAT, the relationship between dSAT and 
VAT remained in the WE men but not the BWA men indicating that dSAT may be more 
closely related to VAT expansion in WE men than BWA men. Furthermore, both dSAT 
and sSAT were associated with VAT in BWA men but not independently of each other; 
this may indicate that the overall expansion of SAT influences VAT in BWA men which 
is not dependent on dSAT.  
3.5.3!Relationships between regional adipose tissue depots and insulin 
sensitivity 
Since VAT is the adipose tissue depot that is most linked to T2D, but is paradoxically 
lower in black populations, the relationships between VAT and measures of insulin 





inversely associated with whole-body insulin sensitivity and hepatic insulin sensitivity in 
both ethnic groups; however, after adjusting for BMI and age, these relationships 
remained significant in the BWA but not WE men. Even though there is evidence 
suggesting that increased age and BMI are related to a decrease in insulin sensitivity in 
both white and black populations (Chandler-Laney et al., 2011), the above ethnic 
difference may indicate that an increase of age and BMI may result in a greater decrease 
of insulin sensitivity in white populations compared to black populations.  
Increased accumulation of VAT is explained by the spill-over theory which suggests that 
with increasing SAT, adipocytes within SAT become dysfunctional and unable to store 
excess triglycerides efficiently which causes the release of excess NEFAs into the 
circulation that get deposited in the VAT depot (Sattar and Gill, 2014, Shulman, 2014). 
One of the features of dysfunctional SAT is reduced adipose tissue insulin sensitivity 
detected by greater lipolytic activity during the insulin-stimulated state (Gastaldelli et al., 
2017). This analysis showed no ethnic differences in adipose tissue insulin sensitivity 
indicating that adipose tissue is equally responsive to the antilipoytic effects of insulin in 
both ethnic groups. However, VAT was significantly inversely associated with adipose 
tissue insulin sensitivity in the WE men but not BWA men. This suggests that VAT 
deposition in WE men occurs with increasing adipose tissue insulin resistance as 
suggested by the spill-over theory. Furthermore, the inverse relationship between adipose 
tissue insulin sensitivity and VAT remained significant after adjustment for age and BMI 
in the WE men; this indicates that the accumulation of VAT may be directly related to 
the dysfunction of SAT, independently of age and BMI. The lack of a significant inverse 
relationship between VAT and adipose tissue insulin sensitivity in the BWA men 
indicates that, unlike WE men, VAT deposition may be influenced to a lesser degree by 





accumulation may differ between WE and BWA men and the spill-over theory may not 
apply to black populations.  
Previous studies have shown that dSAT has a similar relationship with whole-body 
insulin resistance as VAT while sSAT shows no relationship or protective qualities in 
T2D (Golan et al., 2012). However, the data presented here showed that whole-body 
insulin sensitivity decreased with increasing dSAT and sSAT in both WE and BWA men. 
Despite the decrease in sample size, investigation of these relationships in the NGT and 
T2D states showed specific ethnic trends. While whole-body insulin sensitivity decreased 
with an increase of dSAT and sSAT in WE and BWA men in the NGT groups, in the 
T2D groups, these relationships were only present in the WE men. Also evident is the 
consistently stronger inverse relationships between all adipose depots investigated and 
measures of insulin sensitivity in WE men than BWA men. These findings further support 
the notion that the greater prevalence of T2D in black populations are not explained by 
patterns of body adiposity. 
Visceral adipose tissue is thought to cause insulin resistance due to its greater release of 
NEFAs into the circulation particularly into the portal vein which has direct access to the 
liver; the excess NEFAs then cause lipotoxicity of the liver and reduce its sensitivity to 
insulin (Patel and Abate, 2013a). However, it has been postulated that the accumulation 
of VAT is a marker of dysfunctional SAT and, while VAT has several pathogenic 
features, it is strongly related to increased dysfunction of SAT (Smith, 2015). 
Dysfunctional SAT has an increased release of NEFAs that are toxic to all organs and 
cause several disturbances that underlie insulin resistance in the development of T2D 
(Smith and Kahn, 2016). Based on this view, it may be the dysfunction of adipose tissue 





protected from VAT accumulation. Hence, future studies should investigate ethnic 
differences in adipose tissue function which may untangle these speculations. 
While VAT has greater lipolytic activity, SAT accounts for approximately 80% of total 
body adipose tissue in most individuals. Contrary to common belief, the SAT 
compartment contributes more so to the circulatory NEFA pool than VAT (Klein, 2004). 
Nielsen et al. showed this clearly using isotopic tracing of NEFAs from various adipose 
tissue compartments; the findings of this are summarised in Figure 3.10 (Nielsen et al., 
2004). The accumulation of VAT and ASAT has been postulated to be a result of a 
metabolic state of insulin resistance as well as genetic and environmental factors that are 
exacerbated during a positive energy balance (Klein, 2004). This notion is supported by 
several studies attempting to reduce the burden of T2D and insulin resistance by 
surgically removing ASAT and VAT. Surprisingly these studies consistently showed that 
surgical removal of large percentages of ASAT or VAT did not improve insulin 
sensitivity (Fabbrini et al., 2010, Foster and Pagliassotti, 2012, Zhao et al., 2018). The 
lower VAT in BWA men may support these studies that suggest VAT is a marker but not 
















Figure 3.10: Approximate contributions of visceral adipose tissue, upper-body and 
lower-body subcutaneous adipose tissue to the NEFA pool in the systemic and portal 





3.5.4!Strengths and limitations 
This study has several strengths worth noting which include the use of MRI to determine 
measures of regional adipose tissue because MRI is considered to be the gold-standard 
non-invasive method of quantifying body composition components. However, a 
limitation is the analysis of a single MRI image as opposed to all MRI images of the 
whole abdominal cavity. This is of particular importance due to evidence from body 
composition studies that have shown black populations have lower trunk lengths and 
greater limb lengths compared to white populations (Bogin and Varela-Silva, 2010); 
therefore, the total volume of abdominal fat may have differed more greatly between the 
WE and BWA men.  
Another strength is the assessment of dSAT and sSAT as well as their relationships with 
whole-body insulin sensitivity which has not previously been conducted in a black 
population. However, to fully understand whether functional, structural and genetic 
differences exist in dSAT and sSAT between WE and BWA men, further adipose tissue 
biopsy studies are required. The investigation of regional adipose tissue depots by 
ethnicity and glycaemic state is another novel aspect of this analysis; however, the smaller 
sample sizes of the ethnic groups within each glycaemic state, as opposed to all glycaemic 






This study has demonstrated that BWA men have lower VAT, VAT:ASAT and 
dSAT:sSAT compared to BMI-matched WE men while no ethnic differences in ASAT, 
dSAT and sSAT were detected. The lower VAT in the BWA men was present at all 
glycaemic states indicating it appears to be an ethnic characteristic which is unique to 
black populations regardless of T2D risk. Furthermore, VAT showed strong inverse 
relationships with whole-body and hepatic insulin sensitivity in both WE and BWA men. 
This suggests that despite the lower VAT in BWA men, it appears to have similar 
lipotoxic effects in black populations as it does in white population but this lipotoxicity 
occurs at a lower level of VAT in black populations. The relationship between VAT and 
adipose tissue insulin resistance differed by ethnicity where it was present in WE men but 
not BWA men. Hence, dysfunctional SAT, characterised by reduced adipose tissue 





Chapter 4:!Ethnic differences in intrahepatic lipid 
and its relationship with hepatic insulin sensitivity 







Data presented in this chapter have been published in (appendix I and 
appendix II):  
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The liver plays an integral role in glucose metabolism and thus the development of T2D. 
In the NGT state, insulin acts on the liver to mediate both endogenous glucose production 
and insulin clearance; both these functions are altered in individuals with T2D (Defronzo, 
2009, Iozzo et al., 2003). During the progression from NGT to T2D, the liver becomes 
insulin resistant and, therefore, the suppression of glucose production by insulin is 
decreased while the rate of hepatic insulin clearance is reduced. The reduction in insulin 
clearance has been considered a protective mechanism to increase circulating insulin 
levels during insulin resistance in order to preserve beta-cell function (Piccinini et al., 
2017).  
As well as the deterioration of the metabolic functions of the liver, ectopic storage of 
triglycerides in the liver, termed intrahepatic lipid (IHL), is found to be elevated in 
individuals with T2D (Shulman, 2014). Furthermore, the prevalence of non-alcoholic 
fatty liver disease (NAFLD) is alarmingly 65% in populations with T2D, which is 
estimated to be more than twice that of the general population (Doycheva et al., 2016). 
There has been increasing interest in IHL in T2D research particularly since IHL has been 
linked more closely with several metabolic parameters of T2D compared to other fat 
depots, including visceral adipose tissue (VAT) (Lee et al., 2012, Fabbrini et al., 2009, 
Hong et al., 2016). Several studies have compared IHL to VAT and concluded that IHL 
is more strongly linked to T2D than VAT (Kantartzis et al., 2010, Kadowaki et al., 2019). 
One of those studies was a longitudinal study of over 15,000 adults, which was conducted 
by Okamura et al., who showed fatty liver presented a greater risk for incidence T2D 
compared to high VAT and obesity (Okamura et al., 2019). Similarly, Lee et al. showed 
that after, adjustment for age and sex, fatty liver was a significant independent risk factor 





lipotoxicity of the hepatocytes by interfering with cellular signalling functions including 
those mediated by insulin (Snel et al., 2012). Investigations of the role of IHL in the 
development of T2D have shown that IHL is inversely associated with both hepatic 
insulin sensitivity and insulin clearance (Kotronen et al., 2007, Kotronen et al., 2008, 
Seppala-Lindroos et al., 2002). Therefore, there is much evidence that highlights the 
detrimental role of IHL accumulation in the development of T2D. 
The main theory that describes the mechanism behind IHL accumulation is the portal 
theory, which states that IHL deposition results from high flux of NEFAs that are 
transported via the portal vein (Item and Konrad, 2012). NEFAs are detrimental to 
metabolic functions of the liver by causing lipotoxicity to the local environment in which 
they reside as well as promoting the deposition of IHL (Liu et al., 2016). Since, VAT is 
the only adipose depot that has direct access to the portal vein, as well as being a highly 
lipolytic fat depot, an increase of NEFAs from VAT to the liver has been suggested to 
drive IHL accumulation (Rytka et al., 2011); this phenomenon is a key feature of the 
portal theory. However, it is also likely that excess circulating NEFAs from SAT that 
drive VAT accumulation, particularly in a state of dysfunctional SAT, also contribute to 
excess NEFA delivery to the liver (Klein, 2004, Nielsen et al., 2004). These suggestions 
highlight the interrelated nature of the spill-over and portal theories, which most likely 
occur simultaneously (Castro et al., 2014).  
Ethnic differences in IHL, insulin clearance and hepatic insulin sensitivity have been 
reported between black and white populations. Despite the greater risk of T2D in black 
populations, they have consistently been shown to have lower levels of IHL compared to 
their white counterparts (Guerrero et al., 2009, Liska et al., 2007, Liu et al., 2016, 
Schwimmer et al., 2005). The lower levels of IHL in black individuals has been attributed 





the above-mentioned portal theory (Guerrero et al., 2009). However, studies investigating 
relationships between various fat depots in black populations are few, hence, it is unclear 
if the mechanisms that drive IHL accumulation are similar in black and white individuals. 
Therefore, ethnic differences in the mechanisms that drive IHL accumulation will be 
explored in this chapter.  
Investigations of ethnic differences in hepatic insulin sensitivity are few and have shown 
inconsistent conclusions. While some studies report greater hepatic insulin sensitivity in 
blacks compared to whites (Goedecke et al., 2015) others report lower (Ellis et al., 2012), 
however, most report no ethnic differences (DeLany et al., 2014, Arslanian et al., 2002, 
Hannon et al., 2008, Bacha et al., 2012, Lee et al., 2013, Stefan et al., 2004). Consistently, 
insulin clearance has been shown to be lower in black populations compared to white 
populations (Harris et al., 2002, Piccinini et al., 2017, Michaliszyn et al., 2017).  
While several observational studies have investigated IHL in black populations, few have 
explored relationships between IHL and the metabolic parameters of T2D. At present, 
only one study has investigated relationships between IHL and hepatic insulin sensitivity 
(% suppression of EGP) in a black vs white population (Goedecke et al., 2015). 
Additionally, only one study has investigated relationships between IHL and insulin 
clearance in a black vs white population (Chung et al., 2019). Thus, studies of the role of 
IHL on metabolic functions of the liver are lacking in black populations.  
Considering the strong link between IHL and T2D but the paradoxically lower IHL in 
black populations, some researchers have suggested that black individuals appear to be 
more sensitive to the detrimental effects of IHL (Alderete et al., 2013, Goedecke et al., 
2015), while others have suggested that IHL appears to be less detrimental in black 
populations (Chung et al., 2018, Chung et al., 2019). Thus, with the lack of conclusive 





populations. Furthermore, despite ethnic differences being reported in IHL, hepatic 
insulin sensitivity and insulin clearance between black and white populations, they have 
not been previously investigated in a single study to understand the impact of IHL on the 
metabolic functions of the liver and its influence on the development of T2D in black 
populations. Due to the lower levels of IHL present in black populations compared to 
their white counterparts but similar hepatic insulin sensitivity, it is hypothesised that IHL 







The primary aim of this chapter is to assess ethnic differences in intrahepatic lipids (IHL) 
between WE and BWA men of NGT, IGT and T2D glycaemic states. The secondary aim 
is to investigate ethnic differences in the relationships between IHL and hepatic insulin 








The data presented in this chapter were acquired using the methods described in chapter 
2 (sections 2.3.1, 2.3.1.2, 2.3.3, 2.3.3.2, 2.3.4, 2.3.4.1). In brief, IHL was determined by 
the analysis of two abdominal MRI images that have a large area of liver tissue in each 
participant. Four circular regions of interest were positioned on the liver tissue to 
determine % IHL in each region and a mean IHL, using all 8 regions, was calculated. 
Measures of insulin sensitivity were determined using a hyperinsulinaemic-euglycaemic 
clamp test with the infusion of stable glucose and glycerol isotopes to determine whole-
body insulin sensitivity (M-value), hepatic insulin sensitivity (% suppression of EGP), 
and adipose tissue insulin sensitivity (% suppression of lipolysis). Insulin clearance was 
determined using an intravenous glucose challenge (hyperglycaemic clamp). Insulin 
clearance was modelled using c-peptide and insulin data during the intravenous glucose 
challenge. 
4.3.2!Statistical analysis 
IHL, insulin sensitivity and insulin clearance data presented in this chapter for the WE 
and BWA men of NGT, IGT and T2D groups were compared using 2-way between-
groups ANOVA. Ethnicity and glycaemic state were included in the 2-way between-
groups ANOVA as independent variables to assess the main effect of each of the 
independent variables, as well as their interaction (ethnicity*glycaemic state), on the 
outcome measures (dependent variables). Ethnic differences in IHL were tested within 
each glycaemic state using independent samples t-test for normally distributed data or 
Mann-Whitney test for non-parametric data. Strength of relationships between variables 
of interest were tested using Pearson’s correlation test; partial correlation was used when 





the strength of the relationships were examined by fitting a regression with an interaction 








The clinical characteristics of the WE and BWA men of NGT, IGT and T2D groups are 
presented in chapter 3, Table 3.2. The BWA men were slightly older than the WE men 
however there were statistically significant differences in clinical characteristics except 
for waist circumference, triglycerides, which were significantly lower in the BWA men; 
and HbA1c which was greater in the BWA men. 
4.4.2!Intrahepatic lipids 
IHL in the WE and BWA men of NGT, IGT and T2D are presented Table 4.1, which 
shows IHL was significantly lower in the BWA men than WE men, indicated by a 
significant main effect for ethnicity. Additionally, IHL was significantly lower in the 
NGT groups than the IGT and T2D groups, indicated by a significant main effect for 
glycaemic state. Analysis of ethnic differences in IHL within each glycaemic state 
showed IHL was significantly lower in the BWA men within each glycaemic state (NGT: 
p=0.044, IGT: p=0.049, and T2D: p=0.027), as presented in Figure 4.1, which shows the 
individual values of IHL within each ethnic and glycaemic group.  
Non-alcoholic fatty liver disease (NAFLD) can be defined as an IHL level above 5% 
determined by Dixon-MRI (Noureddin et al., 2013); using this criteria, the percentage of 
participants with NAFLD is presented in Table 4.1. The presence of NAFLD was 
significantly lower in the BWA men compared to the WE men within each glycaemic 
state. There were no significant ethnicity by glycaemic state interactions for IHL and 
NAFLD, indicating the ethnic differences in these variables are similar within each 





Table 4.1: IHL and metabolic parameters in the WE and BWA men of NGT, IGT and T2D glycaemic states. 
 
Data presented as mean ± SD or geometric mean (95% CI) for log transformed data (*). P eth: main effect for ethnicity, P gly: main effect for glycaemic state, P eth*gly: interaction 
effect for ethnicity*glycaemic state determined using a 2-way between-groups ANOVA. Insulin clearance data not available for IGT. 
an: NGT: WE=23, BWA=18; IGT: WE=9, BWA=10; T2D: WE=18, BWA=18; bn: NGT: WE=21, BWA=18; IGT: WE=9, BWA=10; T2D: WE=13, BWA=15; cn: NGT: WE=22, 
BWA=18; IGT: WE=7, BWA=9; T2D: WE=11, BWA=15; dn: NGT: WE=21, BWA=19 
 
 































0.001 0.010 0.52 
Non-alcoholic fatty liver disease 
(% of participants) 
35 10 70 30 67 33 0.001 0.014 0.81 
Metabolic parameters          
Whole-body insulin sensitivity 
(M-value)  
(mg/m2 BSA min-1)a 
309.6 ± 
127.5 
313.5 ± 77.0 214.6 ± 99.8 197.0 ± 59.9 154.4 ± 76.2 191.0 ± 85.3 0.71 <0.001 0.56 
Hepatic insulin sensitivity (% 













0.60 <0.001 0.54 
Adipose tissue insulin sensitivity 
(% suppression of lipolysis)c 
53.8 ± 17.4 43.4 ± 25.2 47.8 ± 7.6 46.8 ± 14.0 35.5 ± 14.5 37.2 ± 16.0 0.45 0.027 0.39 
Insulin clearance  































Measures of insulin sensitivity and insulin clearance are presented in Table 4.1. There 
were no ethnic differences in whole-body, hepatic and adipose tissue insulin sensitivity 
between the WE and BWA men. All insulin sensitivity measures differed by glycaemic 
state and showed a deterioration between the NGT to IGT to T2D states. Insulin clearance 
data were available for the NGT and T2D groups, which showed significantly lower 
insulin clearance in the BWA men, indicated by a significant main effect for ethnicity. 
Furthermore, there was a significant ethnicity*glycaemic state interaction for insulin 
clearance. Post-hoc analysis showed this was driven by lower insulin clearance in the 
BWA men of NGT since insulin clearance did not differ between the T2D men (p=0.78) 
but differed significantly between the NGT men (p<0.001).  
Figure 4.1: Intrahepatic lipids in the WE and BWA men of NGT, IGT 





4.4.4!Relationships between intrahepatic lipids and hepatic insulin 
sensitivity 
Relationships between IHL and hepatic insulin sensitivity are presented in Table 4.2 and 
Figure 4.2 (panel A) for the WE and BWA men in all glycaemic cohorts combined. 
Previous studies have shown with increasing age and BMI, IHL also increases (Ulbrich 
et al., 2015) while insulin sensitivity decreases (Cnop et al., 2003); therefore, to reduce 
their influence, the above relationships were adjusted for both age and BMI, Table 4.2. 
IHL was significantly inversely associated with hepatic insulin sensitivity in both WE 
and BWA men; these relationships diminished after adjustment for age and BMI. 
Furthermore, these relationships did not differ by ethnicity indicated by a non-significant 
ethnicity interaction (P=0.21). 
The assessment of relationships in the combined glycaemic cohorts benefits from greater 
sample sizes, however, glycaemic state may influence these relationships. Therefore, the 
above relationships were investigated in the NGT and T2D glycaemic states, which are 
presented in Table 4.3 and Figure 4.2 (panel B). In the NGT groups, IHL was significantly  
 inversely associated with hepatic insulin sensitivity in WE men but not BWA men. No 
significant relationships were present in the T2D groups, which may be due to the 











Table 4.2: Pearson’s correlation and partial correlation coefficients showing 




Table 4.3: Pearson’s correlation coefficients showing relationships between IHL and 
hepatic insulin sensitivity in WE and BWA men of NGT and T2D groups. 
 WE BWA 
Intrahepatic lipids r p r p 
Hepatic insulin sensitivity (% 
suppression of EGP) 
    
NGT -0.55 0.010 -0.17 0.49 
n 21  18  
T2D -0.06 0.85 -0.46 0.10 







Intrahepatic lipids r p r p 
Hepatic insulin sensitivity (% 
suppression of EGP) 
-0.37 0.014 -0.38 0.013 
Adjusted for age -0.23 0.15 -0.28 0.072 
Adjusted for BMI -0.07 0.67 -0.19 0.25 











Figure 4.2: Relationships between IHL and hepatic insulin sensitivity (% 
suppression of endogenous glucose production) in the WE and BWA men of 
all glycaemic states (NGT, IGT and T2D), A; and in the NGT and T2D 





4.4.5!Relationships between intrahepatic lipids and whole-body and 
adipose tissue insulin sensitivity 
Relationships between IHL and whole-body and adipose tissue insulin sensitivity are 
presented in Table 4.4 in all glycaemic cohorts combined. IHL was inversely associated 
with whole-body insulin sensitivity in both WE and BWA men; this relationship 
remained significant after adjustment for age and BMI in the WE men but completely 
diminished in the BWA men. IHL was inversely associated with adipose tissue insulin 
sensitivity in WE men but not BWA men. There were no significant ethnicity interactions 
for the relationships between IHL and whole-body insulin sensitivity (P=0.30) or adipose 
tissue insulin sensitivity (P=0.25).  
To reduce the influence of possible confounders related to glycaemic state, the above 
relationships were investigated in the NGT and T2D groups, presented in Table 4.5. These 
relationships showed distinct ethnic differences where IHL was inversely associated with 
whole-body insulin sensitivity in the WE men but not BWA men of NGT and T2D states. 
Furthermore, IHL was inversely associated with adipose tissue insulin sensitivity in the 
WE men but not BWA men of NGT; however, no significant relationships were present 
in the T2D men which may be due to the low sample sizes. Taken together, the 
correlations between IHL and measures of insulin sensitivity in NGT and T2D groups 





Table 4.4: Pearson’s correlation and partial correlation coefficients showing 
relationships between IHL and whole-body and adipose tissue insulin sensitivity in WE 
and BWA men of all glycaemic states. 
 
Table 4.5: Pearson’s correlation coefficients showing relationships between IHL and 
whole-body and adipose tissue insulin sensitivity in WE and BWA men of NGT and T2D 
groups. 
 WE BWA 
Intrahepatic lipids r p r p 
Whole-body insulin sensitivity 
(M-value) 
-0.70 <0.001 -0.43 0.004 
n 50  44  
Adjusted for age -0.65 <0.001 -0.35 0.023 
Adjusted for BMI -0.43 0.002 -0.19 0.23 
Adjusted for age and BMI -0.45 0.002 -0.15 0.36 
Adipose tissue insulin sensitivity  
(% suppression of lipolysis) 
-0.49 0.001 -0.07 0.65 
n 40  41  
Adjusted for age -0.38 0.020 -0.08 0.64 
Adjusted for BMI -0.09 0.56 -0.07 0.69 
Adjusted for age and BMI -0.07 0.66 -0.07 0.68 
 WE BWA 
Intrahepatic lipids r p r p 
Whole-body insulin sensitivity 
(M-value) 
    
NGT -0.75 <0.001 -0.20 0.42 
n 23  18  
T2D -0.62 0.006 -0.34 0.20 
n 18  16  
Adipose tissue insulin sensitivity 
(% suppression of lipolysis) 
    
NGT -0.56 0.007 -0.04 0.89 
n 22  18  
T2D -0.27 0.42 -0.16 0.58 





4.4.6!Relationships between intrahepatic lipids and insulin clearance 
Relationships between IHL insulin clearance are presented in Table 4.4 and Figure 4.3 
(panel A) for the WE and BWA men in all glycaemic cohorts combined. As previously 
mentioned, IHL increases with increasing age and BMI, while insulin clearance decreases 
(Ehrhardt et al., 2019); therefore, to reduce their influence, the above relationships were 
adjusted for both age and BMI, Table 4.6. IHL was inversely associated with insulin 
clearance in the WE men but not the BWA men; however, this relationship diminished 
after adjustment for age and BMI. There was no significant ethnicity interaction present 
for this relationship (P=0.55). 
Relationships between IHL and insulin clearance are presented in the WE and BWA men 
within the NGT and T2D glycaemic states in Table 4.7 and Figure 4.3 (panel B). In the 
NGT groups, IHL was inversely associated with insulin clearance in the WE men but not 
BWA men. However, no relationships were present in the T2D groups which may be 















Table 4.6: Pearson’s correlation and partial correlation coefficients showing 




Table 4.7: Pearson’s correlation coefficients showing relationships between IHL and 
insulin clearance in WE and BWA men of NGT and T2D groups. 
 WE BWA 
Intrahepatic lipids r p r p 
Insulin clearance     
NGT -0.78 <0.001 -0.12 0.62 
n 21  19  
T2D -0.14 0.58 -0.42 0.085 








Intrahepatic lipids r p r p 
Insulin clearance  -0.43 0.006 -0.26 0.12 
Adjusted for age -0.37 0.021 -0.35 0.039 
Adjusted for BMI -0.18 0.28 -0.24 0.15 







Figure 4.3: Relationships between IHL and insulin clearance in the WE and 
BWA men of the combined NGT and T2D glycaemic states, A; and separately in 





4.4.7!Relationships between intrahepatic lipids and measures of 
regional adiposity 
To investigate ethnic differences in the measures of regional adiposity that may influence 
IHL deposition, relationships between IHL and measures regional adiposity are presented 
in Table 4.6 for the WE and BWA men in all glycaemic cohorts combined. IHL was 
associated with VAT and ASAT in both WE and BWA men. Further analysis of these 
relationships within each glycaemic state are shown in Table 4.7 which showed clear 
ethnic distinctions. In the NGT groups, IHL was associated with VAT and ASAT in WE 
men but not BWA men. However, in the T2D groups, IHL was associated with all 
measures of adiposity in both ethnic groups except for VAT in the WE men and ASAT 
in the BWA men. 
 
Table 4.8: Pearson’s correlation coefficients showing relationships between IHL and 






Intrahepatic lipids r p r p 
VAT 0.48 <0.001 0.65 <0.001 





Table 4.9: Pearson’s correlation coefficients showing relationships between IHL and 





 WE BWA 
Intrahepatic lipids r p r p 
NGT     
n 23  20  
VAT 0.67 <0.001 0.22 0.36 
ASAT 0.55 0.006 0.16 0.51 
T2D     
n 17  18  
VAT 0.30 0.24 0.69 0.002 






The purpose of this chapter was to investigate ethnic differences in intrahepatic lipid 
accumulation between WE and BWA men across three glycaemic states: NGT, IGT and 
T2D. This chapter also explored ethnic differences in relationships between IHL and 
hepatic insulin sensitivity and insulin clearance as well as other parameters related to 
T2D. Ethnic comparisons were conducted between WE and BWA men of all glycaemic 
states combined as well as within each of the glycaemic groups. The present analysis has 
demonstrated that, despite the lower IHL in BWA men at all glycaemic states, it shows 
strong relationships with hepatic and whole-body insulin sensitivity in BWA men and 
WE men. However, IHL was significantly inversely related to adipose tissue insulin 
sensitivity in WE men but not BWA men.  
The lower IHL in BWA men is consistent with previous findings from studies comparing 
black and white populations (Alderete et al., 2014, Goedecke et al., 2017, Guerrero et al., 
2009). Additionally, the lower prevalence rates of NAFLD in the BWA men shown here 
are similar to those previously reported from studies comparing the prevalence of NAFLD 
in different ethnic groups (Browning et al., 2004). The reason for lower IHL in black 
populations may be explained by lower release of circulating NEFAs and triglycerides 
released by the SAT depot which may deposit in the liver. Indeed, White et al. reported 
that black women exhibited significantly lower rates of triglyceride synthesis and de novo 
lipogenesis of the SAT depot compared to white women (White et al., 2018). The liver is 
a principle site of lipid metabolism in the body and an increase of NEFAs, from dietary 
and non-dietary sources, promote hepatic lipid production pathways such as de novo 
lipogenesis and the production of VLDL particles (Berlanga et al., 2014). Since IHL is 
also related to excess hepatic lipid production (Stefan et al., 2008a), the lower IHL in 





populations (Goff et al., 2013, Winkley et al., 2013). Indeed, in this study, the BWA men 
exhibited lower triglyceride levels than WE men. This notion has been suggested by other 
studies which have demonstrated direct relations between IHL and plasma lipoprotein 
levels in black and white adolescents (D'Adamo et al., 2010). 
4.5.1!Intrahepatic lipids and hepatic insulin sensitivity 
Since IHL is lower in BWA men than WE men, it is expected that they would exhibit 
greater hepatic insulin sensitivity as it has been extensively reported that IHL is associated 
with diminished hepatic insulin sensitivity (Kelley et al., 2003, Petersen et al., 2005, 
Seppala-Lindroos et al., 2002, Bajaj et al., 2004, Hwang et al., 2007, Gastaldelli et al., 
2007). However, there were no ethnic differences in hepatic insulin sensitivity indicating 
IHL may not be as important in reducing insulin sensitivity in BWA men as WE men or 
that IHL reduces insulin sensitivity at lower levels in BWA men. To further explore these 
speculations, relationships between IHL and hepatic insulin sensitivity were investigated. 
This investigation showed IHL was inversely related to hepatic insulin sensitivity (% 
suppression of EGP) in both ethnic groups. Hence, it is evident that with an increase of 
IHL there is a similar decrease in hepatic insulin sensitivity in WE and BWA men 
indicating that BWA men appear to experience the detrimental effects of IHL at lower 
levels than WE men. 
The advantage of the analysis of relationships in the combined glycaemic states is the 
greater power; however, the pathophysiology of T2D is better understood during an 
individual glycaemic state since many metabolic parameters, such as insulin sensitivity, 
do not follow a linear pattern in the progression from NGT to T2D (Ramlo-Halsted and 
Edelman, 2000). Furthermore, the understanding of the role of ectopic fat in the 
pathophysiology of T2D has been expanded by studies conducted individual glycaemic 





2007, van der Zijl et al., 2011), therefore, the above relationships were investigated in the 
NGT and T2D groups separately. Even though this analysis included considerably lower 
sample sizes, it may be more informative in untangling the role of IHL in the 
pathophysiology of T2D, particularly in the NGT state. 
The analysis of relationships between IHL and hepatic insulin sensitivity by ethnicity in 
the NGT and T2D glycaemic states showed some ethnic distinctions. In the NGT state, 
IHL was significantly inversely related to hepatic insulin sensitivity in WE men but this 
relationship was not significant in the BWA men, while, in the T2D state, IHL showed 
no associations in either ethnic group. Therefore, due to the stronger inverse relationships 
between IHL and hepatic insulin sensitivity in WE men in the NGT state, it appears that 
IHL may play a lesser role in reducing hepatic insulin sensitivity in BWA men than WE 
men. Only one other study investigated relationships between IHL and hepatic insulin 
sensitivity, measured using the hyerinsulinaemic-euglycaemic clamp with the infusion of 
glucose isotopes, in a black vs white group (Goedecke et al., 2015). They found IHL was 
inversely associated with hepatic insulin sensitivity in NGT black but not white women 
with obesity. While, in a study that explored IHL and basal hepatic insulin sensitivity 
index (HISI), Chung et al. showed IHL was inversely related to basal HISI in black and 
white women (Chung et al., 2018). Both of these studies were conducted in NGT women 
with obesity but showed contrary findings to those in the NGT men in the analysis 
presented here. These disparities may be explained by gender differences as there is 
consistent evidence showing that the phenotype of T2D differs by gender within 
populations of African descent with T2D being more strongly driven by excess adiposity 





4.5.2!Intrahepatic lipids and whole-body insulin sensitivity 
Previous studies have shown that IHL is a stronger predictor of whole-body insulin 
sensitivity than other measures of adiposity including VAT, making a case for IHL being 
the most important ectopic fat depot in T2D risk (Kirchhoff et al., 2007, Hong et al., 2016, 
D'Adamo et al., 2010). Extensive studies have been conducted in both animal and human 
models to elucidate the mechanisms of IHL induced whole-body insulin resistance 
(Trouwborst et al., 2018). Current investigations show excess IHL deposition leads to 
accumulation of lipid intermediates that cause hepatic mitochondrial dysfunction, 
inflammation and increased VLDL-TG production, which may drive systemic insulin 
resistance (Trouwborst et al., 2018). In the present study, IHL was inversely related to 
whole-body insulin sensitivity in both ethnic groups, however, this relationship remained 
significant in only the WE men after adjustment for age and BMI. This indicates that 
individual susceptibility to IHL accumulation may influence whole-body insulin 
sensitivity independently of age and degree of whole-body adiposity in WE men but not 
BWA men. The ethnic disparities in these relationships extend to the individual 
glycaemic states where IHL was inversely related to whole-body insulin sensitivity in the 
WE men but not BWA men. This finding in WE men supports previous studies, which 
highlight the pivotal role of IHL in the pathophysiology of T2D, however, in BWA men 
the influence of IHL is less apparent than in WE men.  
4.5.3!Intrahepatic lipids and adipose tissue insulin sensitivity 
The deposition of IHL is thought to be explained by the spillover theory and the portal 
theory which have similarities in their features. Both these theories describe the excess 
release of NEFAs into the circulation, due to dysfunctional adipose tissue, that become 
deposited as IHL (Bosy-Westphal et al., 2019). Reduced adipose tissue insulin sensitivity 





considered to be one of the drivers of IHL accumulation (Gastaldelli et al., 2017). Indeed, 
several reports have linked dysfunctional adipose tissue and adipose tissue insulin 
resistance to an increase of IHL accumulation (Lomonaco et al., 2012, Bell et al., 2012). 
Shown in this chapter is a significant inverse association between IHL and adipose tissue 
insulin sensitivity in the WE but not BWA men, which was also present in the NGT 
glycaemic state. This indicates that IHL deposition may be more strongly influenced by 
adipose tissue insulin resistance in WE men than BWA men. However, this relationship 
diminished after adjustment for BMI which may indicate that IHL accumulation resulting 
from adipose tissue insulin resistance is dependent upon adipose tissue expansion. Hence, 
considering IHL to be a major contributor to T2D, this finding supports the well-known 
link between increasing whole-body adiposity and risk of T2D. Furthermore, this notion 
may hold true more so in white men compared to black men who have a greater 
prevalence of T2D in the healthy BMI category compared to white populations (Zhang et 
al., 2009).  
It is particularly noticeable that despite the reduction in sample size for the relationships 
presented in the individual glycaemic states, relationships between IHL and all measures 
of insulin sensitivity were stronger in the WE men of NGT but were weaker in the BWA 
men. This interesting phenomenon may be explained by lower sample size in the BWA 
men but may further suggest that IHL is less detrimental in the development of T2D in 
BWA men than WE men. Additionally, genetic predisposition to T2D may play a more 
important role in BWA men because the NGT men had a negative family history of T2D; 
future studies to elucidate these speculations are warranted. 
4.5.4!Intrahepatic lipids and insulin clearance 
Considering the role of IHL in insulin clearance, correlation analysis showed IHL was 





pattern was also evident in the NGT glycaemic state. The findings in the WE men support 
previous findings that suggest IHL may impact insulin clearance, however, in BWA men, 
IHL appears to have less influence on insulin clearance. Supporting the ethnic distinctions 
presented here, Chung et al. showed that IHL was inversely associated with hepatic 
insulin clearance in white but not black women (Chung et al., 2019). However, the data 
in this chapter along with those by Chung et al. are the only two studies that have 
investigated relationships between IHL and insulin clearance in a black population. 
Hence, since reduced insulin clearance has been suggested to be a defect that may play a 
crucial role in the development of T2D in black populations (Bergman et al., 2019), 
further studies are required to clarify whether the reduced insulin clearance is a result of 
hepatic lipotoxicity in black populations (Piccinini et al., 2018, Bergman et al., 2019). 
4.5.5!Intrahepatic lipids and regional adiposity 
To understand the possible drivers of IHL accumulation, relationships between IHL and 
regional measures of adipose tissue were investigated. This analysis showed that both 
abdominal VAT and ASAT were strongly related to IHL accumulation in both ethnic 
groups. Similar findings have previously been reported in black and white adolescents 
with obesity (Lee et al., 2017). IHL accumulation appears to be directly influenced by 
VAT and SAT accumulation, which is consistent with previous studies that show strong 
relationships between IHL and whole-body and abdominal adiposity (Rossi et al., 2011, 
Thomas et al., 2005, Eguchi et al., 2006). When investigated in each glycaemic state, 
despite the reduction in samples size, these relationships showed clear distinctions by 
ethnicity. In the T2D groups, IHL was related to VAT and ASAT in both ethnic groups; 
however, in the NGT groups these relationships were present in only the WE men. It 





deposition. Furthermore, the portal theory, which places VAT as the major determinant 
of IHL accumulation, may not to apply to NGT BWA men. 
4.5.6!Strengths and limitations 
This chapter has several strengths worth noting including the direct quantification of IHL 
using MRI. Another strength is the measurement of whole-body, hepatic and adipose 
tissue insulin sensitivity using the hyperinsulinaemic-euglycaemic clamp with the 
infusion of stable glucose and glycerol isotopes, which is considered to be the gold-
standard method for determining these measures.  
A limitation of the presented measure of insulin clearance is that it represents whole-body 
insulin clearance and is not specific to the liver, however, approximately 80% of insulin 
is cleared by the liver (Ferrannini et al., 1983). Another limitation is the slightly greater 
statin use in the WE men with T2D than BWA men which may have impacted the 
metabolic functions of the liver more so in WE men as statins have been shown to reduce 
IHL and limit their lipotoxic effects (Schierwagen et al., 2017, Sigler et al., 2018). The 
lack of data on alcohol consumption in the participants is also a limitation as alcohol is 
known to affect IHL accumulation and disturb several functions of the liver. However, 
tests were conducted to exclude participants with liver damage as determined by alanine 






This chapter shows that IHL is lower in BWA men at all glycaemic states with a lower 
presence of NAFLD in BWA men compared to WE men. While IHL was inversely 
related to hepatic and whole-body insulin sensitivity in both WE and BWA men, these 
relationships were consistently stronger in the WE men. Furthermore, the inverse 
relationship between IHL and insulin clearance was significant in only the WE men. Also, 
IHL was significantly inversely related to adipose tissue insulin sensitivity in WE men 
but not BWA men. These ethnic discrepancies may be explained by the lower range of 
IHL in the BWA men, however, they may suggest that IHL plays a lesser role in the 
development of T2D in BWA men compared to WE men. To understand the role of IHL 
in T2D in black populations, future studies ought to compare the effects of IHL lowering 






Chapter 5:!Ethnic differences in intrapancreatic 
lipid and its relationship with beta-cell function in 
men of black and white ethnicity 
 
 
Data presented in this chapter have been published in (appendix I and 
appendix III):  
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Beta-cell dysfunction is an integral component in the development of T2D. The prolonged 
exertion of the beta-cells to secrete sufficient insulin to overcome insulin resistance leads 
to exhaustion of beta-cells and impairment of their insulin secretory function (ISF) 
(Defronzo, 2009). Pancreatic abnormalities are evident in patients with T2D which 
include a reduction in pancreatic volume (Macauley et al., 2015, Garcia et al., 2017, 
DeSouza et al., 2018), irregular pancreatic borders (Macauley et al., 2015), substantial 
loss of beta-cell mass (Guillausseau et al., 2008) and a reduction in ISF (Kahn, 1998). 
The abnormalities typically observed in the structure and function of the pancreas during 
the development of T2D have been related to glucotoxicity, lipotoxicity and oxidative 
stress, mediated by excess fat in the pancreas; however, the exact mechanisms that link 
them are poorly understood (Poitout et al., 2010). While the link between VAT and IHL 
with T2D have been well documented, the role of the accumulation of triglycerides in the 
pancreas, termed intrapancreatic lipids (IPL), in the development of T2D has only 
recently gained increasing attention. 
Compared to healthy controls, patients with T2D have been shown to have greater 
accumulation of IPL (Tushuizen et al., 2007, van der Zijl et al., 2011, Ou et al., 2013, 
Begovatz et al., 2015). Following animal studies in the 1990s that showed IPL was related 
to beta-cell dysfunction (Lee et al., 1994), there were several suggestions that IPL is 
related to the development of T2D and pancreatic lipotoxicy by IPL may cause or 
accelerate the deterioration of beta-cell ISF (Yu and Wang, 2017). In the early 2000s, the 
advancement of magnetic resonance technologies made the non-invasive assessment of 
IPL possible in humans; since then, several studies have suggested that IPL may be 
related to beta-cell dysfunction in the development of T2D (Lingvay et al., 2009). More 





related to improved beta-cell ISF, even in patients with T2D (Lim et al., 2011, Taylor et 
al., 2019). IPL is believed to cause beta-cell damage by releasing lipid intermediates and 
NEFAs, which interfere with cellular signalling processes and cause beta-cell apoptosis 
(Sharma and Alonso, 2014). Therefore, there is much evidence that suggests that IPL 
accumulation is an important fat depot in the progression of T2D that deserves further 
attention. 
To elucidate ethnic differences in the pathophysiology of T2D between black and white 
populations, several studies have considered measures of beta-cell ISF. Black populations 
consistently present with greater insulin levels compared to their white counterparts (Osei 
and Schuster, 1994, Hannon et al., 2008). Furthermore, in a meta-analysis, Kodama et al. 
showed black populations had greater beta-cell ISF, determined by the acute insulin 
response, compared to white populations (Kodama et al., 2013). Interestingly, this 
exaggerated insulin secretion in response to a glucose challenge in black populations is 
also present when the black and white groups were matched for insulin sensitivity 
(Kodama et al., 2013, Bacha et al., 2012). However, the possible reasons for the 
commonly reported ethnic differences in beta-cell ISF between black and white 
populations are poorly understood.  
Unlike VAT and IHL, studies of IPL in black versus white populations are more limited 
and report inconsistent conclusions, while some studies report lower levels of IPL in black 
populations (Szczepaniak et al., 2012), others report no difference compared to their 
white counterparts (Trout et al., 2019). While in a study by Lingvay et al., there were no 
ethnic differences in IPL between NGT women within the healthy or obese BMI groups, 
but there was lower IPL in black women with T2D compared to their white/Hispanic 
counterparts (Lingvay I, 2014). With VAT and IHL being consistently lower in black 





of beta-cell ISF in black population, IPL may be a more detrimental fat depot in black 
populations compared to white populations. Supporting this notion is a study by Toledo-
Corral et al. who showed that IPL predicted prediabetes status in black adolescents but 
IHL did not (Toledo-Corral et al., 2013). Meanwhile, in adults, IPL was more strongly 
related to ISF in black adults compared to their white counterparts (Szczepaniak et al., 
2012, Lingvay I, 2014). However, with limited studies conducted on IPL in black 
populations, it is poorly understood whether ethnic differences exist in the role of IPL in 
beta-cell ISF. 
Investigations of regional deposition of IPL have suggested that the distribution of IPL is 
not uniform within the pancreas and may differ between the head, body and tail regions 
of the pancreas. Some studies report greater IPL in the head of the pancreas (Livingstone 
et al., 2014, Chai et al., 2016) while others have shown IPL to be greater in the tail region 
(Idilman et al., 2015, Patel et al., 2013, Pezzilli and Calculli, 2014). Regional IPL 
distribution may be of importance in understanding beta-cell lipotoxicity in the 
development of T2D. Human studies have shown that there is approximately 2-fold 
greater density of beta-cells in the tail of the pancreas compared to the head and body 
(Wang et al., 2013). Furthermore, during the progression of T2D, there is greater loss of 
beta-cells from the head of the pancreas compared to the body and tail (Wang et al., 2013). 
However, it is unknown if IPL impacts beta-cell loss or function differently in the various 
regions of the pancreas. Therefore, regional distribution of IPL is an area that warrants 
investigation in order to increase the understanding of the mechanisms of beta-cell 
lipotoxicity. 
The main theory that describes the mechanism of IPL accumulation is the twin-cycle 
theory which proposes that, during a state of excess energy consumption, excess glucose 





from the liver into the circulation. The excess VLDL-TG in the circulation then deposit 
in the pancreas as IPL, which accelerates beta-cell dysfunction via lipotoxicity, which in 
turn further increases blood glucose levels and drives further production of VLDL-TG in 
the liver (Taylor, 2013). Black populations have been shown to exhibit favourable lipid 
profiles (Gaillard and Osei, 2016, D'Adamo et al., 2010) as well as lower IHL levels 
(Guerrero et al., 2009, Alderete et al., 2014) compared to white populations indicating 
possible lower output of lipids by the liver; however, the impact of this on IPL 
accumulation has not previously been considered in black populations. Thus, the possible 
mechanisms of IPL accumulation will be addressed in the present chapter. 
Due to lower levels of VAT and IHL in black populations compared to white populations, 
it is reasonable to hypothesise that IPL will be lower too. To date, there are only two 
studies that have investigated relationships between IPL and beta-cell ISF in a black 
population (Lingvay I, 2014, Szczepaniak et al., 2012). In these studies, ISF was assessed 
using the intravenous glucose tolerance test to measure the acute insulin response to 
glucose (AIRg) (Lingvay I, 2014, Szczepaniak et al., 2012). However, the AIRg is an 
indirect measure of ISF because it does not typically use c-peptide and therefore cannot 
account for insulin clearance, which is known to differ by ethnicity (Piccinini et al., 2017). 
Therefore, there is a lack of studies investigating the role of IPL on ISF in black 
populations particularly using comprehensive methods to assess beta-cell ISF. This 
chapter will present relationships between IPL and measures of ISF, determined using the 








The primary aim of this chapter is to assess and compare ethnic differences in 
intrapancreatic lipids (IPL) between WE and BWA men of NGT, IGT and T2D glycaemic 
states. The secondary aim is to investigate ethnic differences in the relationships between 







The data presented in this chapter were acquired from the methods described in chapter 
2 (sections 2.3.1, 2.3.1.3, 2.3.3, 2.3.3.1). In brief, IPL was determined by the analysis of 
abdominal MRI images, which have the greatest area of intrapancreatic tissue, for each 
participant. A single circular region of interest was positioned on each of the head, body 
and tail of the pancreas to determine % IPL in each region and a mean IPL, using all 
three regions, was calculated. Measures of insulin secretory function (ISF) were 
determined using an intravenous glucose challenge (hyperglycaemic clamp) method. 
The measures of beta-cell ISF derived from this assessment include insulin secretion 
rate as well as modelled first- and second-phase ISF.  
5.3.2!Statistical analysis 
IPL and beta-cell ISF data presented in this chapter for the WE and BWA men of NGT, 
IGT and T2D groups were compared using 2-way between-groups ANOVA. Ethnicity 
and glycaemic state were included in the 2-way between-groups ANOVA as independent 
variables to assess the main effect of each of the independent variables, as well as their 
interaction (ethnicity*glycaemic state), on the outcome measures (dependent variables). 
Assessment of ethnic differences in measures of IPL within each glycaemic state were 
conducted using independent samples t-test. ISF data were available for only the NGT 
and T2D glycaemic states and were compared between the WE and BWA men using a 2-
way between-groups ANOVA as described above. Strength of relationships between 
variables of interest were tested using Pearson’s correlation test; partial correlation was 
used when assessing relationships while adjusting for confounding variables. Ethnic 
differences in the strength of the relationships were examined by fitting a regression with 







The clinical characteristics of the WE and BWA men of NGT, IGT and T2D are presented 
in chapter 3, Table 3.2. The two ethnic groups were well matched for age and BMI and 
showed no significant differences in clinical characteristics except for waist 
circumference, triglycerides and HbA1c, which were significantly lower in the BWA 
men. 
5.4.2!Intrapancreatic lipids 
IPL of the head (IPLHEAD), body (IPLBODY), tail (IPLTAIL) and the mean of all three regions 
(IPLMEAN) in the WE and BWA men of NGT, IGT and T2D glycaemic states are 
presented Table 5.1. All measures of IPL differed significantly by glycaemic state and 
were greater in the IGT and T2D states compared to the NGT state. The BWA men 
exhibited significantly lower IPLMEAN compared to the WE men which was due to lower 
IPLHEAD (P=0.007) and IPLBODY (P=0.080) in the BWA men. IPLHEAD showed a near 
significant ethnicity by glycaemic state interaction, indicating that the differences in 
IPLHEAD between the glycaemic states differed by ethnicity.  
Analysis of IPLMEAN within each glycaemic state showed it was significantly lower in the 
BWA men in the IGT and T2D glycaemic states but did not differ between the NGT men, 
as presented in Figure 5.1, which shows the individual values of IPLMEAN within each 
ethnic and glycaemic group. Regional measures of IPL are presented for the NGT, IGT 
and T2D glycaemic states in Figures 5.2, 5.3 and 5.4, respectively. Specific patterns of 
regional IPL deposition were evident in the individual glycaemic states. In the NGT state 
there were no ethnic differences in IPL deposition of the head, body and tail; however, in 
both IGT and T2D states, IPLHEAD was significantly lower in the BWA men with no 






Table 5.1: Measures of regional IPL and mean IPL in the WE and BWA men of NGT, IGT and T2D glycaemic states. 
 
 
Data presented as geometric mean (95% CI) as all data was log transformed to achieve a normal distribution. P eth: main effect for ethnicity, P gly: main effect for glycaemic 
state, P eth*gly: interaction effect for ethnicity*glycaemic state determined using a 2-way between-groups ANOVA.  
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Figure 5.1: Mean intrapancreatic lipid in the WE and BWA men of 
NGT, IGT and T2D groups. Boxplots show median (IQR). 
Figure 5.2: Regional deposition of intrapancreatic lipid in the WE 





























Figure 5.3: Regional deposition of intrapancreatic lipid in the WE 
and BWA men of IGT glycaemic state. Boxplots show median (IQR). 
Figure 5.4: Regional deposition of intrapancreatic lipid in the 





5.4.3!Measures of insulin secretory function 
Metabolic measures of basal and stimulated ISF in the WE and BWA men of NGT and 
T2D glycaemic states are presented in Table 5.2. ISF data were not available for the IGT 
glycaemic state due to on-going assessment of these measures. All measures of ISF 
differed significantly by glycaemic state and, as expected, indicated poorer ISF in the 
T2D state. In the basal state, insulin did not differ by ethnicity however c-peptide was 
significantly lower in the BWA men indicting ethnic differences in basal insulin 
clearance.  
C-peptide iAUC determined during the first-phase (0-10 minutes) period was similar in 
the WE and BWA men, however, c-peptide iAUC during the second-phase (10-120 
minutes) was significantly lower in the BWA men. Post-hoc analysis showed this was 
mainly present in the men with T2D, suggesting poorer ISF in the BWA men with T2D 
compared to the WE men. However, when c-peptide was used along with glucose 
concentrations in the modelling of first- and second-phase ISF, no ethnic differences were 
present in both modelled measures of ISF. The insulin secretion rate, determined by c-
peptide concentrations during the stimulated period, was also lower in the BWA men, 
which was driven by lower insulin secretion rate in the BWA men in the T2D glycaemic 
state. Taken together, while absolute insulin secretion was lower in the BWA men, there 








Table 5.2: Measures insulin secretory function (ISF) determined during a 2-hour hyperglycaemic clamp test in the WE and BWA men of NGT and 
T2D glycaemic states. 
 
Data presented as geometric mean (95% CI) as all data was log transformed to achieve a normal distribution. P eth: main effect for ethnicity, P gly: main effect for glycaemic 
state, P eth*gly: interaction effect for ethnicity*glycaemic state determined using a 2-way between-groups ANOVA. 
an: NGT WE=22 
 
 















Basal insulin (pmol/l) 39.4 (30.1-51.6) 44.9 (36.9-54.5) 100.1 (68.8-145.7) 71.2 (54.6-92.7) 0.43 <0.001 0.082 
Basal c-peptide (nmol/l) 0.69 (0.54-0.83) 0.56 (0.48-0.64) 0.93 (0.75-1.11) 0.57 (0.48-0.66) <0.001 0.050 0.073 
c-peptide iAUC 0-10 mins  
(nmol/l min-1)a 
7.17 (6.10-8.31) 8.48 (5.94-
11.42) 
0.90 (0.33-1.50) 0.55 (0.04-1.08) 0.64 <0.001 0.22 
c-peptide iAUC 10-120 mins  
(nmol/l min-1)a 
203 (176-235) 213 (170-267) 108 (86-136) 56 (39-79) 0.009 <0.001 0.003 
First-phase ISF 





49.6 (15.0-131.9) 51.7 (27.4-139.3) 0.53 <0.001 0.22 
Second-phase ISF 
[(pmol min-1 m2 BSA)/mmol/l)]a 
43.0 (35.1-52.8) 44.2 (34.8-56.3) 13.1 (8.02-21.5) 7.4 (4.5-12.1) 0.77 <0.001 0.87 
















5.4.4!Relationships between intrapancreatic lipids and measures of 
insulin secretory function 
Relationships between mean IPL and measures of ISF are presented in Table 5.3 for the 
WE and BWA men of NGT and T2D glycaemic states combined. IPLMEAN was inversely 
associated with first-phase ISF in WE men but this relationship was only trending towards 
significance in BWA men. IPLMEAN was inversely associated with second-phase ISF in 
WE men but not BWA men. There were no relationships between IPLMEAN and insulin 
secretion rate in both ethnic groups. There were no significant interactions by ethnicity 
for the relationships between IPLMEAN and all measures of ISF (all Pinteraction>0.05). All 
associations between IPLMEAN and measures of ISF diminished after adjustment for age 
and BMI (all P>0.05). Investigating these relationships for the regional measures of IPL 
showed distinct ethnic patterns; in WE men, the relationships with first-phase and second-
phase ISF were stronger in the head than the body and tail of the pancreas. In contrast, in 
the BWA men, the relationships between regional measures of IPL with first-phase ISF 
were stronger for the body and tail regions (data not shown).  
 
Table 5.3: Pearson’s correlation coefficients showing relationships between mean IPL 
and measures of insulin secretory function in WE and BWA men of NGT and T2D 






IPLMEAN r p r p 
First-phase ISF -0.42 0.006 -0.30 0.067 
Second-phase ISF -0.34 0.031 -0.15 0.37 





Relationships between mean IPL and measures of ISF are presented for the WE and BWA 
men within the NGT and T2D glycaemic state in Table 5.4. While, there is considerably 
lower sample sizes in these analyses, a specific trend was evident: all significant 
relationships in the combined ethnic cohorts were not present in the individual glycaemic 
states. Furthermore, the only significant relationship present was that of IPLMEAN and 
insulin secretion rate in NGT WE men but not BWA men.  
 
Table 5.4: Pearson’s correlation coefficients showing relationships between mean IPL 




 WE BWA 
IPLMEAN r p r p 
NGT     
n 22  20  
First-phase ISF 0.001 0.99 -0.12 0.61 
Second-phase ISF 0.32 0.14 0.35 0.13 
Insulin secretion rate 0.46 0.033 0.22 0.36 
T2D     
n 18  19  
First-phase ISF -0.13 0.61 -0.27 0.27 
Second-phase ISF -0.31 0.21 -0.19 0.43 





5.4.5!Relationships between intrapancreatic lipids and measures of 
regional adiposity 
To investigate ethnic differences in the measures of adiposity that may influence IPL 
deposition, relationships between IPLMEAN and measures of regional adiposity are 
presented in Table 5.5 for the WE and BWA men in all glycaemic cohorts combined. 
IPLMEAN was associated with VAT, ASAT and IHL in both WE and BWA men.  
 
Table 5.5: Pearson’s correlation coefficients showing relationships between mean IPL 
and measures of whole-body and regional adiposity in WE and BWA men of all glycaemic 
states. 
N: aWE=50; bBWA=48 
 
Further analysis of the above relationships within the NGT and T2D glycaemic states are 
shown in Table 5.6 which shows clear distinctions by glycaemic state. In the NGT men, 
IPLMEAN was associated with VAT and ASAT in the WE and BWA men. Whereas, 
IPLMEAN was associated with IHL in the NGT WE men but not BWA men. In complete 
contrast, in the T2D state, there were no relationships between IPLMEAN and all measures 







IPLMEAN r p r p 
VATa 0.58 <0.001 0.43 0.002 
ASATa 0.58 <0.001 0.44 0.002 





Table 5.6: Pearson’s correlation coefficients showing relationships between mean IPL 
and measures regional adiposity in WE and BWA men of NGT and T2D groups. 
N: T2D: aWE=17; bBWA=18 
 
5.4.6!Relationships between adipose tissue insulin sensitivity and 
intrapancreatic lipids 
Relationships between adipose tissue insulin sensitivity and IPLMEAN were investigated 
to elucidate the influence of adipose tissue dysfunction on IPL accumulation. In the 
combined glycaemic cohorts, adipose tissue insulin sensitivity was inversely associated 
with IPLMEAN in the WE men (n=51, r=-0.50, P=0.001) but not BWA men (n=49, r=-
0.14, P=0.37). Further analysis of these relationships within the NGT and T2D glycaemic 
states show similar patterns to those of the whole cohorts where adipose tissue insulin 
sensitivity was inversely associated with IPLMEAN in NGT WE men (n=22, r=-0.50, 
P=0.001) but not BWA men (n=18, r=-0.14, p=0.57). No relationships were present in 
the T2D groups which may have been due to low sample sizes (n: WE=11 and BWA=15).
 WE BWA 
IPLMEAN r p r p 
NGT     
n 23  20  
VAT 0.78 <0.001 0.65 0.002 
ASAT 0.80 <0.001 0.59 0.007 
Intrahepatic lipid 0.85 <0.001 0.24 0.31 
T2D     
n 18  19  
VATa -0.16 0.54 0.38 0.11 
ASATa 0.16 0.54 0.34 0.16 






The purpose of this chapter was to investigate ethnic differences in intrapancreatic lipid 
accumulation between WE and BWA men across three glycaemic states: NGT, IGT and 
T2D. The present chapter demonstrates distinct ethnic differences in IPL and its 
relationship with measures of ISF which differ by both ethnicity and glycaemic state. 
Generally, IPL was lower in BWA men and was more strongly related to measures of ISF 
in the WE men. 
Intrapancreatic lipid was lower in BWA men in the IGT and T2D glycaemic states, 
however, there were no ethnic differences in IPL in the NGT state. The lack of ethnic 
differences in IPL in the NGT state may be due to the lower level of adiposity in 
comparison to the IGT and T2D groups. Generally, BWA men appear to be less 
susceptible to ectopic fat storage with increasing overall adiposity. This finding is 
supported by a study by Lingvay et al. who reported lower IPL in black women with 
obesity and T2D compared to their white/Hispanic counterparts; however, no ethnic 
difference was found in the lean NGT women (Lingvay I, 2014). In contrast to these 
findings, Szczepaniak et al. reported lower IPL in black adults compared to white adults 
who had mild obesity (Szczepaniak et al., 2012). However, Trout et al. showed no ethnic 
differences in IPL between black and white adults with obesity; although, the black group 
had a significantly greater BMI than the white group which may have influenced IPL 
deposition (Trout et al., 2019).  
Previous chapters showed both VAT and IHL were lower in the BWA men of NGT but 
this was not the case for IPL. This suggests that the pancreas may be more susceptible to 
ectopic fat storage compared to the liver in black populations. Furthermore, this may 
indicate that beta-cell lipotoxicity might play a greater role in the pathophysiology of T2D 





findings of Toledo-Corral et al. who showed that IPL predicted prediabetes status in black 
adolescents, however, IHL did not (Toledo-Corral et al., 2013).  
5.5.1!Intrapancreatic lipids and insulin secretory function 
Previous studies have indicated that IPL contributes to the progressive beta-cell 
dysfunction that occurs during the pathophysiology of T2D. In the NGT state, IPL 
deposition and circulating triglycerides proposedly cause lipotoxicity and promote insulin 
secretion thereby exerting an additional stress to the beta-cells in addition to glucose 
(Rebelos et al., 2015, Sharma and Alonso, 2014, Hughan et al., 2013, Szczepaniak et al., 
2012). While in T2D, IPL is related to reduced insulin secretion whereby lipotoxicity 
interferes with the cellular process that enhance insulin secretion (Gaborit et al., 2015, 
Giacca et al., 2011). Even though the BWA men had lower levels of IPL than WE men, 
there were no ethnic differences in beta-cell glucose sensitivity (modelled ISF) while 
absolute insulin secretion was lower in the BWA men. This suggests that there may be 
ethnic differences in the influence of IPL on beta-cell function between WE and BWA 
men, which may be clarified by examining relationships between IPL and measures of 
ISF. 
Intrapancreatic lipid was significantly related to first-phase ISF in WE men, while, in 
BWA men, this relationship trended towards significance which may be explained by a 
lower range of IPL in the BWA men. During the progression from NGT to T2D, the loss 
of first-phase ISF is the critical step that ultimately determines the onset of T2D (Gerich, 
2002), hence, most studies that investigate the influence of IPL on beta-cell function, 
focus on first-phase ISF. Considering this, the stronger relationship between IPL and first-
phase ISF in the WE men suggests that IPL may impair first-phase ISF and, in turn, play 
a greater role in the development of T2D in WE men compared to BWA men. 





not BWA men. The insulin secretion rate is determined by c-peptide concentrations 
during the glucose stimulated period and depict the amount of insulin secretion, 
irrespective of glucose concentrations. Previous studies have suggested that IPL enhances 
beta-cell insulin secretion even in the absence of glucose stimulation (Cen et al., 2016, 
Giacca et al., 2011, Steven et al., 2016, Gaborit et al., 2015). The lack of relationship 
between IPL and insulin secretion rate in the BWA men may indicate that IPL exposure 
may have a lesser influence on insulin secretion in BWA men compared to WE men.  
Only two previous studies have investigated relationships between IPL and metabolic 
parameters in a black versus white population which showed stronger relationships in 
black populations compared to their white (Szczepaniak et al., 2012) and white/Hispanic 
(Lingvay I, 2014) counterparts. The differences between those findings and the data 
presented here may be explained by differences in the techniques used to determine IPL 
since both the above studies used MRS. While MRS was once considered to be a valid 
method to determine IPL, advancements in imaging methods have confirmed that MRI is 
superior to MRS due to the high risk of contamination with VAT when measuring IPL 
with MRS (Hu et al., 2010, Al-Mrabeh et al., 2017). Furthermore, in both the 
aforementioned studies, ISF was determined by measuring insulin concentrations, 
however, this study measured c-peptide levels which is a more accurate indicator of 
insulin secretion (Polonsky et al., 1984, Polonsky and Rubenstein, 1986). 
5.5.2!Regional intrapancreatic lipids and insulin secretory function 
Ethnic differences were present in the deposition of regional IPL where, in both the IGT 
and T2D states, the lower mean IPL was driven by lower IPL in the head of the pancreas. 
Considering the relationships between regional measures of IPL and the various measures 
of ISF, there were specific patterns evident in each ethnic group. In the WE men, stronger 





those with the body and tail regions. Increased IPL has been linked with increased beta-
cell apoptosis (Oh et al., 2018, Sharma and Alonso, 2014). Additionally, during the 
progression from NGT to T2D, there is greater loss of beta-cells from the head of the 
pancreas compared to the body and tail regions (Wang et al., 2013). Considering this, the 
stronger relationships between IPL of the head and measures of ISF in WE may indicate 
that IPL may be more toxic to the beta-cells within the pancreas head and may contribute 
to this loss of beta-cell mass. In contrast, in the BWA men, relationships with measures 
of ISF appeared to be stronger with IPL of the body and tail regions compared to the head. 
This may suggest that beta-cells within the body and tail regions may be more susceptible 
to lipotoxicity in BWA men. However, this area of research is novel and future studies 
should be conducted to untangle these speculations on regional pancreatic lipotoxicity.  
5.5.3!Intrapancreatic lipids and measures of regional adiposity 
As an ectopic fat depot, IPL is thought to accumulate as a result of the expansion and 
dysfunction of adipose tissue depots, which leads to an overspill of NEFAs into the 
circulation, that subsequently deposit as ectopic fat in various organs including the 
pancreas (Sattar and Gill, 2014). Additionally, IPL is believed to be strongly linked to 
IHL accumulation as described in the previously-described twin-cycle hypothesis (Taylor, 
2013). Considering these hypotheses, relationships between IPL and various measures of 
adiposity were assessed to investigate ethnic differences in the mechanisms of IPL 
deposition. IPL was related to VAT, ASAT and IHL in both ethnic groups. This is in 
agreement with the finding of Le et al. who showed that IPL was related to SAT, VAT 
and IHL in a cohort of black and Hispanic adolescents (Le et al., 2011). In individual 
glycaemic states, despite the lower sample size, IPL was related to VAT and ASAT in 
the WE and BWA men of NGT. However, IPL was related to IHL in the NGT WE men 





men but not WE men. The lack of association between IPL and IHL in NGT BWA men 
may indicate that the twin-cycle hypothesis occurs to a lesser extent in them; additionally, 
VAT and SAT may be greater influencers of IPL deposition in BWA men. However, the 
positive association between IHL and IPL in the BWA men with T2D may indicate that 
a greater level of obesity may drive the twin-cycle hypothesis of IPL deposition in black 
populations.  
5.5.4!Intrapancreatic lipids and adipose tissue insulin sensitivity 
One of the main features of adipose tissue dysfunction is insulin resistance which is 
believed to drive ectopic fat accumulation, including IPL. The inverse relationships 
between adipose tissue insulin sensitivity and IPL in the WE men appears to support the 
current belief that dysfunctional adiposity and ectopic fat storage are closely connected 
(Bosy-Westphal et al., 2019, Kim et al., 2017, Smith and Kahn, 2016). However, this 
relationship was not present in the BWA men which indicates that adipose tissue insulin 
resistance may not be a principle determinant of IPL accumulation as it appears to be in 
WE men. This further supports the notion that the mechanisms of IPL accumulation 
appear to differ by ethnicity.  
To current knowledge, this is the first investigation of relationships between IPL and 
adipose tissue insulin sensitivity in a black population. However, Le et al. have 
investigated relationships between IPL and pro-inflammatory markers which are another 
feature of adipose tissue dysfunction (Le et al., 2011). They showed that IPL was related 
to several pro-inflammatory markers in a mixed black and Hispanic cohort, which 
indicates that adipose tissue inflammation may influence IPL accumulation in black 
populations. While the Soul-Deep study lacks data on pro-inflammatory markers, they 





5.5.5!Strengths and limitations 
This chapter has several strengths worth noting including the assessment of IPL using 
MRI which is considered to be superior to MRS. Previous studies have confirmed that 
IPL analysis using MRS carries a high risk of signal contamination from VAT particularly 
in subjects with T2D who typically have smaller and deformed pancreata (Hu et al., 2010, 
Al-Mrabeh et al., 2017). Furthermore, during the analysis of IPL by MRI, small regions 
of interest of 1cm2 were used to minimise the risk of contamination from VAT in the IPL 
analysis. Additionally, to ensure the positioning of the regions of interest in the head, 
body and tail regions of the pancreas were accurate, the MRI analysis of IPL was 
conducted alongside a consultant radiologist (Dimitra Christodoulou) with expertise of 
MRI pancreas anatomy. Another strength is the assessment of regional IPL deposition in 
a black population which is a novel aspect of this analysis.  
This study is not without its limitations which include the inclusion of intraorgan fat in 
the measure of IPL that is presented here. Unlike the liver, where triglyceride 
accumulation occurs only within hepatocytes, histological studies have shown that fat 
accumulation in the pancreas is inhomogeneous. To expand, pancreatic triglycerides are 
deposited in peripancreatic, intralobular and interlobular adipose tissue (i.e. adipocyte 
infiltration in the pancreas) as well as within pancreatic endocrine and exocrine cells 
including beta-cells (i.e. parenchymal tissue). The measure of IPL presented in this report 
includes both parenchymal and adipocyte infiltration of the pancreas and is not specific 
to triglycerides deposited within pancreatic cells. However, previous studies in rats have 
confirmed that fat infiltration in the whole pancreas paralleled the triglyceride 
accumulation within the islets which may suggest that IPL as determined by the presented 






The BWA men exhibited lower IPL levels in the IGT and T2D states compared to WE 
men with no differences in the NGT state. While IPL was inversely related to first-phase 
ISF in both WE and BWA men, this relationship was stronger in the WE men, which may 
be explained by a lower range in IPL in the BWA men. Furthermore, in the NGT state, 
IPL was related to insulin secretion rate in WE men but not BWA men. Therefore, the 
lower levels of IPL and weaker relationships with ISF in BWA men suggests that IPL 
may play a lesser role in the deterioration of beta-cell ISF during the progression of T2D 
in BWA men compared to WE men. Furthermore, the lack of relationship between IHL 
and IPL in NGT BWA men, a relationship which was present in the WE men, may 
indicate that the twin-cycle hypothesis may occur to a lesser extent in BWA men. Since 
IPL was inversely related to adipose tissue insulin sensitivity in WE men but not in BWA 
men, dysfunctional adipose tissue may be a lesser determinant of IPL deposition in BWA 
men compared to WE men. To further understand the role of IPL in T2D in black 
populations, future studies that explore the effects of IPL lowering therapies on T2D in 






Chapter 6:!Ethnic differences in intramyocellular 
lipid and its relationship with skeletal muscle 




Muscle insulin resistance is a crucial defect in individuals with T2D since muscles are a 
major site of glucose disposal (approximately 70-80% under hyperinsulinaemic-
euglycaemic clamp conditions but only 30% in the postprandial state) (DeFronzo and 
Tripathy, 2009, Taylor et al., 1993). Hence, understanding the mechanisms the lead to 
reduced insulin sensitivity of myocytes is of paramount importance in T2D research. 
There are several determinants of muscle insulin resistance which include increasing age 
(DeFronzo, 1979), a family history of diabetes (Petersen et al., 2004a) and many diseases 
such as polycystic ovary syndrome (Lankarani et al., 2009), chronic kidney failure 
Data presented in this chapter have been published in (appendix I):  
 
Hakim O, Bello O, Ladwa M, Christodoulou D, Bulut E, Shuaib H, 
Peacock JL, Umpleby AM, Charles-Edwards G, Amiel SA, Goff LM. 
Ethnic differences in hepatic, pancreatic, muscular and visceral fat 
deposition in healthy men of white European and black west African 







(Bailey et al., 2006), heart failure (Swan et al., 1997) and lipodystrophy (Simha and Garg, 
2006). However, many investigations that consider the cellular mechanisms of muscle 
insulin resistance in obesity-driven T2D have focused on the role of lipids (Abdul-Ghani 
and DeFronzo, 2010). 
In the 1920s researchers demonstrated that both glucose and fatty acids are oxidised in 
muscle cells to yield energy during muscle contraction (Li et al., 2015). However, excess 
lipids stored within myocytes have been proposed to play a role in T2D from as early as 
the 1960s when researchers described possible mechanisms of NEFA-induced muscle 
insulin resistance (Randle et al., 1963). Many of the early studies of the role of muscle 
lipids in T2D utilised muscle biopsy methods for the assessment of muscle lipids. During 
this era, it was hypothesised that NEFAs caused insulin resistance in the myocytes by 
competing with glucose for oxidation to produce energy, called Randle’s hypothesis, 
named after Professor Philip Randle who led the research (Hue and Taegtmeyer, 2009). 
Recent research has disproved some features of Randle’s hypothesis but have agreed that 
excess muscle lipids are related to insulin resistance, however, the mechanisms are more 
complex than initially understood (Li et al., 2015, Lewis et al., 2002, Petersen and 
Shulman, 2018). 
With the advancement of proton-magnetic resonance spectroscopy (1H-MRS) for the 
non-invasive analysis of muscle lipids in the 1990s, the study of muscle lipids in T2D 
became an area of increasing research (Boesch et al., 2006, Schick et al., 1993). The main 
feature of 1H -MRS that has made it superior to other measures for measuring muscle 
lipids is its ability to distinguish between lipid droplets stored within myocytes, termed 
intramyocellular lipids (IMCL), and lipids stored in adipocytes located between the 
muscle fibres, termed extramyocellular lipids (EMCL) (Thomas et al., 2013). By using 





related to insulin sensitivity, while EMCL is considered to be metabolically inert due to 
its lack of relation to insulin sensitivity (Thamer et al., 2003, Sinha et al., 2002, Perseghin 
et al., 1999, Krssak et al., 1999, Jacob et al., 1999). Furthermore, IMCL is found to be 
elevated in individuals with T2D compared to healthy controls (Perseghin et al., 1999) 
and  in healthy offspring of individuals with T2D compared to non-offspring controls 
(Jacob et al., 1999, Perseghin et al., 1999, Petersen et al., 2004b). From the above 
evidence, several studies have suggested that the accumulation of triglycerides within 
muscle cells precedes and causes insulin resistance and plays a crucial role in the 
development of T2D (Eriksson et al., 1999, Spalding et al., 2008, Kelley et al., 2002).  
Prior to the study of IMCL in black populations, researchers hypothesised that since 
visceral and hepatic fat are lower in black populations compared to their white 
counterparts, IMCL might explain the greater prevalence of T2D among black 
populations. However, subsequent studies showed no differences in IMCL in blacks 
compared to whites (Ingram et al., 2011, Lawrence et al., 2011, Goedecke et al., 2015, 
Lee et al., 2013), with one study even reporting lower levels of IMCL in blacks compared 
to whites (Smith et al., 2010). Furthermore, several studies have reported that IMCL was 
inversely associated with insulin sensitivity in white populations but not black 
populations (Ingram et al., 2011, Lawrence et al., 2011, Smith et al., 2010). In contrast, 
Goedecke et al. reported IMCL was inversely associated with insulin sensitivity in black 
but not white women (Goedecke et al., 2015). Therefore, studies of relationships between 
IMCL and measures of insulin sensitivity in black populations have shown inconclusive 
findings. While most studies of IMCL in black populations have been conducted in 
women or mixed gender populations, currently no studies have been conducted in black 







The primary aim of this chapter is to assess and compare ethnic differences in IMCL 
between WE and BWA men of NGT, IGT and T2D glycaemic states. The secondary aim 








The data presented in this chapter were acquired from the methods described in chapter 
2 (sections 2.3.2, 2.3.2.1, 2.3.4, 2.3.4.1). In brief, IMCL and EMCL were determined by 
deconvolution of the lipid peaks from a 1H-MRS spectra acquired from a voxel of interest 
in the soleus muscle. Measures of insulin sensitivity were determined using a 
hyperinsulinaemic-euglycaemic clamp test with the infusion of stable glucose and 
glycerol isotopes to determine whole-body insulin sensitivity (M-value), skeletal muscle 
insulin sensitivity (% change in glucose rate of disappearance [Rd]) and adipose tissue 
insulin sensitivity (% suppression of lipolysis).  
6.3.2!Statistical analysis 
The IMCL and EMCL data presented in this chapter for the WE and BWA men of NGT, 
IGT and T2D groups were compared using a 2-way between-groups ANOVA where 
ethnicity and glycaemic state were included as independent variables to assess the main 
effect of each, as well as their interaction (ethnicity*glycaemic state), on the dependent 
variables (IMCL or EMCL). When significant main effects were present, post-hoc 
comparisons were undertaken using the Tukey Honestly Significant Difference test to 
assess which groups differed significantly. The strength of relationships between 
variables of interest were tested using Pearson’s correlation test; partial correlation was 
used when assessing relationships while adjusting for confounding variables. Ethnic 
differences in the strength of the relationships between IMCL with measures of insulin 
sensitivity were examined by fitting a regression with an interaction term for ethnicity 







6.4.1!Participant characteristics  
The clinical characteristics of the WE and BWA men of NGT, IGT and T2D groups are 
presented in chapter 3, Table 3.2. The two ethnic groups were well matched for age and 
BMI and showed no significant differences in clinical characteristics except for waist 
circumference, triglycerides and HbA1c which were significantly lower in the BWA men. 
6.4.2!Metabolic characteristics 
Whole-body insulin sensitivity (M-value), skeletal muscle insulin sensitivity (% change 
in glucose Rd) and adipose tissue insulin sensitivity (% suppression of lipolysis) are 
presented for the WE and BWA men in Chapter 3, Table 3.3. There were no ethnic 
differences in all the above measures of insulin sensitivity between the WE and BWA 
men within each glycaemic group as well as the combined glycaemic cohorts.  
6.4.3!Intramyocellular lipids 
Differences in IMCL and EMCL, tested by ethnicity and glycaemic state, between the 
WE and BWA men of NGT, IGT and T2D are presented in Table 6.1. There were no 
ethnic differences in either IMCL or EMCL between the WE and BWA men as indicated 
by non-significant main effects for ethnicity. However, IMCL and EMCL differed by 
glycaemic state and were significantly greater in the IGT and T2D states compared to the 
NGT state. There were no significant ethnicity and glycaemic state interactions for IMCL 
and EMCL. Individual values of IMCL within each ethnic and glycaemic group are 








Table 6.1: IMCL and EMCL in the WE and BWA men of NGT, IGT and T2D glycaemic states. 
 
 
Data presented as geometric mean (95% CI) as the data were log transformed to achieve normal distribution. P eth: main effect for ethnicity, P gly: main effect for 























































































6.4.4!Relationships between intramyocellular lipids and measures of 
insulin sensitivity 
Relationships between IMCL and measures of insulin sensitivity are presented in Table 
6.2 and Figures 6.2, 6.3 and 6.4 (panels A) for the WE and BWA men in all glycaemic 
cohorts combined. Previous studies have shown with increasing age and BMI, IMCL 
increases while insulin sensitivity decreases (Nakagawa et al., 2007, Ingram et al., 2011, 
Krssak et al., 1999). Therefore, to reduce the influence of age and BMI, the above 
relationships were adjusted for these confounders, Table 6.2.  
IMCL was inversely associated with whole-body insulin sensitivity in the WE men while 
in the BWA men this relationship approached significance. IMCL was inversely 
Figure 6.1: Intramyocellular lipid determined as the ratio of the methylene 
IMCL peak to water peak from a 1H-MRS spectra in the WE and BWA men of 





associated with skeletal muscle insulin sensitivity in the WE men but not the BWA men. 
All significant relationships diminished after adjustments for age and BMI. There were 
no significant relationships between IMCL and adipose tissue insulin sensitivity in either 
ethnic group. Analysis of interaction by ethnicity for the relationships between IMCL and 
measures of insulin sensitivity showed near significant ethnicity interactions for the 
relationships between IMCL and whole-body insulin sensitivity (Pinteraction=0.081) as well 
as IMCL and muscle insulin sensitivity (Pinteraction=0.088).  
A limitation of conducting correlational analyses in the combined glycaemic cohorts the 
possible influence of glycaemic state on the relationships between IMCL and insulin 
sensitivity. To overcome this limitation, relationships between IMCL and measures of 
insulin sensitivity in the WE and BWA men, shown separately for the NGT and T2D 
groups, are presented in Table 6.3 and Figures 6.2, 6.3 and 6.4 (panels B). While the 
resultant correlations were weak, this analysis revealed distinct relationships between the 
NGT and T2D BWA men which may explain the weak correlations between IMCL and 
whole-body and muscle insulin sensitivity in the combined glycaemic cohorts (described 
above). In the NGT BWA men there was no relationship between IMCL and whole-body 
insulin sensitivity while IMCL and muscle and adipose tissue insulin sensitivity showed 
positive relationships. However, in the BWA T2D men, the relationships between IMCL 
and all measures of insulin sensitivity showed negative relationships but did not reach 
statistical significance. In the WE men, IMCL was significantly inversely associated with 
whole-body and muscle insulin sensitivity in NGT group, however, no significant 
relationships were found between IMCL and all measures of insulin sensitivity in the T2D 





Table 6.2: Pearson’s correlation and partial correlation coefficients showing 
relationships of IMCL and measures of insulin sensitivity in WE and BWA men of all 
glycaemic states. 








Intramyocellular lipid r p r p 
Whole-body insulin sensitivity -0.43 0.002 -0.28 0.070 
Adjusted for BMI and age 0.07 0.63 -0.06 0.72 
Skeletal muscle insulin sensitivitya -0.41 0.005 -0.10 0.52 
Adjusted for BMI and age -0.05 0.76 0.09 0.59 
Adipose tissue insulin sensitivityb -0.26 0.110 -0.12 0.46 














Figure 6.2: Relationships between IMCL and whole-body insulin sensitivity (M-value) 
in the WE and BWA men of all glycaemic states (NGT, IGT and T2D), A; and in the NGT 












Figure 6.3: Relationships between IMCL and skeletal muscle insulin sensitivity 
(% change in glucose Rd from basal) in the WE and BWA men of all glycaemic 






Figure 6.4: Relationships between IMCL and adipose tissue insulin sensitivity 
(% suppression of lipolysis) in the WE and BWA men of all glycaemic states 






Table 6.3: Pearson’s correlation coefficients showing relationships between IMCL and measures of insulin sensitivity in WE and BWA men of NGT 




 NGT T2D 
 WE BWA WE BWA 
Intramyocellular lipids r p r p r p r p 
Whole-body insulin sensitivity -0.54 0.010 -0.04 0.89 -0.16 0.52 -0.25 0.32 
n 22  16  18  18  
Skeletal muscle insulin sensitivity -0.58 0.005 0.18 0.50 0.09 0.77 -0.18 0.52 
n 22  16  13  15  
Adipose tissue insulin sensitivity -0.34 0.13 0.31 0.24 -0.12 0.72 -0.35 0.20 





6.5!Relationships between measures of regional adiposity and 
intramyocellular lipids  
Relationships between measures of regional adiposity and IMCL are presented in Table 
6.4 for the WE and BWA men of all glycaemic cohorts. In the WE and BWA men, IMCL 
was significantly associated with VAT, and ASAT. While IMCL was associated with IPL 
in both ethnic groups this relationship was stronger in the WE men than BWA men who 
showed a trend towards significance. IMCL was associated with IHL in WE but not BWA 
men.  
 
Table 6.4: Pearson's correlation coefficients showing relationships between IMCL and 
measures of regional adiposity in the WE and BWA men of all glycaemic states. 







Intramyocellular lipids r p r p 
VAT 0.41 0.004 0.56 <0.001 
ASAT 0.35 0.014 0.33 0.024 
IHLa 0.34 0.017 0.21 0.16 






The purpose of this chapter was to investigate ethnic differences in intramyocellular lipids 
between WE and BWA men across three glycaemic states: NGT, IGT and T2D. Findings 
from the present investigation revealed no ethnic differences in IMCL between BWA and 
WE men in NGT, IGT and T2D states. However, there were ethnic differences in the 
relationships between IMCL and measures of insulin sensitivity where IMCL was more 
strongly related to insulin resistance in WE men compared to BWA men.  
The lack of ethnic difference in IMCL between the BWA and WE men is consistent with 
previous findings in adolescents (Liska et al., 2007) and women (Goedecke et al., 2015, 
Ingram et al., 2011, Lawrence et al., 2011) of black ethnicity compared to their white 
counterparts.  
6.6.1!Intramyocellular lipids and insulin sensitivity 
Intramyocellular lipid was inversely associated with whole-body insulin sensitivity in 
both WE and BWA men, however, this relationship differed by ethnicity (near significant 
ethnicity interaction) and was more strongly related to whole-body insulin sensitivity in 
WE men than BWA men. IMCL was inversely associated with muscle insulin sensitivity 
in WE men but not BWA men, a relationship which also differed by ethnicity (near 
significant ethnicity interaction). The above findings suggest that IMCL may impact 
muscle insulin sensitivity to a lesser extent in BWA men compared to WE men. This 
finding supports two previous studies, conducted in US populations, which reported 
significant inverse relationships between IMCL and insulin sensitivity in white but not 
black women (Lawrence et al., 2011) and mixed-gender cohorts (Ingram et al., 2011). 
However, the opposite was reported in a study conducted in South African women, where 
IMCL was inversely related to insulin sensitivity in the black but not white women 





adiposity, because the cohorts in the US studies were in the overweight BMI category 
while the South African study was conducted in women with obesity. It is possible that 
the harmful effects of IMCL may only occur in black populations with severe obesity or 
specifically in black women but not black men. Interestingly, it has previously been 
recognised in large epidemiological studies that the prevalence of T2D in black women 
is largely explained by their level of adiposity but this was not the case in black men 
(Brancati et al., 2000, Signorello et al., 2007). 
While EMCL has received less attention in research due to its supposed lack of influence 
on insulin sensitivity, few studies have reported EMCL in black vs white populations. In 
this investigation, EMCL did not differ between the WE and BWA men which was similar 
to findings previously reported in South African women (Goedecke et al., 2015) and 
American adolescents (Liska et al., 2007). In contrast to these findings, EMCL was 
reportedly greater in African American women compared to their white counterparts 
(Albu et al., 2005, Gallagher et al., 2005, Lawrence et al., 2011) indicating that other 
factors such as gender may impact EMCL accumulation.  
6.6.2!Intramyocellular lipids and adipose tissue insulin sensitivity 
The spillover theory is the main theory proposed to describe the mechanisms of ectopic 
fat storage, including IMCL (Brons and Grunnet, 2017). This theory proposes that the 
dysfunction of adipose tissue, that occurs partly due to its severe expansion, facilitates 
the storage of excess NEFAs in non-adipose depots (Brons and Grunnet, 2017, 
Cuthbertson et al., 2017). Decreased insulin sensitivity of the adipose tissue is a 
prominent feature of dysfunctional adipose tissue, which is also related to ectopic fat 
storage (Smith and Kahn, 2016). However, the present analysis revealed no relationship 
between IMCL and adipose tissue insulin sensitivity in either ethnic group, which 





dysfunction and insulin resistance of adipose tissue. Other theories that may explain the 
mechanisms of IMCL accumulation include the reduced oxidation capacity of fatty acids 
within the muscle cells (Li et al., 2015). This theory proposes that fatty acids within the 
muscle cells, that are not oxidised due to the lack of energy expenditure, are stored as 
IMCL. The present study may support this theory due to the lack of association between 
IMCL and adipose tissue insulin resistance in both ethnic groups; however, further 
investigations of IMCL and fatty acid oxidative capacity within muscle cells are 
warranted to elucidate these mechanisms. 
6.6.3!Intramyocellular lipids and regional adiposity 
To understand the possible drivers of IMCL accumulation, relationships between IMCL 
and measures of regional fat deposition were assessed, which revealed distinct patterns in 
each ethnic group. IMCL was associated with VAT, ASAT and IPL in both ethnic groups, 
however, IMCL was associated with IHL in WE men but not BWA men. This suggests 
that the increase of SAT and VAT may result in the spillover of NEFAs that subsequently 
deposit in myocytes, a process which may occur in both WE and BWA men. However, 
the role of IHL in IMCL accumulation may differ by ethnicity. Since the liver is an 
important site of lipid metabolism, an increase of IHL may promote the excess release of 
lipids, that are stored within other organs including the pancreas and muscles. This 
process may occur to a greater extent in WE men than BWA men. In a similar manner, 
data presented in Chapter 5 showed IHL was related to IPL in WE men but not BWA. 
Taken together, it appears that IHL accumulation is less influential in driving ectopic fat 
deposition in the pancreas and myocytes in BWA men compared to WE men. 
Furthermore, there is additional evidence, within this study, that suggests lipid output 
from the liver is lower in BWA men than WE men, indicated by significantly lower TG 





6.6.4!Strengths and limitations 
There are several strengths worth noting, which include the use of 1H-MRS to determine 
IMCL and EMCL, which allows for the differentiation between lipids stored within and 
between myocytes. However, a limitation is the difficulty in deconvolution of the lipid 
peaks when analysing the spectra obtained from participants with obesity due to the 
greater overlap of lipid peaks in their spectra which makes the separation of the lipid 
peaks more challenging. Due to this limitation, some of the IMCL or EMCL values may 
have been exaggerated owing to contamination from neighbouring lipid peaks that have 
merged together. Another limitation is the assessment of muscle lipids only within the 
soleus muscle as others have reported varying proportions of IMCL to EMCL in different 
muscle groups (Boesch et al., 1997, Just Kukurova et al., 2014). Another limitation is the 
lack of assessment of aerobic capacity levels in the participants as VO2 max has been 






Though there were no ethnic differences in IMCL accumulation between WE and BWA 
men, IMCL was more strongly inversely related to measures of peripheral insulin 
sensitivity in WE than BWA men. This suggests that IMCL may play a more relevant 
role in the development of T2D in WE men compared to BWA men. Furthermore, the 
relationships between IMCL and VAT and ASAT in both WE and BWA men suggests 
that IMCL accumulation may be driven by increasing SAT and VAT accumulation in 
both ethnic groups. However, the stronger relationships between IHL and IMCL in WE 
men suggests that excess lipid output by the liver may be a greater driver of IMCL 






Chapter 7:!Discussion and conclusions 
The main objective of this thesis was to investigate ethnic differences in ectopic fat 
deposition and their relationships with the metabolic parameters of T2D between white 
European (WE) and black west African (BWA) men. This was accomplished by the 
comprehensive analysis of ectopic fat deposition and their relationships with metabolic 
parameters of T2D across three glycaemic states: normal glucose tolerance (NGT), 
impaired glucose tolerance (IGT) and T2D.  
The WE and BWA men were similar in their clinical and metabolic characteristics in the 
NGT, IGT and T2D groups. Furthermore, both ethnic groups showed similar patterns of 
deterioration in metabolic parameters in the T2D compared to the NGT states which was 
evident in the greater level of ectopic fat and a lower level of insulin sensitivity and insulin 
secretory function in the T2D states. Also similar between the WE and BWA men, was 
the strong relationships of visceral adipose tissue (VAT) and intrahepatic lipid (IHL) with 
measures of insulin sensitivity. However, some important ethnic differences include: 1) 
despite no ethnic differences in overall adiposity, VAT, IHL and intrapancreatic lipid 
(IPL) were lower in the BWA men compared to the WE men; 2) relationships of IHL and 
IMCL with metabolic parameters of T2D were weaker in the BWA men compared to the 
WE men; 3) VAT, IHL and IPL were significantly inversely related to adipose tissue 
insulin sensitivity in the WE men but not the BWA men; 4) interrelationships between 
ectopic fat depots were weaker in the BWA men than the WE men. Overall, the evidence 
presented in this thesis suggests that an increase of ectopic fat deposition that is related 
to an increase in adiposity is a key component in the progression of T2D in both WE and 
BWA men. However, there is a lack of evidence to suggest that the greater risk of T2D 





7.1!Ethnic differences in ectopic fat deposition 
Previous studies have shown that, at a similar level of overall adiposity, black populations 
have lower levels of VAT, IHL and IPL compared to their white counterparts (Goedecke 
et al., 2017, Alderete et al., 2014, Liska et al., 2007, Le et al., 2011, Szczepaniak et al., 
2012). The VAT, IHL and IPL data presented in the current analysis of WE and BWA 
men are consistent with previous reports, which adds to the paradox of greater T2D risk 
in black populations despite lower VAT, IHL and IPL. The regional fat depots that were 
investigated include ASAT (dSAT and sSAT), VAT, IHL, IPL and IMCL. There were 
no ethnic differences in ASAT, dSAT or sSAT, however, VAT, IHL and IPL were lower 
in BWA men compared to WE men with no differences in IMCL. These ethnic patterns 
were present within each glycaemic state for all fat depots except for IPL, which was 
lower in the BWA men of IGT and T2D groups but did not differ by ethnicity in the NGT 
state.  
In both WE and BWA men, VAT, IHL, IPL and IMCL were similarly greater in the IGT 
and T2D states compared to the NGT state indicted by non-significant 
ethnicity*glycaemic state interactions. However, the differences in VAT, IHL and IPL 
levels between the WE and BWA men was greater in the IGT and T2D groups than the 
NGT groups. Furthermore, relationships between ASAT with IHL, IPL and IMCL were 
consistently stronger in the WE men than BWA men. This may indicate that with 
increasing adiposity, the BWA men appear to be less susceptible to ectopic fat storage 
than WE men. With adipose tissue expansion, the point at which it becomes 
dysfunctional, and shows a reduced capacity to store triglycerides, varies from one 
individual to another, and is coined “the personal fat threshold” (Taylor and Holman, 
2015). The apparent lower susceptibility of BWA men to ectopic fat storage suggest they 





tissue function, such as the mechanisms of the breakdown and storage of triglycerides, 
should be investigated to confirm these speculations. 
7.2!Ethnic differences in relationships between regional and ectopic fat 
depots and metabolic parameters of type 2 diabetes 
Studies investigating the role of ectopic fat in the pathophysiology of T2D in black 
populations have provided inconsistent conclusions. Among studies that specifically 
investigated relationships between ectopic fat and metabolic parameters of T2D, some 
suggest ectopic fat is more detrimental in black populations than white populations 
(Alderete et al., 2013, Goedecke et al., 2015, Szczepaniak et al., 2012) while others 
suggest it is less detrimental (Ingram et al., 2011, Lawrence et al., 2011, Chung et al., 
2019). The evidence presented in this thesis supports the notion that ectopic fat may be 
less important in the development of T2D in black populations than white populations. 
Even though several associations were present between ectopic fat depots and metabolic 
parameters in both WE and BWA men indicating that ectopic fat is an important 
component of T2D in both ethnic groups, these relationships were consistently stronger 
in the WE men.  
It is well accepted that VAT is strongly related to T2D (Smith et al., 2012); however, 
recent research suggests that IHL may be more strongly related to T2D than VAT 
(Fabbrini et al., 2009, Okamura et al., 2019). A comparison of the relationships between 
VAT and IHL with whole-body and hepatic insulin sensitivity reveals distinct ethnic 
patterns. In the WE men, VAT and IHL showed similar strengths in their associations 
with the measures of insulin sensitivity; however, in BWA men, the associations of VAT 
were markedly stronger than those of IHL. Additionally, the inverse relationships 
between VAT and whole-body and hepatic insulin sensitivity persisted after adjustment 





relationship between IHL and whole-body insulin sensitivity persisted after adjustment 
for age and BMI in the WE men but not the BWA men. Thus, VAT appears to be more 
dominant than IHL in its relation to insulin resistance in BWA men while IHL appears to 
be more dominant in WE men. However, despite the above findings, the high risk of a 
type 2 statistical error in the relationships involving VAT and IHL in the BWA men must 
be acknowledged; this type of error may occur when there is no statistically significant 
correlation present between two variables despite a clear trend and may be explained by 
the low range of VAT and IHL in the BWA men in comparison to the WE men.  
The analysis of relationships between ectopic fat depots and metabolic parameters of T2D 
in the combined glycaemic cohorts, as well as within the NGT and T2D states, each have 
their advantages and limitations. Analysis of the combined glycaemic cohorts benefits 
from greater statistical power; however, relationships may be influenced by glycaemic 
state of the populations assessed. On the other hand, the individual glycaemic cohorts are 
more homogenous populations but have considerably lower sample sizes. Despite these 
limitations, certain trends were particularly evident, which may provide insights into 
ethnic differences in the role of ectopic fat in T2D. It was particularly noticeable that 
several relationships between ectopic fat depots and metabolic parameters were stronger 
in NGT WE men than WE men of combined glycaemic cohorts; however, these 
relationships were not present in the NGT BWA men but were present in the BWA men 
of combined glycaemic cohorts. Relationships where this trend occurred include: VAT 
and M-value, IHL and hepatic insulin sensitivity, IHL and M-value, IHL and insulin 
clearance, and IMCL and M-value. The lack of significant relationships between ectopic 
fat depots and metabolic parameters in NGT BWA men may be explained by a low level 
of adiposity in the NGT groups. Hence, ectopic fat may be more detrimental in black 





the amount of ectopic fat and a decline in metabolic responses even at lower levels of 
adiposity. 
The greater prevalence of T2D among black populations may be explained by the greater 
levels of insulin that they exhibit in comparison to their white counterparts, which has 
been detected from as early as childhood (Kodama et al., 2013, Ku et al., 2000). 
Prolonged hyperinsulinaemia itself has been proposed to exacerbate insulin resistance, 
which may be a driver insulin resistance in black individuals (Shanik et al., 2008, Thomas 
et al., 2019). Indeed, the data presented here showed greater fasting insulin levels and 
lower insulin clearance in the BWA men of NGT compared to WE men. Over a prolonged 
period, the greater insulin levels may accelerate the development of insulin resistance in 
black populations, and may explain their greater risk of T2D despite their lower ectopic 
fat deposition. 
7.3!Ethnic differences in the mechanisms of ectopic fat deposition 
There are a number of proposed theories that are thought to explain the mechanisms by 
which ectopic fat accumulates that are summarised in Figure 7.1 (Goff et al., 2019). The 
spillover theory explains the process by which dysfunctional adipose tissue leads to 
excess release of NEFAs that deposit in ectopic depots (Snel et al., 2012, Sattar and Gill, 
2014); the portal theory explains the mechanism by which VAT releases excess NEFAs 
into the portal vein that deposit in the liver (Item and Konrad, 2012); and the twin-cycle 
theory explains the mechanisms by which excess IHL promotes excess VLDL-TG release 
by the liver which deposit in the pancreas (Taylor, 2013). The data presented in this thesis 
suggest ethnic differences exist in the mechanisms of ectopic fat storage. Firstly, ASAT 
and VAT were related to ectopic fat depots in both WE and BWA men; however, 
interrelationships between IHL, IPL and IMCL were weaker in the BWA men compared 





insulin sensitivity in WE men but not BWA men, with significant ethnicity interactions 
present for these relationships. Since, reduced adipose tissue insulin sensitivity is a key 
feature of dysfunctional adipose tissue, it appears that adipose tissue dysfunction is a 











7.4!Strengths and limitations 
This thesis has several strengths worth noting with some limitations to consider. The 
assessments of ectopic fat depots were conducted using MRI and 1H-MRS, which are 
currently considered the most precise non-invasive methods for quantifying body 
composition components. The comprehensive assessment of several metabolic 
parameters is also another strength which includes the assessment of organ-specific 
measures of insulin sensitivity via the use of stable glucose and glycerol isotopes during 
the hyperinsulinaemic-euglycaemic clamp; this is currently considered the gold-standard 
method to determine organ-specific insulin sensitivity. Furthermore, insulin clearance 
and ISF were determined using the comprehensive hyperglycaemic clamp with the 
sophisticated modelling analyses of insulin clearance and parameters of ISF using c-
peptide deconvolution models. However, a limitation to both the clamp techniques 
mentioned above, is their disregard to the physiological responses that may influence 
insulin sensitivity and beta-cell function. For example, it is well established that an oral 
glucose ingestion stimulates significantly greater insulin secretion and insulin clearance 
than a similar concentration of intravenous glucose (Perley and Kipnis, 1967, Shapiro et 
al., 1987). Therefore, considering ethnic differences in metabolic parameters of T2D 
under physiological conditions should also be an important focus for future studies. 
The analysis of VAT, ASAT, dSAT and sSAT, as well as the three main ectopic fat depots 
related to T2D, in a single study is another strength of this thesis, since most previous 
studies of ectopic fat in black populations investigated only one or two fat depots. 
Furthermore, there are several novel aspects of this thesis that are worth noting, including 
the assessment of regional IPL and the investigation of relationships between ectopic fat 
depots and adipose tissue insulin sensitivity; to current knowledge, both these analyses 





This thesis is limited in the study of only men; hence, the findings may not apply to black 
women who have distinct metabolic functions compared to black men. However, while 
several previous ethnicity studies in T2D have been conducted in women, there is a 
relative lack of focus on men making this study of particular importance (Goedecke et 
al., 2017). 
While several trends were evident, the cross-sectional nature of this study limits the 
speculations of whether ectopic fat causes the decline in metabolic parameters, since 
correlation does not imply causation. Furthermore, with the strong interlinkage of several 
parameters related to glucose metabolism, it is particularly difficult to untangle which 
factors influence others. Therefore, longitudinal studies are highly warranted to aid the 
understanding of ethnic differences in the role of ectopic fat in T2D.  
7.5!Future directions 
Ectopic fat is believed to deposit due to the progressive failure of the SAT to store excess 
energy as triglycerides (Bosy-Westphal et al., 2019, Castro et al., 2014). However, while 
the evidence presented here suggests that the increase of SAT is accompanied by an 
increase of ectopic fat in both ethnic groups, there may be some indications that the role 
of the adipose tissue in ectopic fat accumulation may differ by ethnicity. To expand, in 
the WE men, ectopic fat appeared to be linked to adipose tissue insulin resistance, a well-
known feature of dysfunctional adipose tissue; however, this was not the case in BWA 
men. Therefore, the study of adipose tissue dysfunction, including ethnic differences in 
the structure and function of adipose tissue, are strongly proposed for future studies. 
Furthermore, ethnic differences in factors other than adipose tissue dysfunction may 
influence ectopic fat storage in black populations that warrant further investigation. Such 





oxidative capacity, sex hormones, glucocorticoid hormones and pro-inflammatory 
cytokines, all of which may differ by ethnicity.  
Studies that directly compare the pathophysiology of T2D between men and women of 
black ethnicity are also highly warranted. Several findings differed between the present 
study and those previously published that may be explained by gender. Indeed, several 
epidemiological studies have shown that T2D differs between black men and women, and 
T2D is driven by adiposity more so in women than men (Signorello et al., 2007, Brancati 
et al., 2000); however, there is a lack of physiological studies that explain the reasons 





7.6!Conclusion and final remarks 
While the BWA men had lower levels of VAT, IHL and IPL than the WE men, with no 
ethnic differences in IMCL, the increase of these fat depots was related to the 
deterioration of several metabolic parameters of T2D in both ethnic groups. Furthermore, 
VAT, IHL, IPL and IMCL were greater in the T2D and IGT states compared to the NGT 
state in both WE and BWA men. This indicates that the increase of ectopic fat is an 
important component of the progression of T2D in both ethnic groups. Albeit, ethnic 
distinctions occurred in the strengths of the relationships between specific fat depots and 
relevant metabolic parameters where weaker relationships were commonly reported in 
the BWA men compared to the WE men. This phenomenon may be explained by the 
lower range of VAT, IHL and IPL in BWA men but may also suggest that ectopic fat 
may have lesser lipotoxic effects in BWA men than WE men. Furthermore, the lack of 
inverse associations between VAT, IHL and IPL with adipose tissue insulin sensitivity 
suggests that the dysfunction of SAT may be a lesser determinant of ectopic fat storage 
in BWA men than WE men. Taken together the evidence in this thesis suggests that 
ectopic fat is related to the progression of T2D in both WE and BWA men but may not 
explain the greater risk of T2D in black populations and other factors, such as genetic 
susceptibility to insulin resistance, may be greater determinants. To further elucidate the 
role of ectopic fat in the development of T2D in black populations, future studies 
investigating the effects of ectopic fat lowering therapies in a black vs white population 
are highly warranted. In an era approaching personalised medical treatment of T2D, the 
findings presented in this thesis may inform future treatment and prevention strategies for 
T2D in black populations. Finally, considering the worldwide increase in the prevalence 
of T2D in populations of African descent, ethnicity is an area deserving of greater 
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